Monitoring HIV Reservoirs After CCR5Δ32 HSCT: From Eradication Mechanisms to Clinical Cure Validation

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with CCR5Δ32/Δ32 donor cells represents a groundbreaking intervention capable of achieving sustained HIV-1 remission, offering unprecedented insights for cure strategies. This article provides a comprehensive overview for researchers and drug development professionals on the monitoring of HIV reservoirs post-transplant, synthesizing evidence from established cure cases (Berlin, London, Düsseldorf) and recent breakthroughs (Geneva patient with wild-type CCR5). We explore the foundational mechanisms of reservoir reduction, detail state-of-the-art virological and immunological monitoring methodologies, address critical challenges in interpreting residual viral signals and managing complications like GvHD, and present a comparative analysis of cure validation criteria. The synthesis of these intents outlines a definitive framework for assessing HIV cure and informs the development of scalable, next-generation therapeutic modalities.

The Scientific Basis: How CCR5Δ32 HSCT Resets the HIV Landscape

The pursuit of a sterilizing cure for human immunodeficiency virus (HIV) has been revolutionized by the discovery of the critical role of C-C chemokine receptor type 5 (CCR5) in viral entry and the remarkable natural resistance conferred by its genetic disruption. The CCR5Δ32/Δ32 mutation, a 32-base pair deletion in the CCR5 gene, results in a non-functional receptor that is not expressed on the cell surface, rendering individuals highly resistant to infection by R5-tropic HIV strains that predominantly initiate and propagate HIV infection [1] [2]. This biological phenomenon has been translated into clinical cures through allogeneic hematopoietic stem cell transplantation (allo-HSCT) from CCR5Δ32/Δ32 donors to patients with HIV and hematological malignancies, providing both a proof-of-concept and a framework for developing scalable cure strategies [2] [3]. This technical guide examines the establishment of this natural barrier to HIV reinfection within the context of monitoring and eradicating the persistent viral reservoir, the primary obstacle to an HIV cure.

Biological Mechanism of CCR5Δ32-Mediated Resistance

Structural and Functional Impact of the Δ32 Deletion

The CCR5 protein is a seven-transmembrane G-protein coupled receptor that normally serves as a co-receptor for HIV-1 entry. The Δ32 deletion occurs in the gene's open reading frame, causing a frameshift mutation that results in a severely truncated and non-functional protein [2]. This mutated protein is not transported to the cell surface but is instead retained in the endoplasmic reticulum [4]. Consequently, CD4+ T cells and other target cells from CCR5Δ32/Δ32 homozygous individuals lack the primary entry portal for R5-tropic HIV-1 viruses.

Interestingly, the heterozygous CCR5/Δ32 genotype also confers a degree of protection, delaying the onset of AIDS by 2–4 years [4]. This partial resistance occurs through a transdominant inhibition mechanism where the mutant ccr5Δ32 subunit heterocomplexes with the wild-type CCR5 subunit, sequestering it in the endoplasmic reticulum and reducing its cell surface expression [4].

HIV Entry Pathway and CCR5 Antagonism

HIV-1 entry requires sequential binding of the viral envelope glycoprotein gp120 to the CD4 receptor followed by interaction with a coreceptor, primarily CCR5 or CXCR4. The V3 loop of gp120 is particularly critical for coreceptor specificity, with R5-tropic strains (which account for initial infections in >90% of cases) relying exclusively on CCR5 [5].

CCR5 antagonists like maraviroc inhibit HIV-1 entry via an allosteric mechanism rather than competitive binding. They bind to a hydrophobic pocket formed by the transmembrane helices of CCR5, inducing conformational changes in the extracellular loops that prevent recognition by gp120 [6] [5]. Resistance to these drugs can emerge through two pathways: outgrowth of pre-existing CXCR4-using variants, or viral adaptation to utilize the antagonist-bound form of CCR5 through mutations in the V3 loop that increase reliance on the CCR5 N-terminus [6] [5].

Clinical Evidence from CCR5Δ32/Δ32 Hematopoietic Stem Cell Transplantation

The Curative Cases

To date, seven people living with HIV (PLHIV) have been declared cured following allogeneic hematopoietic stem cell transplants (allo-HSCT) for hematological malignancies, five of whom received CCR5Δ32/Δ32 donor cells [2] [3]. These cases demonstrate that complete donor chimerism with CCR5-deficient cells can eliminate the viral reservoir and prevent rebound, even after antiretroviral therapy (ART) discontinuation.

Table 1: Clinical Cases of HIV Cure via Allo-HSCT

Patient Reference	Malignancy	Donor CCR5 Genotype	Pre-conditioning Therapy	GvHD Prophylaxis	HIV Outcome
Berlin [2]	AML	Δ32/Δ32	Chemotherapy, Radiotherapy	Yes	No rebound >15 years
London [2]	Hodgkin's	Δ32/Δ32	Chemotherapy	Yes	No rebound >5 years
Düsseldorf [2]	AML	Δ32/Δ32	Chemotherapy, Radiotherapy	Yes	No rebound >4 years
New York [2]	AML	Δ32/Δ32	Chemotherapy	Yes	No rebound >3 years
City of Hope [2]	AML	Δ32/Δ32	Chemotherapy	Yes	No rebound >2 years
IciSema [2]	Hodgkin's	WT/WT	Chemotherapy	Yes	No rebound >4 years
Geneva [2]	Myeloid Sarcoma	WT/WT	Chemotherapy	Yes	No rebound >2 years

Critical Mechanisms of Reservoir Elimination

The success of CCR5Δ32/Δ32 HSCT in curing HIV involves multiple interconnected mechanisms that extend beyond simple CCR5 disruption:

• Myeloablative Conditioning: Pre-transplant chemotherapy and/or radiotherapy effectively eliminate substantial portions of the HIV reservoir, particularly in circulating CD4+ T cells [2].

• Graft-versus-Host Disease (GvHD): The graft-versus-host response contributes to reservoir reduction through "graft-versus-reservoir" effects, wherein donor immune cells recognize and eliminate remaining HIV-infected host cells [2] [3].

• Complete Donor Chimerism: The replacement of the recipient's entire hematopoietic system with CCR5-deficient cells establishes a genetically resistant immune population. This prevents new infection cycles and allows the natural attrition of residual infected host cells [2].

• Anatomical Reservoir Targeting: The donor-derived CCR5-deficient cells reconstitute all lymphoid tissues, including sanctuary sites such as the gut-associated lymphoid tissue (GALT) and central nervous system, where the reservoir typically persists [3] [2].

Monitoring the HIV Reservoir Post-Transplantation

Quantitative HIV DNA Assays

Accurate quantification of the total HIV DNA reservoir is essential for evaluating the efficacy of curative interventions. Digital PCR (dPCR) has emerged as a superior alternative to qPCR due to its absolute quantification without standard curves and enhanced sensitivity for low-abundance targets [7].

A recently developed duplex digital PCR assay on the Absolute Q platform simultaneously targets the HIV LTR-RU5 region and the human RPP30 reference gene, providing precise reservoir quantification in persons with HIV (PWH) on ART [7]. This microfluidic chamber array-based approach offers fully automated workflows, reducing hands-on time and contamination risk while maintaining high precision.

Table 2: Performance Characteristics of Digital PCR HIV Reservoir Assay

Parameter	Specification	Experimental Value
Target Genes	HIV LTR-RU5 & RPP30 (reference)	Duplex detection
Linearity (R²)	Across 78-5,000 copies/10⁶ cells	0.977
Lower Limit of Detection (LLOD)	95% confidence	79.7 copies/10⁶ cells
Limit of Quantification (LOQ)	100% accuracy	5 copies/reaction
Intra-assay Precision (CV)	1,250 copies/10⁶ cells	8.7%
Inter-assay Precision (CV)	1,250 copies/10⁶ cells	10.9%
Clinical Range (ART-treated)	CD4+ T cells	21.5-5,694 copies/10⁶ cells
Clinical Range (ART-naïve)	PBMCs	4,612-36,919 copies/10⁶ cells

Specialized Methodological Protocol

Duplex Digital PCR for Total HIV DNA Quantification in PBMCs or CD4+ T Cells

Sample Preparation:

• Isolate PBMCs or CD4+ T cells from peripheral blood using Ficoll density gradient centrifugation followed by magnetic bead separation for CD4+ cells.
• Extract genomic DNA using silica-membrane based kits, ensuring elution in low-EDTA TE buffer to prevent inhibition.
• Quantify DNA concentration by fluorometry and adjust to working concentration of 10-50 ng/μL.

Reaction Setup:

• Prepare master mix containing: 1× Absolute Q Digital PCR Mix, 900 nM each of LTR-RU5 forward (5'-ACAAGCAGTCAGTACAGAAA-3') and reverse (5'-TACCACATACAATTCACCC-3') primers, 250 nM FAM-labeled LTR-RU5 probe, 900 nM RPP30 forward (5'-GATTTGGACCTGCGAGCG-3') and reverse (5'-GCGGCTGTCTCCACAAGT-3') primers, and 250 nM VIC-labeled RPP30 probe.
• Add 10-100 ng template DNA per reaction, adjusting volume with nuclease-free water to 20 μL total reaction volume.

Partitioning and Amplification:

• Load samples into the Absolute Q array plate following manufacturer's instructions for automated partitioning.
• Perform amplification with thermal cycling conditions: 10 min at 96°C (initial denaturation); 40 cycles of 10 s at 96°C (denaturation) and 50 s at 60°C (annealing/extension); final hold at 4°C.

Analysis and Interpretation:

• Use Absolute Q Analyzer software for automated fluorescence detection and thresholding.
• Apply Poisson statistics to calculate absolute copy numbers of HIV LTR and RPP30 targets.
• Normalize results to copies per million cells using the formula: (HIV copies/RPP30 copies) × 2 × 10⁶.

Gene Editing Approaches to Recapitulate CCR5Δ32 Homozygosity

CRISPR/Cas9-Mediated CCR5 Disruption

The limited availability of naturally CCR5Δ32/Δ32 donors has spurred the development of gene editing strategies to recreate this phenotype in a patient's own cells. CRISPR/Cas9 has demonstrated remarkable efficiency in generating CCR5-null hematopoietic stem/progenitor cells (HSPCs) [8].

Recent optimization has identified guide RNAs (e.g., TB48 and TB50) that achieve >90% editing efficiency in mobilized CD34+ HSPCs when delivered as ribonucleoprotein (RNP) complexes [8]. This high-frequency editing is critical for therapeutic efficacy, as titration studies demonstrate a clear threshold effect:

• >90% editing: Robust protection against HIV challenge in xenograft models
• 54%-26% editing: Diminishing protective benefit
• <26% editing: Negligible protection against viral replication [8]

The "dual guide" approach using TB48 and TB50 simultaneously creates small deletions that approximate the natural Δ32 mutation, resulting in robust ablation of CCR5 surface expression and superior HIV protection compared to single guides [8].

Research Reagent Solutions for CCR5 Gene Editing

Table 3: Essential Research Reagents for CCR5 Gene Editing Studies

Reagent/Category	Specific Examples	Function/Application
Gene Editing Systems	CRISPR/Cas9 (SpCas9), ZFNs, TALENs, Base Editors	Induction of site-specific DNA breaks or precise nucleotide changes in CCR5 locus
Guide RNA Design	TB48: 5'-GACATCACCATCTAACTT-3', TB50: 5'-GTTGTCATCAAGCAGGAAG-3'	High-efficiency gRNAs targeting CCR5 exon 3 with minimal off-target effects
Delivery Systems	Electroporation (Neon, Amaxa), Lentiviral Vectors, AAV6	Introduction of editing components into HSPCs and T cells
Cell Culture	Immunodeficient Mice (NSG), StemSpan Media, Cytokine Cocktails	In vivo modeling of human hematopoiesis and HIV infection; ex vivo HSPC expansion
Analysis Tools	Flow Cytometry (CCR5 surface staining), T7E1 Assay, Next-gen Sequencing	Assessment of editing efficiency, protein expression, and off-target effects
HIV Challenge Models	HIVJRCSF, HIVNL4-3, CCR5-tropic reporter viruses	In vitro and in vivo validation of HIV resistance in edited cells

Future Directions and Combinatorial Strategies

While CCR5 disruption represents a powerful approach, several challenges remain for broader application. HIV can potentially switch to CXCR4 usage, necessitating strategies that target both coreceptors [9]. Multiplexed gene editing approaches simultaneously targeting CCR5, CXCR4, and the HIV proviral LTR region are being developed to create comprehensive viral barriers [9].

The integration of gene editing with immunotherapy holds particular promise. Combination strategies include:

• Engineering HIV-specific CAR-T cells with disrupted CCR5 genes to enhance their persistence and efficacy [9]
• Incorporating immune checkpoint inhibitors to reverse T-cell exhaustion and improve clearance of infected cells [9] [3]
• Developing base-edited cells that avoid double-strand breaks while achieving CCR5 knockout [9]

Additionally, advancements in reservoir monitoring through ultrasensitive detection assays will be crucial for accurately assessing the efficacy of these interventions and confirming HIV eradication [7] [3].

CCR5Δ32/Δ32 homozygosity establishes a formidable natural barrier to R5-tropic HIV reinfection by eliminating the essential coreceptor required for viral entry. The successful application of CCR5Δ32/Δ32 hematopoietic stem cell transplantation has provided both a proof-of-concept for HIV cure and a roadmap for developing more scalable approaches through gene editing. Current research focuses on achieving high-frequency CCR5 disruption in autologous HSPCs, precise monitoring of the residual viral reservoir, and developing combinatorial strategies that address the challenges of coreceptor switching and latent reservoir persistence. As these technologies mature, they hold the potential to transform the CCR5Δ32 natural resistance phenomenon into a widely applicable curative intervention for HIV.

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a cornerstone intervention for treating hematologic malignancies and, unexpectedly, a powerful model for achieving HIV-1 remission or cure. The graft-versus-leukemia (GvL) effect, a well-established immunotherapeutic principle in oncology, has a critical parallel in HIV research: the graft-versus-reservoir (GvR) effect. This in-depth technical guide synthesizes current evidence, defining the GvR effect as the targeted elimination of the latent HIV reservoir by allogeneic immune cells from the transplant donor. We detail the cellular mechanisms, present key clinical and preclinical evidence, standardize methodologies for reservoir monitoring, and provide a toolkit of essential reagents, framing these findings within the broader context of HIV cure strategies after CCR5Δ32/Δ32 HSCT.

1 Introduction: From Graft-versus-Leukemia to Graft-versus-Reservoir

The latent reservoir of HIV-1, primarily composed of resting CD4+ T cells harboring replication-competent provirus, is the principal barrier to cure [10]. Allo-HSCT, a procedure designed to reconstitute a patient's immune system with that of a donor, has led to the only documented cases of HIV-1 cure [11] [12] [13]. Initially, the curative mechanism was attributed almost exclusively to the replacement of susceptible host CD4+ T cells with those bearing the CCR5Δ32/Δ32 mutation, conferring innate resistance to CCR5-tropic HIV-1 [11]. However, emerging evidence from clinical cases and animal models demonstrates that the conditioning regimen alone is insufficient for reservoir clearance and that allogeneic immunity is the major driver [14] [15] [16].

The GvR effect is a specific application of the broader graft-versus-tumor (GvT) effect, where donor-derived immune cells recognize and eliminate recipient cells [17]. In the context of HIV, this alloreactivity is fortuitously directed against host cells that harbor the latent viral reservoir. This effect is closely linked to, but conceptually separable from, graft-versus-host disease (GvHD), wherein alloreactivity causes pathology by attacking healthy host tissues [17] [18]. The challenge and goal of current research are to harness the beneficial GvR effect while minimizing detrimental GvHD.

2 Mechanisms of the Graft-versus-Reservoir Effect

The GvR effect is mediated by a complex interplay of donor-derived immune cells that recognize and clear residual recipient cells, including those latently infected with HIV.

2.1 Effector Cells and Pathways

The primary cellular mediators of the GvR effect are donor T cells and natural killer (NK) cells. The logical flow of reservoir clearance involves a series of critical steps, from engraftment to targeted elimination.

Figure 1: Logical Workflow of the GvR Effect. The process initiates with transplant and engraftment, leading to allorecognition and effector cell activation, which can result in the beneficial GvR effect and/or the pathological GvHD.

• Cytotoxic T Lymphocytes (CTLs): Donor-derived CD8+ CTLs are considered the primary mediators of GvR. They recognize recipient-specific alloantigens, such as minor histocompatibility antigens (miHAs) or HLA disparities, presented on the surface of host cells [17]. Upon recognition, CTLs initiate killing of target cells through perforin-granzyme pathways and Fas/FasL interactions. Evidence suggests these cells can also recognize and eliminate latently infected cells, even in the absence of active viral gene expression, likely through miHA recognition [17] [16].
• Natural Killer (NK) Cells: NK cells contribute to GvR, particularly in T-cell-depleted or haploidentical transplants [17]. Their activity is regulated by killer-cell immunoglobulin-like receptors (KIRs) interacting with host HLA class I molecules. "Alloreactive" NK cells emerge when donor KIRs do not recognize the recipient's HLA, leading to the killing of host cells, including reservoir-harboring CD4+ T cells [17] [18]. This mechanism is independent of viral antigen recognition.

2.2 The Role of CCR5Δ32/Δ32 and Full Donor Chimerism

The establishment of full donor chimerism—where nearly 100% of hematopoietic cells are of donor origin—is a key determinant for profound reservoir reduction and is a prerequisite for sustained HIV remission [15] [19]. The CCR5Δ32/Δ32 genotype in donor cells provides a critical layer of protection by rendering the new immune system highly resistant to infection by CCR5-tropic HIV, which constitutes the vast majority of rebounding virus [11] [13]. This creates a favorable environment where the GvR effect can eliminate the reservoir, and any residual virus that reactivates cannot efficiently infect the new, resistant CD4+ T cells. However, the case of the "Geneva patient," who achieved sustained remission after transplantation with wild-type CCR5 donor cells, provides compelling evidence that a potent GvR effect alone can be sufficient for cure, even in the absence of CCR5 ablation [15] [19].

3 Evidence Base: Clinical and Preclinical Findings

3.1 Quantitative Data from Key Studies Table 1: Summary of Quantitative Data on Reservoir Clearance Post-Allo-HSCT

Study / Patient Case	Donor CCR5 Status	Reservoir Reduction (Assay)	Time Post-ATI without Rebound	Key GvR Evidence
Düsseldorf Patient [12]	CCR5Δ32/Δ32	HIV DNA undetectable (ddPCR, QVOA); No virus in humanized mice	>48 months	Loss of HIV-specific Abs & T cells; sporadic traces of HIV DNA but no replication-competent virus.
Geneva Patient [19]	Wild-type	HIV DNA largely undetectable; No replication-competent virus in QVOA	>32 months	Sustained remission with wild-type CCR5 donor, demonstrating potency of GvR alone.
Wu et al. (NHP Model) [14]	Wild-type	SIV DNA cleared in blood, peripheral & mesenteric LNs	>2.5 years (in 2/4 animals)	Direct evidence that allogeneic immunity is the major driver of reservoir clearance.
London Patient [11]	CCR5Δ32/Δ32	HIV DNA undetectable in CD4+ T cells; QVOA negative	>18 months (at publication)	No CCR5 expression on CD4+ cells; resistant to R5-tropic virus ex vivo.
Mixed-Race Woman [13]	CCR5Δ32/Δ32	No detectable HIV-1 DNA/RNA; loss of Ab response	>18 months	100% cord blood chimerism by week 14; no detectable replication-competent virus.

3.2 Insights from Non-Human Primate Models

A pivotal study by Wu et al. provides the most direct experimental evidence for the GvR effect [14]. SIV-infected, ART-suppressed Mauritian cynomolgus macaques underwent MHC-matched allo-HSCT with CCR5 wild-type donor cells. The study demonstrated that allogeneic immunity was the major driver of reservoir clearance, which occurred sequentially from peripheral blood to lymph nodes. Crucially, two of the four transplant recipients maintained aviremia for over 2.5 years after ART interruption, despite their reconstituted immune systems being fully susceptible to SIV, proving that an immune-mediated cure is possible without CCR5 disruption [14].

4 Monitoring the GvR Effect: Experimental Protocols and Assays

Rigorous monitoring of the HIV reservoir and immune reconstitution is essential for evaluating the GvR effect. The following are standardized protocols for key assays.

4.1 Reservoir Quantification Assays

A. Quantitative Viral Outgrowth Assay (QVOA)

• Objective: To quantify the frequency of resting CD4+ T cells harbarding replication-competent HIV.
• Workflow:

Figure 2: Experimental Workflow for QVOA. This assay provides a minimal estimate of the replication-competent reservoir by physically activating latently infected cells to produce virus.

• Procedure:
  • Cell Isolation: Resting CD4+ T cells are negatively selected from patient PBMCs using magnetic bead kits [11] [12].
  • Limit Dilution & Activation: Cells are serially diluted and activated using mitogens like phytohemagglutinin (PHA) and interleukin-2 (IL-2) to induce viral production [16].
  • Co-culture: Activated cells are co-cultured with CD8-depleted PBMCs from healthy donors (feeder cells) to amplify any released virus.
  • Virus Detection: Culture supernatants are tested periodically (e.g., days 7, 14, 21) for HIV p24 antigen by ELISA.
  • Calculation: The frequency of latently infected cells is calculated using statistical models (e.g, maximum likelihood) and reported as Infectious Units per Million (IUPM) cells [11] [12]. A result of "negative" is reported as below the limit of detection (e.g., <0.063 IUPM [12]).

B. Intact Proviral DNA Assay (IPDA)

• Objective: To precisely quantify the genetically intact (and thus potentially replication-competent) proviruses, distinguishing them from the vast majority of defective provinces.
• Procedure:
  • DNA Extraction: Genomic DNA is extracted from PBMCs or CD4+ T cells.
  • Droplet Digital PCR (ddPCR): The DNA is partitioned into thousands of nanodroplets. Each droplet undergoes a multiplex PCR reaction with two probe sets: one targeting the HIV packaging signal (Ψ) and another targeting the Rev-Responsive Element (RRE), regions frequently mutated in defective viruses [12].
  • Analysis: Droplets are analyzed for fluorescence. Proviruses positive for both Ψ and RRE are scored as "intact." The result is reported as intact proviral copies per million cells. This assay often shows a >100-fold lower count than total HIV DNA assays, providing a more accurate reservoir measure [12].

4.2 Monitoring Immune Reconstitution and Chimerism

A. Donor Chimerism Analysis

• Method: Quantitative PCR (qPCR) targeting informative single nucleotide polymorphisms (SNPs) or short tandem repeats (STRs) that differ between donor and recipient.
• Application: Performed on total PBMCs or specific cell subsets (T cells, B cells, granulocytes). Achieving >95% donor chimerism in CD3+ T cells is strongly associated with reservoir reduction and is a critical parameter for considering ART interruption [15] [19].

B. HIV-Specific Immune Responses

• Methods:
  • ELISpot: Measures IFN-γ production by T cells in response to HIV peptide pools (Gag, Pol, Nef) [12].
  • Intracellular Cytokine Staining (ICS): Flow cytometry-based assay to characterize HIV-specific CD4+ and CD8+ T cells (producing IFN-γ, TNF-α, IL-2) [12].
• Interpretation: A progressive decline and eventual loss of HIV-specific antibody levels and T-cell responses are strong indicators of absent antigen stimulation and successful reservoir clearance, as observed in cured individuals [11] [12].

5 The Scientist's Toolkit: Essential Research Reagents Table 2: Key Reagent Solutions for Investigating the GvR Effect

Research Reagent / Tool	Primary Function in GvR Research	Specific Examples & Applications
CD4+ T Cell Isolation Kits	Isolation of target reservoir cells from patient blood and tissue samples.	Negative selection magnetic bead kits (e.g., Miltenyi Biotec) to purify resting CD4+ T cells for QVOA and DNA analysis [12].
PCR/Digital PCR Assays	Quantification of total/infectious HIV reservoir size and donor chimerism.	ddPCR for IPDA; qPCR for total HIV DNA and chimerism analysis [11] [19] [12].
Cell Culture & Activation Reagents	In vitro reservoir activation and immune cell expansion.	PHA, IL-2, and anti-CD3/CD28 beads for T-cell activation in QVOA and T-cell expansion assays [16] [12].
Flow Cytometry Antibodies	Immunophenotyping of immune reconstitution and analysis of specific cell populations.	Antibodies against CD3, CD4, CD8, CD45, CD56, CCR5, and activation markers (HLA-DR, CD38) [19] [12].
Humanized Mouse Models	In vivo assessment of replication-competent virus via outgrowth assay.	NSG or BLT mice injected with patient cells; used to validate the absence of infectious virus when in vitro assays are negative [12].
Cytokine/Kits	Measurement of soluble inflammatory mediators and immune activation.	Multiplex bead arrays (e.g., Luminex) to profile plasma cytokines; ELISA for p24 antigen detection in QVOA [14] [12].

6 Conclusion and Future Directions

The GvR effect represents one of the most powerful, albeit rare and high-risk, proofs-of-concept that the latent HIV reservoir can be completely cleared, leading to a cure. The evidence is clear that allogeneic immunity is a primary driver of this clearance, a mechanism that can function independently of, but is reinforced by, CCR5 deficiency. The challenge now is to translate this knowledge into safer, scalable curative strategies for the broader population of people living with HIV. Future research must focus on identifying the specific antigenic targets of the GvR effect, potentially leading to targeted immunotherapies that can mimic this allogeneic response without requiring a full transplant. Furthermore, optimizing conditioning regimens and immunosuppressive drugs (like ruxolitinib, used in the Geneva patient [19]) to favor GvR over GvHD will be crucial. The insights gained from these rare cases of cure continue to illuminate the path toward a universally applicable HIV-1 cure.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a pivotal intervention for achieving HIV-1 remission and cure in individuals with concomitant hematological malignancies. This technical guide elucidates the critical roles of pre-transplant conditioning regimens and the establishment of donor chimerism in reducing the persistent HIV-1 reservoir. Conditioning chemotherapy and radiotherapy are instrumental in ablating recipient immune cells, including those harboring latent HIV-1, while simultaneously creating space for donor engraftment. Subsequent establishment of full donor chimerism enables a graft-versus-reservoir effect, wherein donor-derived immune cells target and eliminate residual HIV-1 infected cells. Supported by clinical evidence from documented cases of HIV-1 cure, this review details the mechanistic basis, monitoring methodologies, and quantitative impacts of these processes on viral reservoir dynamics, providing a comprehensive framework for researchers and drug development professionals engaged in HIV-1 cure strategies.

The persistence of replication-competent HIV-1 proviral DNA within cellular reservoirs during suppressive antiretroviral therapy (ART) remains the principal barrier to achieving a cure for HIV-1 infection [20]. Allogeneic hematopoietic stem cell transplantation (allo-HSCT), primarily administered for treating hematological cancers, has emerged as the only intervention to date that has consistently led to sustained HIV-1 remission and cure, as evidenced in several reported cases including the Berlin, London, Düsseldorf, and Geneva patients [12] [19] [15]. The procedure's efficacy in reducing the viral reservoir is attributed to two interconnected biological processes: the conditioning regimen and the establishment of donor chimerism.

The conditioning regimen, involving chemotherapy and/or radiotherapy, serves a dual purpose: eradicating malignant cells and eliminating a significant proportion of the recipient's HIV-1 susceptible and infected CD4+ T-cells [15]. Following this cytoreduction, the infusion of donor hematopoietic stem cells repopulates the immune system. The degree to which donor cells replace the recipient's immune system, quantified as donor chimerism, is critical. Achieving high levels of donor chimerism, particularly within T-cell subsets, is strongly associated with a powerful graft-versus-reservoir (GvR) effect, whereby donor-derived allogeneic immunity recognizes and clears residual infected cells that survived the conditioning regimen [15]. This guide provides an in-depth technical examination of these components, their interplay, and their collective role in depleting the HIV-1 reservoir.

Conditioning Regimens: Mechanisms and Protocols

Objectives and Mechanisms of Action

Conditioning regimens administered prior to HSCT are designed to create a foundational environment for successful reservoir reduction through three primary mechanisms:

• Myeloablation and Lymphodepletion: The intensive chemotherapy and/or radiotherapy systemically ablate the bone marrow, eliminating a substantial fraction of recipient-derived CD4+ T cells, which constitute the primary reservoir for HIV-1 [15] [20]. This direct cytoreduction directly diminishes the number of cells harboring integrated provirus.
• Creation of "Space" for Donor Engraftment: By clearing the host's hematopoietic niche, the conditioning regimen creates the necessary physiological space for the infused donor stem cells to engraft and initiate reconstitution of a new, donor-derived immune system [15].
• Prevention of Graft Rejection: The profound suppression of the host immune system is crucial to prevent immunological rejection of the donor graft, thereby ensuring the long-term persistence and function of the new immune cells [21].

Common Regimens in HIV-1 Cure Cases

The specific conditioning protocols vary based on the patient's malignancy, age, and comorbidities. The table below summarizes the regimens used in several prominent cases of HIV-1 remission or cure.

Table 1: Conditioning Regimens in Documented HIV-1 Remission/Cure Cases

Patient Case	Underlying Malignancy	Conditioning Regimen	Donor CCR5 Status	Reference
IciStem No. 19	Acute Myeloid Leukemia	Fludarabine, Treosulfan, Anti-thymocyte Globulin	CCR5Δ32/Δ32	[12]
Geneva Patient	Myeloid Sarcoma	Clofarabine, Cyclophosphamide, Fludarabine, Total Body Irradiation (8 Gy)	Wild-type	[19]
Mixed-Race Woman	Acute Myeloid Leukemia	Not Specified in Excerpt	CCR5Δ32/Δ32	[13]
Referenced Cohort	Various Hematological Malignancies	Fludarabine + Busulfan	Mixed	[21]

Reduced-intensity conditioning (RIC) regimens, such as fludarabine-based protocols, are frequently employed to minimize treatment-related mortality, particularly in older patients or those with comorbidities [21]. While RIC is less toxic, its association with a higher risk of disease and reservoir relapse underscores the necessity of a potent graft-versus-reservoir effect for successful viral eradication [21].

Donor Chimerism: Monitoring and Significance

Definition and Measurement

Donor chimerism refers to the proportion of donor-derived hematopoietic and immune cells in the recipient's body post-transplant. It is a critical quantitative metric for assessing engraftment success and is typically measured using short tandem repeat (STR) analysis on peripheral blood or bone marrow samples [21]. Chimerism can be assessed in whole blood (WB) or within specific immune cell subsets, most importantly T-cells (CD3+).

Chimerism as a Predictive Biomarker

Early measurement of donor chimerism, particularly at day 30 post-transplant, has proven to be a powerful predictive biomarker for clinical outcomes. Landmark analyses demonstrate that low early chimerism levels are significantly associated with an increased risk of disease relapse and poorer survival.

Table 2: Predictive Value of Day-30 Donor Chimerism Levels on Clinical Outcomes

Outcome Measure	Chimerism Type	Hazard Ratio (HR)	P-value	Statistical Analysis
Relapse	Whole Blood	HR=0.90	p<0.001	Multivariate Analysis
Relapse	T-cell	HR=0.97	p=0.002	Multivariate Analysis
Relapse-Free Survival	Whole Blood	HR=0.89	p<0.001	Multivariate Analysis
Relapse-Free Survival	T-cell	HR=0.97	p<0.001	Multivariate Analysis
Overall Survival	Whole Blood	HR=0.94	p=0.01	Multivariate Analysis
Overall Survival	T-cell	HR=0.99	p=0.05	Multivariate Analysis

Data adapted from a cohort study of 121 patients who underwent RIC HSCT [21]. The analyses treated chimerism levels as continuous variables. Lower HR values indicate a protective effect of higher chimerism.

Studies indicate that T-cell chimerism often provides a more sensitive and superior predictive value for relapse and survival compared to whole blood chimerism [21]. This is logically consistent with the central role of T-cells in mediating the graft-versus-leukemia and graft-versus-reservoir effects.

The Concept of Full Donor Chimerism

Full donor chimerism, defined as the near-complete replacement (≥95%) of recipient hematopoietic cells with donor-derived cells, is a cornerstone for achieving HIV-1 cure. The IciStem consortium has reported that the most dramatic reduction in the HIV-1 reservoir occurs after full donor chimerism is established [15]. The relationship between conditioning, chimerism, and reservoir reduction can be conceptualized as follows:

Synergistic Reservoir Reduction: Conditioning and Graft-versus-Reservoir Effect

The combination of the conditioning regimen and the subsequent graft-versus-reservoir effect leads to a dramatic depletion of the HIV-1 reservoir, with kinetics far exceeding the natural decay observed under ART alone.

Quantitative Assessment of Reservoir Decay

Post-allo-HSCT, the half-life of the HIV-1 reservoir is drastically reduced. The IciStem consortium reported a reservoir half-life of only several months post-transplant, a stark contrast to the ~44-month half-life estimated during long-term ART [15] [20]. This accelerated decay is dependent on achieving full donor chimerism and is comparable regardless of whether the donor cells are CCR5Δ32/Δ32 or wild-type, highlighting the critical role of alloreactivity [15]. The following workflow outlines the key experimental steps for confirming reservoir reduction in a research setting:

Monitoring for HIV-1 Remission

Confirming HIV-1 remission requires a multifaceted assay approach to probe for any residual replication-competent virus. Key methodologies include:

• Ex vivo Quantitative and In vivo Outgrowth Assays: These assays are the gold standard for detecting replication-competent virus. CD4+ T cells from the patient are stimulated ex vivo (QVOA) or injected into immunodeficient mice to amplify any latent virus. Consistent failure to recover replication-competent virus is a strong indicator of reservoir elimination [12] [19].
• Intact Proviral DNA Assay (IPDA): A droplet digital PCR (ddPCR)-based method that discriminates between genetically intact and defective proviruses. A decline and eventual absence of intact proviruses supports the case for cure [19] [20].
• HIV-1-Specific Immune Responses: The waning and eventual loss of HIV-1-specific antibody levels and T-cell responses indicate a lack of ongoing antigenic stimulation, providing indirect evidence for the absence of a replicating reservoir [12] [19].

The Scientist's Toolkit: Key Reagents and Assays

Table 3: Essential Research Reagents and Assays for Monitoring Post-HSCT Outcomes

Tool/Reagent	Primary Function	Technical Application
Short Tandem Repeat (STR) Kits	Quantify donor vs. recipient DNA	Measurement of donor chimerism in whole blood or sorted cell subsets (e.g., CD3+ T-cells).
Anti-CD3 Magnetic Beads	Immunomagnetic selection of T-cells	Isolation of pure T-cell populations for subset-specific chimerism analysis.
Droplet Digital PCR (ddPCR) Systems	Absolute quantification of nucleic acids	Precise measurement of HIV-1 DNA levels and application of the Intact Proviral DNA Assay (IPDA).
In situ Hybridization Assays (RNAscope/DNAscope)	Visualize HIV-1 RNA/DNA in tissue sections	Detection and spatial localization of rare, residual HIV-1 nucleic acids in tissue reservoirs (e.g., lymph nodes, gut).
Quantitative Viral Outgrowth Assay (QVOA) Components	Induce and measure latent virus	Includes mitogens (PHA), IL-2, and target cells to activate and expand replication-competent virus from patient CD4+ T cells.
MHC Tetramers / ELISpot Kits	Detect antigen-specific T-cells	Monitoring the frequency and function of HIV-1-specific T-cell responses post-transplant.

Conditioning regimens and the establishment of donor chimerism are interdependent pillars in the reduction of the HIV-1 reservoir following allo-HSCT. The conditioning regimen initiates the process by forcefully depleting the recipient's immune system, creating the conditions for donor cell engraftment. The subsequent achievement of full donor chimerism, particularly within the T-cell lineage, enables a critical graft-versus-reservoir effect that clears residual infected cells. This synergistic relationship results in a rapid, orders-of-magnitude decline in the viral reservoir, creating the possibility for sustained ART-free remission and cure.

While allo-HSCT is not a scalable cure for the global population of people living with HIV-1 due to its inherent risks and complexities, the insights gleaned from these cases are profound. They provide definitive proof-of-concept that a cure is achievable and illuminate the fundamental immunological mechanisms required to eliminate the persistent reservoir. These principles are now guiding the development of safer, more accessible curative strategies, including gene therapies that recapitulate CCR5 deficiency and immunotherapies designed to harness a targeted graft-versus-reservoir effect without the need for full transplantation.

Allogeneic hematopoietic stem cell transplantation (HSCT) using stem cells from donors with a homozygous CCR5Δ32 mutation has led to sustained HIV-1 remission in a small number of individuals, providing critical insights for cure research. The CCR5 coreceptor is essential for most HIV-1 variants to enter host CD4+ T-cells; the Δ32 mutation results in a truncated protein that is not expressed on the cell surface, conferring natural resistance to R5-tropic HIV-1 infection [11]. This scientific overview details the patient profiles, experimental methodologies, and key virological and immunological findings from the Berlin, London, and Düsseldorf cases, which represent milestones in the pursuit of an HIV cure.

Clinical Case Profiles and Outcomes

The Berlin, London, and Düsseldorf patients underwent CCR5Δ32/Δ32 HSCT primarily to treat hematological malignancies. Their subsequent sustained HIV remission off antiretroviral therapy (ART) provides a unique opportunity for comparative analysis.

Table 1: Clinical Profiles of Patients with Sustained HIV Remission

Parameter	Berlin Patient	London Patient	Düsseldorf Patient
Primary Malignancy	Acute Myeloid Leukemia	Refractory Hodgkin's Lymphoma	Acute Myeloid Leukemia
Conditioning Regimen	Total Body Irradiation (x2), Chemotherapy	Reduced-Intensity Chemotherapy	Reduced-Intensity Chemotherapy (Fludarabine, Treosulfan)
HSCT Details	Two allogeneic CCR5Δ32/Δ32 HSCTs	Single allogeneic CCR5Δ32/Δ32 HSCT	Single allogeneic CCR5Δ32/Δ32 HSCT
GvHD	Present	Mild Gut GvHD	Mild Chronic Ocular GvHD
ART Cessation	Post-HSCT	16 months post-HSCT	69 months post-HSCT
Remission Duration	>10 years until death	>30 months post-ATI	>48 months post-ATI
Key Evidence of Cure	No detectable replication-competent virus, loss of HIV-specific immune responses	No replication-competent virus in blood, CSF, semen, gut, lymphoid tissue; mathematical model predicts >99% probability of cure [22]	No replication-competent virus in QVOA & humanized mouse models; waning HIV-specific immunity [12]

Table 2: Virological and Immunological Monitoring Post-ATI

Assay Type	London Patient Findings	Düsseldorf Patient Findings
Ultrasensitive Viral Load (Plasma)	Undetectable (<1 copy/mL) at 30 months [22]	Undetectable at 48 months [12]
Total Cell-Associated HIV DNA	Very low-level signal in peripheral CD4 memory cells at 28 months; negative in gut and lymph node tissue by ddPCR [22]	Sporadic traces detected by ddPCR and in situ hybridization, but levels higher than HIV-negative controls [12]
Intact Proviral DNA Assay (IPDA)	Negative in lymph node tissue [22]	Not detected [12]
Quantitative Viral Outgrowth Assay (QVOA)	Not performed post-ATI; pre-ATI showed no reactivatable virus [11]	Negative in repeated assays [12]
In Vivo Outgrowth (Humanized Mice)	Not Reported	Negative in two different mouse models [12]
HIV-Specific T-cell Responses	Absent at 27 months [22]	Waned and not detected in most recent samples [12]
HIV-Specific Antibodies	Low-avidity Env antibodies continued to decline [22]	Progressive loss of antibody responses [12]

Core Experimental Protocols for Reservoir Analysis

Monitoring HIV remission requires a multi-faceted assay approach to detect any residual replication-competent virus. The following methodologies are critical.

Droplet Digital PCR (ddPCR) for HIV DNA Quantification

Function: This highly sensitive technique precisely quantifies low levels of HIV DNA in patient cells, crucial for assessing reservoir size reduction post-HSCT [22] [12].

Detailed Protocol:

• DNA Extraction: Isolate genomic DNA from patient cells (e.g., peripheral blood mononuclear cells (PBMCs), purified CD4+ T-cells, or tissue biopsy homogenates) using a commercial kit (e.g., DNeasy Blood and Tissue Kit, Qiagen).
• Target Selection: Design ddPCR assays to amplify specific regions of the HIV genome, such as the long terminal repeat (LTR), gag, or integrase. A human reference gene (e.g., RPP30) is simultaneously targeted to quantify the input cell number.
• Droplet Generation: The PCR reaction mixture, containing DNA, primers, probes, and ddPCR supermix, is partitioned into ~20,000 nanoliter-sized droplets.
• Endpoint PCR: The droplets undergo thermal cycling.
• Droplet Reading and Analysis: A droplet reader counts the number of fluorescence-positive and negative droplets for each target. Poisson statistics are applied to determine the absolute copy number of the HIV target per million cells [22].

Intact Proviral DNA Assay (IPDA)

Function: The IPDA distinguishes genetically intact HIV proviruses from the far more abundant defective proviruses, providing a more accurate measure of the rebounding competent reservoir [22] [23].

Detailed Protocol:

• Multiplex ddPCR: A duplex ddPCR reaction is performed that simultaneously targets two regions of the HIV genome essential for replication: the packaging signal (ψ) and the Rev response element (RRE) within the env gene.
• Identification of Intact Proviruses: Proviruses that are positive for both ψ and RRE signals are scored as "intact." Probes are also designed to identify hypermutated or otherwise defective sequences.
• Data Correction: The proportion of proviruses with a sheared DNA template is assessed by measuring the RPP30 reference gene and used to correct the final count of intact provinces [22] [23].

Quantitative Viral Outgrowth Assay (QVOA)

Function: This is the "gold standard" functional assay for estimating the frequency of resting CD4+ T-cells that harbor replication-competent HIV.

Detailed Protocol:

• Cell Isolation: Resting CD4+ T-cells are purified from patient PBMCs.
• Limiting Dilution and Activation: The cells are serially diluted and cultured in replicate. A key step is the activation of the cells using mitogens (e.g., PHA) and mixed leukocyte reaction (MLR) to induce viral latency reversal.
• Co-culture: The activated patient CD4+ T-cells are co-cultured with CD8-depleted PBMCs from healthy donors, which act as amplification targets for any induced virus.
• Viral Detection: Culture supernatants are tested periodically (e.g., days 7, 14, 21) for HIV p24 antigen by ELISA.
• Statistical Analysis: The frequency of infectious units per million (IUPM) resting CD4+ T-cells is calculated using statistical models (e.g, IUPMStats v1.0) based on the pattern of positive and negative wells [11].

In Vivo Outgrowth Assays using Humanized Mice

Function: This highly sensitive in vivo method tests for the presence of replication-competent virus by injecting patient cells into immunodeficient mice reconstituted with a human immune system.

Detailed Protocol:

• Mouse Reconstitution: Immunodeficient mice (e.g., NSG or BRG strains) are engrafted with human CD34+ hematopoietic stem cells or PBMCs to create a human-like immune system (humanized mice).
• Adoptive Cell Transfer: Patient-derived cells (e.g., PBMCs, tissue homogenates) are injected into these humanized mice.
• Long-Term Monitoring: The mice are monitored over several weeks to months without ART.
• Viral Rebound Assessment: Periodic blood samples are collected from the mice and tested for human CD4+ T-cell levels and for HIV RNA. The absence of viral rebound strongly indicates the lack of replication-competent virus in the patient sample [12].

Figure 1: Experimental workflow for comprehensive HIV reservoir analysis post-HSCT, integrating molecular, cellular, and in vivo assays.

Immunological Correlates of Cure

A common feature across these cure cases is the progressive decline of HIV-specific immune responses, suggesting a lack of antigenic stimulation.

Waning Adaptive Immunity

Both the London and Düsseldorf patients exhibited a marked decline in HIV-1-specific T-cell responses and antibody levels post-transplantation and after ART interruption [22] [12]. This is in stark contrast to persistent, strong responses to other pathogens like cytomegalovirus (CMV). The loss of HIV-specific adaptive immunity is a strong indirect indicator that the source of viral antigens has been eliminated.

Innate Immunity and the "Second Berlin Patient"

A recent case, the "Second Berlin Patient," provides novel immunological insights. This patient achieved sustained remission despite receiving a transplant from a donor who was heterozygous for CCR5Δ32 (CCR5 WT/Δ32), meaning the new immune cells remained susceptible to HIV infection [24]. Research presented at EACS 2025 revealed that his cure was associated with an unusual innate immune response.

His natural killer (NK) cells, characterized by high expression of the NKG2A⁺ receptor, stimulated the production of highly potent antibodies. These antibodies excelled at antibody-dependent cellular cytotoxicity (ADCC), a process where antibodies tag infected cells for destruction by NK cells. This potent ADCC response, more effective than known broadly neutralizing antibodies, is believed to have cleared the residual HIV reservoir [25]. This highlights that for a cure, replacing the susceptible immune system with a resistant one may not be the only mechanism; a potent immune-mediated clearance of infected cells is a critical alternative pathway.

Figure 2: Proposed innate immune mechanism in the "Second Berlin Patient," where NK cells drive a potent antibody response that clears infected cells via ADCC.

The Scientist's Toolkit: Key Research Reagents

Table 3: Essential Research Reagents for HIV Reservoir Studies

Reagent / Assay	Primary Function	Specific Example / Target
ddPCR Supermix & Probes	Absolute quantification of HIV DNA targets without a standard curve.	Bio-Rad ddPCR system; targets: HIV LTR, gag, pol; reference gene RPP30 [22].
IPDA Primers/Probes	Multiplexed detection of intact vs. defective proviruses.	Probe 1: HIV Ψ site; Probe 2: RRE in env; hypermutation probe [22] [23].
T-cell Activation Reagents	Latency reversal in QVOA and T-cell stimulation assays.	Phytohemagglutinin (PHA), anti-CD3/CD28 antibodies [11].
Humanized Mouse Models	In vivo outgrowth assay for replication-competent virus.	Immunodeficient mice engrafted with human CD34+ cells (e.g., NSG mice) [12].
MHC Tetramers & Peptide Pools	Ex vivo detection and characterization of HIV-specific T-cells.	HLA-A*02-restricted RT-YV9 tetramer; overlapping Gag/Pol/Nef peptide pools [12].
Antibody Avidity Assays	Measurement of antibody maturation, which wanes without antigen.	Low-avidity Env antibody assays to monitor decline post-cure [22].

The cases of the Berlin, London, and Düsseldorf patients demonstrate that CCR5Δ32/Δ32 HSCT can lead to sustained HIV-1 remission, likely representing a cure. The collective evidence points to a multi-faceted mechanism: replacement of susceptible host cells with resistant ones, a potent graft-versus-reservoir effect that eliminates residual infected cells, and the contribution of unique immune responses, such as potent NK cell-mediated ADCC. The consistent observation of waning HIV-specific immunity across these cases is a critical biomarker for cured infection.

While HSCT itself is too risky and resource-intensive to be a widespread cure strategy, these patients provide an invaluable proof-of-concept. They validate CCR5 as a therapeutic target and underscore the importance of eliminating the viral reservoir, not just inducing latency. The insights gained are directly informing the development of safer, scalable strategies, such as gene editing to disrupt CCR5, therapeutic vaccination, and immune therapies designed to recapitulate the potent reservoir-clearing effects observed in these exceptional individuals [26] [27].

The pursuit of an HIV-1 cure achieved a pivotal milestone with the case of the "Geneva Patient" (IciS-34), who has maintained sustained HIV remission for 32 months after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with wild-type CCR5 donor cells and subsequent antiretroviral treatment (ART) interruption. This report provides an in-depth technical analysis of this case, which challenges the established paradigm that CCR5Δ32/Δ32 donor cells are strictly necessary for HIV cure through stem cell transplantation. We detail the virological and immunological methodologies employed to demonstrate remission, present quantitative evidence of reservoir reduction, and discuss the proposed mechanisms including alloimmune activity and the potential role of pharmacologic immunosuppression. The findings suggest that HIV remission may be achievable through alternative mechanisms that do not require CCR5 ablation, potentially expanding the therapeutic landscape for cure strategies.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been successfully used to induce long-term HIV remission in a limited number of individuals, primarily those receiving cells from donors with a homozygous CCR5Δ32 mutation [12] [28]. The absence of the CCR5 coreceptor in donor-derived cells provides a protective barrier against R5-tropic HIV-1 variants, which predominately establish infection [28]. This approach seemed essential for preventing viral rebound from residual reservoirs after ART interruption.

The case of the Geneva Patient (IciS-34) fundamentally challenges this assumption. This individual achieved sustained HIV remission for 32 months post-ART interruption after receiving a transplant from a donor with wild-type CCR5 [19] [29]. This unprecedented success suggests that alternative biological mechanisms, independent of CCR5 disruption, can effectively control HIV-1 replication and prevent viral rebound. This technical guide provides a comprehensive analysis of the experimental approaches and findings from this landmark case, situating it within the broader research on HIV reservoir monitoring after CCR5Δ32 hematopoietic stem cell transplantation.

Case Presentation and Clinical Timeline

The Geneva Patient is a 53-year-old male diagnosed with HIV-1 clade B in 1990 who commenced ART immediately after diagnosis [19]. Despite various ART regimens, the patient experienced periods of detectable viremia before achieving consistent viral suppression. In January 2018, he was diagnosed with a myeloid sarcoma with lymph node and bone marrow involvement [19].

Key clinical interventions and their timeline are summarized below:

In July 2018, the patient underwent allo-HSCT from an unrelated, HLA-matched (9/10) donor with wild-type CCR5 to treat the malignancy [19] [29]. The conditioning regimen consisted of clofarabine, cyclophosphamide, fludarabine, and total body irradiation (8 Gy). Full donor chimerism in both granulocytes and mononuclear cells was achieved within one month post-transplant, indicating complete replacement of the recipient's hematopoietic system with donor-derived cells [19].

The patient developed hepatic acute graft-versus-host disease (GvHD) 120 days post-HSCT, requiring treatment with corticosteroids and tacrolimus [19]. Subsequent GvHD flares led to the initiation of ruxolitinib (10 mg twice daily) in August 2019, which was maintained for chronic GvHD management [19]. ART was simplified over time and finally discontinued in November 2021 through a consensual treatment interruption [19]. As of the latest report, the patient has maintained an undetectable plasma viral load for 32 months post-ART interruption [19] [29].

Experimental Framework for HIV Cure Assessment

Virological Monitoring Protocols

Comprehensive virological assessments were performed using highly sensitive assays to detect any residual HIV-1 components.

3.1.1 Plasma Viral Load Testing

• Method: Ultrasensitive HIV-1 RNA assays with a limit of detection of <1 copy/mL [19]
• Frequency: Monthly testing after ART interruption [19]
• Protocol: Plasma samples were subjected to reverse transcription followed by digital droplet PCR (ddPCR) to precisely quantify HIV-1 RNA copies

3.1.2 Cell-Associated HIV DNA Quantification

• Sample Types: Peripheral blood mononuclear cells (PBMCs), purified CD4+ T cells, bone marrow cells [19]
• Extraction Method: DNA extracted using commercial kits (e.g., Qiagen AllPrep kit) [30]
• Quantification Assay: Real-time PCR targeting conserved LTR/gag regions, normalized to cell count using a conserved region of the CCR5 gene [30]
• Analysis: Testing performed in triplicate to ensure reproducibility [30]

3.1.3 Viral Outgrowth Assays

• In vitro culture: CD4+ T cells were co-cultured with stimulated healthy donor cells to amplify replication-competent virus [19] [12]
• In vivo xenotransplantation: CD4+ T cells from the patient were adoptively transferred into humanized mouse models (NSG mice) to detect latent, replication-competent reservoir [12]
• Readout: p24 antigen production in supernatant and viral RNA detection by RT-PCR [12]

Immunological Monitoring Protocols

3.2.1 HIV-Specific Antibody Responses

• Method: Immunoblot analysis to detect antibodies against HIV-1 antigens [12]
• Measurement: Quantitative assessment of antibody titer decline over time [19]

3.2.2 HIV-Specific T-Cell Responses

• IFN-γ ELISpot: Ex vivo response to overlapping peptide pools spanning HIV-1 Gag, Pol, and Nef [12]
• Intracellular Cytokine Staining: Flow cytometry-based detection of cytokine-producing T cells after peptide stimulation [12]
• MHC Tetramer Staining: Direct enumeration of T cells specific for known HIV-1 epitopes [12]

Key Experimental Findings

Virological Profile

Table 1: Summary of Virological Findings in the Geneva Patient

Parameter	Pre-Transplant	Post-Transplant (Pre-ATI)	Post-ART Interruption
Plasma HIV RNA	Detectable with historical viremia	Undetectable (<1 copy/mL)	Remained undetectable for 32+ months
Cell-Associated HIV DNA	457 copies/10^6 CD4+ T cells	Dramatically reduced to near undetectable levels	Only sporadic detection of defective provinces
Replication-Competent Virus	Not reported	Not detected in QVOA	Not detected in in vivo or in vitro outgrowth assays
HIV Antibodies	Present	Progressive decline in levels and functionality	Continued waning, suggesting absent antigen stimulation

Immunological Profile

Table 2: Summary of Immunological Findings in the Geneva Patient

Immune Parameter	Findings	Interpretation
T Cell Reconstitution	Incomplete with low CD4+ counts and inverted CD4/CD8 ratio	Typical post-HSCT pattern
HIV-Specific T Cells	Weak responses pre-ATI that declined further post-ATI	Lack of antigenic stimulation
HIV-Specific Antibodies	Progressive decline in levels and functionality	Absence of viral antigen production
NK Cell Profiles	Elevated frequencies with normal activation levels	Potential role in viral control
Alloimmune Responses	Documented GvHD requiring immunosuppression	Possible graft-versus-reservoir effect

Proposed Mechanisms for Remission

The surprising remission despite susceptible CCR5-expressing cells suggests multiple non-exclusive mechanisms may be at play:

5.1 Alloimmune Effects (Graft-versus-Reservoir) The observed graft-versus-host disease suggests vigorous alloreactive immune responses that may have concurrently targeted HIV-infected recipient cells [29]. Mathematical modeling from the IciStem consortium indicates that allogeneic immunity from donor cells serves as the primary reservoir depletion mechanism after the initial massive reduction from conditioning chemotherapy, reducing the half-life of latently infected cells from 44 months to just 1.5 months [31].

5.2 Conditioning Regimen Intensity The sequential conditioning regimen (clofarabine, cyclophosphamide, fludarabine, and total body irradiation) likely achieved substantial depletion of the viral reservoir by eliminating recipient hematopoietic cells, including those harboring HIV provirus [19].

5.3 Pharmacologic Actions of Ruxolitinib The JAK1/2 inhibitor ruxolitinib, administered for GvHD management, may provide an additional benefit through potential inhibition of HIV replication and prevention of reservoir reactivation, as suggested by in vitro studies [29].

5.4 Natural Killer Cell Activity Robust NK cell reconstitution post-transplant may contribute to the elimination of residual HIV-infected cells through innate immune mechanisms, providing continuous surveillance against viral rebound [29].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for HIV Reservoir Studies Post-HSCT

Reagent/Category	Specific Examples	Research Application
Nucleic Acid Extraction	Qiagen AllPrep DNA/RNA Kit	Simultaneous extraction of DNA and RNA from limited clinical samples
PCR Reagents	LTR/gag primer-probe sets, CCR5 reference gene assays	Quantification of HIV DNA and RNA with cellular normalization
Cell Culture Media	T-cell activation cytokines (IL-2, etc.)	Viral outgrowth assays to detect replication-competent virus
Flow Cytometry Antibodies	Anti-CD3, CD4, CD8, CD38, HLA-DR, CCR5	Immunophenotyping of immune reconstitution and activation markers
ELISpot Reagents	IFN-γ capture antibody, HIV peptide pools (Gag, Pol, Nef)	Detection of HIV-specific T-cell responses
Specialized Assays	DNAscope/RNAscope in situ hybridization probes	Spatial localization of HIV nucleic acids in tissue sections
Animal Models	Humanized mouse models (NSG, BLT)	In vivo viral outgrowth and reservoir studies

Discussion and Research Implications

The Geneva Patient case provides compelling evidence that CCR5Δ32/Δ32 donor cells are not an absolute requirement for HIV cure through allo-HSCT. This finding significantly expands our understanding of the mechanisms underlying HIV remission and suggests alternative pathways to achieving sustained virologic control.

The observation that wild-type CCR5 donor cells can lead to HIV remission has immediate implications for clinical practice. It effectively expands the potential donor pool for HIV-positive individuals requiring transplantation for hematological malignancies, as donors without the protective CCR5Δ32 mutation may now be considered viable options for achieving both cancer remission and HIV cure [29] [28].

From a research perspective, this case highlights the critical importance of alloimmune responses in targeting and eliminating the viral reservoir. The graft-versus-reservoir effect appears sufficiently potent to control or eliminate HIV despite the presence of target cells fully susceptible to infection [31]. This insight should guide the development of novel immunotherapeutic approaches that seek to recapitulate these effects without the risks associated with full transplantation.

Future research directions should include:

• Elucidating the precise mechanisms of the graft-versus-reservoir effect
• Optimizing conditioning regimens to maximize reservoir reduction
• Exploring the potential of JAK inhibitors and other immunomodulators as adjunctive therapies
• Developing safer approaches to harness alloimmunity for HIV cure

The Geneva Patient represents a paradigm shift in HIV cure research, demonstrating that sustained remission is achievable without CCR5-protected donor cells. The comprehensive virological and immunological profiling of this case provides strong evidence for alternative mechanisms of HIV control, primarily mediated through alloimmune effects. These findings open promising new avenues for therapeutic development that focus on harnessing immune mechanisms rather than relying solely on CCR5 ablation. As research continues to unravel the complex interplay between transplantation immunology and HIV persistence, the insights gained from this case will undoubtedly inform the next generation of cure strategies.

Advanced Assays and Biomarkers: A Toolkit for Reservoir Monitoring

Ultrasensitive qPCR/ddPCR for HIV DNA in Blood and Tissues

The quantification of persistent HIV DNA reservoirs in blood and tissues represents a critical technical challenge in the evaluation of curative strategies, particularly following transformative interventions such as CCR5Δ32 hematopoietic stem cell transplantation (allo-HSCT). The establishment of the latent HIV reservoir primarily in CD4+ T cells remains the principal barrier to cure, as these cells harbor integrated proviral DNA that persists despite long-term antiretroviral therapy (ART) [7]. Following allo-HSCT, the accurate measurement of dramatically reduced reservoir sizes requires exceptional analytical sensitivity and precision, pushing the limits of conventional molecular detection methods [15] [19].

Digital PCR (dPCR) has emerged as a third-generation PCR technology capable of absolute nucleic acid quantification without calibration curves, offering significant advantages for HIV reservoir monitoring in the context of transplantation research [32] [7]. By partitioning a PCR reaction into thousands of individual reactions, dPCR enables single-molecule detection and counting, providing the sensitivity necessary to characterize the minimal residual HIV DNA that may persist after intensive conditioning regimens and donor cell engraftment [32]. This technical guide provides researchers with comprehensive methodologies for implementing ultrasensitive dPCR assays to monitor HIV DNA in blood and tissues within transplantation studies, with particular emphasis on applications in CCR5Δ32 allo-HSCT research.

Technological Foundations of dPCR for HIV Reservoir Quantification

Principles of Digital PCR and Droplet Digital PCR

Digital PCR operates on a simple yet powerful principle: limiting dilution of nucleic acid templates across thousands of partitions, end-point amplification, and binary counting of positive versus negative reactions [32]. The fraction of negative partitions follows Poisson statistics, enabling absolute quantification of target molecules without reference to standards [32]. Two primary dPCR platform types have been developed: droplet-based systems (ddPCR) that encapsulate samples in water-in-oil emulsions, and microchamber-based systems (pdPCR) that utilize nanoscale wells on chips [32] [7]. The fundamental workflow encompasses four critical steps: (1) partitionment of the PCR mixture containing the sample into thousands of compartments; (2) PCR amplification to endpoint; (3) fluorescence analysis of each partition; and (4) Poisson statistical calculation of target concentration based on the fraction of positive partitions [32].

Comparative Advantages Over qPCR for HIV Reservoir Monitoring

In the context of HIV reservoir quantification, dPCR offers several distinct advantages over quantitative PCR (qPCR). dPCR provides absolute quantification without standard curves, eliminating potential variability introduced by external standards and offering superior accuracy at low target concentrations [7] [33]. The technology demonstrates enhanced resistance to PCR inhibitors, a valuable characteristic when analyzing complex biological matrices like tissue samples [7]. Furthermore, dPCR exhibits greater precision for detecting rare targets and improved sensitivity for quantifying the minimal residual HIV DNA typically observed in allo-HSCT recipients [7] [33]. These technical advantages make dPCR particularly suited for monitoring the dramatic reservoir reductions following transplantation, where accurate measurement of low-abundance targets is essential for evaluating intervention efficacy [19].

Figure 1: Digital PCR Workflow and Platform Options. The dPCR process involves sample partitioning, endpoint amplification, fluorescence detection, and statistical analysis. Two main partitioning methods are available: droplet-based (ddPCR) and microchamber-based (pdPCR) systems.

Experimental Protocols for HIV DNA Quantification

Duplex dPCR Assay for Total HIV DNA Reservoir Quantification

A robust duplex digital PCR assay for simultaneous quantification of total HIV DNA and a reference human gene has been successfully implemented on the Absolute Q dPCR platform, providing a complete methodology for reservoir assessment in clinical samples [7]. The assay targets the HIV LTR-RU5 region and the human RPP30 gene as a cellular control, enabling normalized reporting of HIV DNA copies per million cells.

Sample Preparation and DNA Extraction:

• Isolate peripheral blood mononuclear cells (PBMCs) or CD4+ T cells from fresh or cryopreserved blood samples using standard Ficoll density gradient centrifugation.
• Extract genomic DNA using commercial kits (e.g., AllPrep DNA/RNA Mini kit, Qiagen) with elution in low-EDTA TE buffer or nuclease-free water.
• Quantify DNA concentration using fluorometric methods and adjust to working concentrations of 10-50 ng/μL for dPCR analysis.
• For tissue samples, mechanical disruption followed by proteinase K digestion is recommended prior to nucleic acid extraction.

Primer and Probe Design:

• HIV-1 LTR-RU5 Target: Forward primer: 5'-GCCTCAATAAAGCTTGCCTTGA-3', Reverse primer: 5'-GGCGCCACTGCTAGAGATTTT-3', Probe: 5'-[FAM]AAATCTCTAGCAGTGGCGCCCGAACAG-[BHQ1]-3'
• RPP30 Reference Gene: Forward primer: 5'-AGATTTGGACCTGCGAGCG-3', Reverse primer: 5'-GAGCGGCTGTCTCCACAAGT-3', Probe: 5'-[VIC]TTCTGACCTGAAGGCTCT-[BHQ1]-3'
• Final optimized concentrations: 900 nM for each primer, 250 nM for each probe

dPCR Reaction Setup and Thermal Cycling:

• Prepare 40 μL reaction mixtures containing 10 μL 4× QIAcuity Probe PCR Master Mix, 900 nM each primer, 250 nM each probe, and DNA template (recommended input: 165-330 ng total DNA).
• Load reactions onto 26k 24-well Nanoplates and partition using the Standard Priming Profile.
• Perform amplification with the following conditions: enzyme activation for 2 min at 95°C; 45 cycles of 15 s at 95°C and 30 s at 59°C; final hold at 4°C.
• Image partitions with 400 ms (FAM) and 300 ms (VIC) exposure times, with gain set to 6 for both channels.

Data Analysis and Normalization:

• Apply manual global thresholding based on negative control samples using the QIAcuity Software Suite.
• Calculate HIV DNA copies per million cells using the formula: (HIV copies/μL ÷ RPP30 copies/μL) × (2 × 10^6) × dilution factor.
• Only include samples with partition numbers within the manufacturer's recommended range and positive control counts within expected values.

HIV Transcription Profiling Assay Adaptation to dPCR

The HIV transcription profiling technique, which quantifies mechanistically distinct HIV RNA species to assess transcriptional activity, has been successfully adapted to modern dPCR platforms [33]. This methodology provides insights into the transcriptional activity of proviruses that persist in cells and tissues during ART, offering complementary information to DNA-based reservoir measurements.

RNA Extraction and Reverse Transcription:

• Extract total RNA from CD4+ T cells using TRI Reagent or commercial kits (e.g., AllPrep DNA/RNA Mini kit).
• Treat samples with DNase I to eliminate genomic DNA contamination.
• Perform reverse transcription in 50 μL reactions containing 5 μL 10× SuperScript III buffer, 5 μL 50 mM MgCl2, 2.5 μL random hexamers (50 ng/μL), 2.5 μL 50 μM poly-dT15, 2.5 μL 10 mM dNTPs, 1.25 μL RNAseOUT (40 U/μL), and 2.5 μL SuperScript III RT (200 U/μL).
• Incubate at 25°C for 10 min, 50°C for 50 min, followed by enzyme inactivation at 85°C for 5 min.
• Split resultant cDNA evenly across triplicate wells for dPCR analysis.

Multiplex dPCR Assays for HIV Transcript Quantification:

• Target multiple HIV RNA species including TAR (transactivation response element), LongLTR (full-length transcript), Pol (polymerase), Nef (negative regulatory factor), PolyA (polyadenylated transcript), and Tat-Rev (multiply spliced regulatory transcripts).
• Prepare dPCR reactions with platform-specific master mixes (e.g., QIAcuity 4× Probe PCR Master Mix) using the same primer and probe concentrations as the DNA assay.
• Include no-reverse transcription (no-RT) controls and no-template controls (NTCs) in each run to detect DNA contamination and reagent background.

Analytical Validation and Quality Control:

• Calculate limits of blank (LoB), detection (LoD), and quantification (LoQ) for each assay using established formulas: LoB = meanNTC + 3 × SDNTC.
• Determine intra-assay and inter-assay variability using replicate measurements at different target concentrations.
• Establish assay linearity using serial dilutions of in vitro transcribed RNA standards across the expected quantification range.

Performance Validation and Analytical Metrics

Assay Performance Characteristics for HIV DNA Quantification

Comprehensive validation of the duplex dPCR assay for total HIV DNA quantification demonstrates performance characteristics suitable for monitoring reservoir changes in transplantation settings [7].

Table 1: Analytical Performance of HIV DNA dPCR Assay

Parameter	Performance	Experimental Details
Linearity	R² = 0.977, p < 0.0001	Range: 78 - 5,000 HIV DNA copies/10⁶ cells
Lower Limit of Detection (LLOD)	79.7 HIV copies/10⁶ cells (95% CI: 47.7 - 323.3)	95% confidence level
Limit of Quantification (LOQ)	5 HIV copies/reaction	Concentration detected with 100% accuracy
Repeatability (Intra-assay CV)	8.7% at 1,250 copies/10⁶ cells; 26.9% at 150 copies/10⁶ cells	Coefficient of variation
Reproducibility (Inter-assay CV)	10.9% at 1,250 copies/10⁶ cells; 19.9% at 150 copies/10⁶ cells	Coefficient of variation
Specificity	No signal in HIV-negative donors	No bleed-through between fluorescence channels

Platform Comparison and Technical Optimization

Direct comparison between ddPCR (Bio-Rad QX200) and dPCR (Qiagen QIAcuity) platforms for HIV transcription profiling reveals equivalent performance characteristics, enabling flexible platform selection based on laboratory infrastructure and throughput requirements [33]. Both technologies demonstrated no significant differences in sensitivity, specificity, linearity, or intra- and inter-assay variability when tested in parallel using the same cDNA aliquots and primer/probe sets.

Critical optimization parameters for dPCR assays targeting GC-rich HIV sequences include systematic adjustment of primer and probe concentrations, annealing/extension times, and cycle numbers to minimize "rain" (ambiguous partitions between positive and negative clusters) [34]. For challenging templates such as the PRV genome (74% GC content), which shares structural similarities with difficult HIV regions, optimization of primer concentrations (900 nM) and probe concentrations (150 nM) significantly improved peak resolution and reduced amplification bias [34].

Figure 2: dPCR Assay Optimization Strategy. Systematic optimization of multiple parameters is required to minimize amplification bias and "rain" in dPCR assays, particularly for challenging targets like GC-rich HIV sequences.

Applications in HIV Remission Research Following CCR5Δ32 Allo-HSCT

Monitoring Reservoir Dynamics in Transplantation Settings

Ultrasensitive dPCR assays have proven invaluable for characterizing the dramatic reductions in HIV reservoirs following allo-HSCT, providing critical insights into the mechanisms underlying potential cure. In the notable case of the "Geneva patient" who achieved sustained HIV remission after allo-HSCT with wild-type CCR5 donor cells, dPCR-based monitoring detected only sporadic low levels of defective HIV DNA without evidence of replication-competent virus [19]. Similarly, comprehensive assessment of ten cases of HIV remission following allo-HSCT has revealed that achievement of full donor chimerism is a key determinant of successful reservoir reduction, with dPCR measurements demonstrating reservoir half-lives of only several months post-transplantation [15].

The application of dPCR in transplantation research extends beyond simple reservoir quantification to include monitoring of donor chimerism, assessment of viral transcriptional activity, and characterization of residual proviral populations. These applications provide a comprehensive picture of the complex interplay between conditioning regimens, graft-versus-host reactions, and reservoir elimination that occurs following transplantation [15] [19].

Correlation with Clinical Outcomes in Remission Studies

Longitudinal dPCR monitoring of HIV DNA levels in allo-HSCT recipients has revealed strong correlations between reservoir metrics and clinical outcomes. Studies within the IciStem consortium have demonstrated that similar dramatic reductions in HIV reservoirs occur regardless of donor CCR5Δ32 status, suggesting that alloreactive immunity rather than CCR5 disruption may be the primary driver of reservoir elimination [15]. Furthermore, dPCR-based measurements have documented significantly higher HIV DNA levels in ART-naïve individuals (median 16,565 copies/10⁶ PBMCs) compared to ART-treated individuals (median 995.3 copies/10⁶ CD4+ T cells), highlighting the substantial reservoir reduction achievable with effective ART and providing context for interpreting post-transplantation reservoir levels [7].

Table 2: HIV Reservoir Measurements in Clinical Samples Using dPCR

Sample Type	Population	HIV DNA Level (copies/10⁶ cells)	Significance
CD4+ T cells	ART-treated PWH (n=50)	Median: 995.3 (IQR: 646.9-1,572)	Baseline reservoir during ART
PBMCs	ART-treated PWH (n=15)	Median: 506.1 (Range: 98.6-1,925)	Comparable to CD4+ T cell measurements
PBMCs	ART-naïve PWH (n=6)	Median: 16,565 (IQR: 6,560-35,465)	Significantly higher than ART-treated (p<0.0001)
Post-allo-HSCT	Remission cases	Near or below detection limit	Demonstrates dramatic reservoir reduction

Table 3: Key Research Reagents for HIV dPCR Assays

Reagent/Resource	Function	Implementation Example
dPCR Platforms	Sample partitioning, amplification, and imaging	Absolute Q, QIAcuity, QX200 ddPCR system
Primer/Probe Sets	Target-specific amplification and detection	HIV LTR-RU5, RPP30 reference gene, transcription-specific targets
Nucleic Acid Extraction Kits	Isolation of high-quality DNA/RNA from clinical samples	AllPrep DNA/RNA Mini kit, TRI Reagent with polyacryl carrier
Reverse Transcription Kits	cDNA synthesis for RNA quantification	SuperScript III with random hexamers and poly-dT primers
Digital PCR Master Mixes	Optimized reaction components for partitioning	QIAcuity Probe PCR Master Mix, ddPCR Supermix (no dUTP)
HIV RNA/DNA Standards	Assay validation and quantification standards	In vitro transcribed RNA, virion RNA from NL4-3 strain
Reference Cell Lines	Control materials for assay standardization	8E5 cells (contains 1 copy HIV/cell)

Ultrasensitive dPCR technologies have revolutionized HIV reservoir monitoring in CCR5Δ32 allo-HSCT research by enabling precise quantification of the minimal residual viral DNA that persists following intensive conditioning and immune reconstitution. The methodologies outlined in this technical guide provide researchers with robust, validated protocols for implementing these powerful assays in translational cure research. As HIV remission strategies continue to evolve, particularly in the context of transplantation and other intensive interventions, dPCR-based reservoir monitoring will remain an essential component of the analytical toolkit for evaluating intervention efficacy and predicting long-term outcomes.

The persistence of a latent reservoir of HIV-1-infected cells remains the principal barrier to achieving a cure for HIV. This reservoir, composed of integrated proviral DNA within the host genome, persists for decades despite effective antiretroviral therapy (ART) and can reignite systemic viral replication upon treatment interruption [35] [36]. A key challenge in HIV cure research has been the accurate quantification of this reservoir. The replication-competent, or intact, proviruses are the functional units capable of causing viral rebound, but they are vastly outnumbered by a background of defective proviruses that are genetically mangled and cannot produce new virus [36] [37]. Traditional PCR assays overestimate the size of the rebound-competent reservoir because they amplify all proviruses, intact and defective alike, while the gold-standard quantitative viral outgrowth assay (QVOA) is labor-intensive, low-throughput, and may underestimate the reservoir because not all intact proviruses are induced by a single round of T-cell activation [35] [36]. The Intact Proviral DNA Assay (IPDA) was developed to address this critical methodological gap, providing a scalable, precise, and accurate tool to distinguish intact from defective proviruses, thereby enabling meaningful evaluation of HIV cure strategies [35] [36].

The IPDA: Core Principles and Workflow

The IPDA is a multiplexed droplet digital PCR (ddPCR) assay that simultaneously interrogates two specific, highly conserved regions of the HIV-1 proviral genome. Its power lies in its ability to digitally partition individual proviral templates into nanoliter-sized droplets, allowing for simultaneous dual-target analysis of single molecules [36].

The Dual-Target Strategy for Genetic Integrity Assessment

The assay targets two regions:

• The Packaging Signal (Ψ): A region near the 5' end of the genome, located between the major 5' splice donor and the start of the gag gene.
• The Rev-Responsive Element (RRE) within the env gene.

This dual-amplicon strategy is designed to detect the most common fatal defects that render a provirus non-functional. Proviruses with large internal deletions, often generated during erroneous reverse transcription, will typically lose at least one of these two amplicons. Furthermore, hypermutation mediated by the host enzyme APOBEC3G introduces premature stop codons that can also be inferred by this approach [36] [37]. A provirus is only classified as "intact" if it is positive for both the Ψ and RRE signals.

Table 1: Interpretation of IPDA Results

Provirus Classification	Ψ Signal	RRE Signal	Clinical Relevance
Intact	Positive	Positive	Replication-competent; capable of causing viral rebound
5' Defective	Negative	Positive	Contains large deletions or mutations in the 5' region
3' Defective	Positive	Negative	Contains large deletions or mutations in the 3' region
Other Defective	Negative	Negative	Heavily deleted or hypermutated

Detailed Experimental Protocol

The following is a detailed methodology for performing the IPDA, as derived from the cited literature.

1. Sample Preparation and DNA Extraction

• Source Material: Isolate peripheral blood mononuclear cells (PBMCs) from fresh or frozen blood samples. For higher precision, isolate CD4+ T cells from PBMCs using positive or negative selection methods.
• DNA Extraction: Extract high-molecular-weight genomic DNA using a commercial kit. Prefer methods that minimize DNA shearing. Prefer methods that minimize DNA shearing. Quantify DNA concentration using a fluorescence-based assay (e.g., Qubit) for accuracy.
• Input Requirement: The ideal input is 1-2 µg of genomic DNA, which corresponds to approximately 150,000-300,000 nucleated cells. Lower inputs can be used but may reduce sensitivity [35] [36].

2. Droplet Digital PCR (ddPCR) Setup

• Reaction Mixture: Prepare a duplex ddPCR reaction containing:
  • Extracted genomic DNA (1-2 µg).
  • Two primer/probe sets:
    • Ψ-specific primers and a FAM-labeled probe.
    • RRE-specific primers and a HEX/VIC-labeled probe.
  • ddPCR Supermix for Probes (no dUTP).
  • Restriction enzyme (e.g., HindIII) to digest genomic DNA and facilitate access to the proviral DNA [36].
• Droplet Generation: Transfer the reaction mixture to a droplet generator cartridge. Following manufacturer's protocols, generate approximately 20,000 nanoliter-sized droplets per sample, effectively partitioning the DNA template into individual reactions.

3. End-Point PCR Amplification

• Place the generated droplets into a 96-well PCR plate and seal.
• Perform PCR amplification in a thermal cycler using the following cycling conditions, as optimized from the original publication [36]:
  • Enzyme activation: 95°C for 10 minutes.
  • 40-45 cycles of:
    • Denaturation: 94°C for 30 seconds.
    • Annealing/Extension: 60°C for 60 minutes (This extended time is critical for efficient amplification within droplets).
  • Enzyme deactivation: 98°C for 10 minutes.
  • Hold: 4°C or 12°C.

4. Droplet Reading and Analysis

• Load the PCR-amplified plate into a droplet reader.
• The reader flows each droplet single-file past a two-channel optical detector that measures fluorescence in the FAM (Ψ) and HEX/VIC (RRE) channels.
• Software analyzes each droplet and classifies it as:
  • Ψ-positive (FAM+)
  • RRE-positive (HEX/VIC+)
  • Double-positive (FAM+ and HEX/VIC+)
  • Double-negative

5. Data Analysis and Quantification

• The concentration (copies/µL) of each proviral population is calculated using the reader's software based on the fraction of positive droplets and applying Poisson statistics.
• Results are normalized to the input cell number, typically using a reference gene (e.g., RPP30 or CCR5) assayed in a separate, singleplex ddPCR reaction [36] [38].
• Final results are expressed as copies per million CD4+ T cells or per microgram of DNA.

Diagram 1: IPDA Workflow. The core process from sample preparation to the digital classification of individual proviruses based on their Ψ and RRE status.

IPDA Performance and Insights into Reservoir Dynamics

Application of the IPDA to large, diverse cohorts has yielded critical quantitative benchmarks and novel biological insights into the behavior of the HIV reservoir during long-term ART.

Quantitative Profile of the Reservoir

Analysis of 400 ART-treated individuals with HIV-1 subtype B revealed that defective proviruses dominate the proviral landscape. The median frequency of intact proviruses was 54 per million CD4+ T cells, while defective proviruses were present at a median frequency of 675 per million CD4+ T cells—a more than 12.5-fold excess [36]. This confirms that the vast majority of HIV DNA detected by standard PCR is not replication-competent.

Table 2: IPDA Results from a Large Cohort (n=400) [36]

Provirus Type	Median Frequency (per 10^6 CD4+ T cells)	Interquartile Range (IQR)	Ratio (Intact:Defective)
Intact	54	11 - 163	1 : >12.5
Defective (Total)	675	237 - 1575	-
3' Defective (Ψ-)	274	91 - 698	-
5' Defective (RRE-)	223	72 - 529	-

Differential Decay Kinetics

Longitudinal studies using the IPDA have demonstrated that intact and defective proviruses decay at different rates. One study of 81 individuals over a median of 7.3 years showed that the intact reservoir decays in a biphasic manner [35]:

• An initial rapid decline of 15.7% per year (half-life of ~4.0 years) through the first 7 years of ART.
• A subsequent slower decline of 3.6% per year (half-life of ~18.7 years) after 7 years of ART.

In contrast, the defective reservoir decays much more slowly, at a rate of about 4.0% per year through the first 7 years [35]. This differential decay underscores the distinct biology of the two proviral populations and suggests that the replication-competent reservoir is less stable than the bulk of defective proviral DNA.

Limitations and Considerations for Implementation

Despite its advantages, users must be aware of the IPDA's limitations to ensure proper implementation and data interpretation.

• Impact of HIV-1 Sequence Polymorphism: The primary limitation of the IPDA is its susceptibility to sequence variation in primer and probe binding sites. Studies report failure rates from 6.3% to as high as 28% in different cohorts due to natural polymorphisms that prevent probe binding, leading to underestimation or complete failure to detect intact proviruses [39] [36]. This issue is readily apparent in the ddPCR plots as an absence of expected positive droplet populations, which is an advantage over standard PCR that would silently report a false negative [36].
• Risk of Misclassification: The IPDA infers intactness based on only two genomic regions. It is possible for a provirus to have both amplicons intact but harbor fatal defects elsewhere in the genome. Mathematical modeling suggests that this can lead to approximately 5% of "intact" calls being misclassified defective proviruses. This misclassification can create the illusion of a stable, long-lived intact reservoir in long-term ART, as the slower-decaying misclassified proviruses become a larger proportion of the signal over time [37].
• Subtype Specificity: The IPDA was designed for HIV-1 subtype B. Its performance on non-B subtypes is variable and often suboptimal, necessitating the development of subtype-specific primers and probes for global application [38].

Diagram 2: IPDA Limitations. A logic flow highlighting the two major limitations: false negatives due to viral polymorphism and misclassification of defective proviruses as intact.

The Scientist's Toolkit: Essential Reagents and Materials

Table 3: Key Research Reagents for the IPDA

Reagent / Material	Function	Implementation Example
Primer/Probe Set for HIV-1 Ψ	Amplifies and detects the 5' packaging signal region. FAM-labeled.	Critical for identifying proviruses with an intact 5' genome [36].
Primer/Probe Set for HIV-1 RRE	Amplifies and detects the env region. HEX/VIC-labeled.	Critical for identifying proviruses with an intact 3' genome [36].
Reference Gene Assay (e.g., RPP30, CCR5)	For cell number quantification and data normalization.	Enables reporting of results as "copies per million cells" [38].
Droplet Digital PCR System	Partitions samples into droplets for absolute quantification.	e.g., Bio-Rad QX200 or a chip-based dPCR system [36] [38].
Restriction Enzyme (e.g., HindIII)	Digests genomic DNA to improve access to integrated provirus.	Enhances assay efficiency and consistency [36].

Application in HIV Cure Research: The Context of CCR5Δ32 HSCT

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from CCR5Δ32/Δ32 donors has led to the only documented cures of HIV-1 infection. The IPDA has played a pivotal role in characterizing the virological status of these patients post-transplant.

In these cases, the IPDA has been used to demonstrate the absence of intact provirus in peripheral blood and tissues, even when highly sensitive assays detected trace amounts of defective proviral DNA. For example, in the case of the "Düsseldorf patient" (a cure after CCR5Δ32/Δ32 HSCT), sporadic traces of HIV DNA were detected, but the IPDA and repeated outgrowth assays consistently failed to find any intact, replication-competent proviruses [12]. Similarly, the "Geneva patient," who achieved remission after HSCT with wild-type CCR5 cells, showed only defective—not intact—HIV DNA via IPDA after ART interruption [19]. These findings, corroborated by other assays, provide strong evidence for HIV-1 cure or sustained remission and highlight the IPDA's value as a key tool in the monitoring and validation of cure strategies.

The Intact Proviral DNA Assay represents a significant methodological advance in HIV cure research. By enabling the precise differentiation and quantification of intact versus defective proviruses, it provides a scalable and highly informative metric for evaluating the replication-competent reservoir. While considerations around viral diversity and misclassification require attention, its application has already refined our understanding of reservoir dynamics and become an indispensable component in the assessment of curative interventions, particularly in the context of high-impact research such as CCR5Δ32 hematopoietic stem cell transplantation.

The quantitative viral outgrowth assay (QVOA) is the gold-standard method for quantifying the frequency of resting CD4+ T cells harboring replication-competent, inducible HIV-1 proviruses. This latent reservoir represents the major barrier to curing HIV-1 infection, as it persists despite suppressive antiretroviral therapy (ART) and can cause viral rebound if treatment is interrupted [40] [41]. In the context of CCR5Δ32/Δ32 haematopoietic stem-cell transplantation (HSCT)—a intervention that has led to sustained HIV-1 remission in a few documented cases—QVOA serves as a critical tool for demonstrating the absence of replication-competent virus [11] [12]. Unlike PCR-based methods that detect both defective and intact proviruses, QVOA provides a minimal estimate of the reservoir size by measuring only the virus capable of in vitro growth, expressed as infectious units per million (IUPM) cells [40] [42]. This technical guide details the methodologies, applications, and quantitative findings of QVOA in HIV-1 cure research.

Core Principles and Methodological Workflow

The fundamental principle of QVOA is to activate latently infected CD4+ T cells ex vivo, inducing viral production, and then to amplify and detect this replication-competent virus. The assay involves several key stages, from cell purification to viral detection, with specific variations in methodology influencing its sensitivity and reproducibility.

Key Experimental Protocols

Table 1: Key Methodological Variations in QVOA Protocols

Protocol Component	Classical Approach	Modified/Rapid Approaches
Resting CD4+ T Cell Purification	Multi-step process: PBMC isolation → CD4+ enrichment → depletion of activated cells (CD25+, CD69+, HLA-DR+) via FACS or beads [41].	One-step negative selection using custom antibody cocktails (e.g., against CD4, CD25, CD69, HLA-DR), reducing processing time to ~3 hours [42].
T Cell Activation & Latency Reversal	Stimulation with phytohaemagglutinin (PHA) and irradiated allogeneic PBMC feeder cells [41].	Stimulation with anti-CD3/CD28 monoclonal antibodies coated on culture plates [40].
Viral Amplification System	Co-culture with CD4+ lymphoblasts from HIV-negative donors (added on days 2, 7, etc.), requiring multiple blood donors [41].	Co-culture with clonal cell lines (e.g., SupT1-CCR5 or MOLT-4/CCR5), providing a standardized, readily available source [42] [41].
Virus Detection Method	ELISA for p24 antigen in culture supernatant after 14-21 days [41].	Quantitative RT-PCR for HIV-1 RNA (e.g., polyadenylated RNA) in supernatant, offering greater sensitivity and speed [40] [41].
Reservoir Quantification	Calculation of IUPM using Poisson statistics based on limiting dilutions of resting CD4+ T cells [40] [41].	Calculation of IUPM; newer inducible RNA assays may report frequency of RNA+ cells/10^6 CD4+ T cells [40].

Diagram 1: Simplified QVOA Workflow. The core steps involve purifying target cells, activating them to reverse latency, amplifying the released virus, and detecting it to calculate the reservoir size.

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Research Reagent Solutions for QVOA

Reagent / Material	Function in Assay	Specific Examples & Notes
Resting CD4+ T Cell Isolation Kits	To obtain a highly pure population of resting CD4+ T cells (CD69-, CD25-, HLA-DR-) from patient PBMCs, minimizing activated cells that could spontaneously produce virus.	EasySep CD4 Enrichment Kit; custom cocktails with anti-CD25/CD69/HLA-DR antibodies. Purity of >96% is typically achieved [40] [42].
T Cell Activators	To provide a strong mitogenic signal to reverse viral latency and initiate transcription and translation of HIV-1 proviruses.	Anti-CD3/CD28 coated beads/plates; Phytohaemagglutinin (PHA) with IL-2 [40] [41].
Amplifier Cells	To support the replication and expansion of HIV-1 released from patient cells, enabling detection.	SupT1-CCR5 cells: A clonal cell line expressing CD4, CXCR4, and CCR5, providing standardization and high sensitivity for diverse viral tropisms [42].MOLT-4/CCR5 cells: Another CCR5-expressing cell line alternative to donor PBMCs [41].CD8-depleted PBMCs from healthy donors: The classical method, but introduces donor-to-donor variability [41].
Virus Detection Assays	To identify the presence of replication-competent virus in culture supernatants.	HIV-1 p24 ELISA: Traditional, costlier method [41].qRT-PCR for HIV-1 RNA: More sensitive and cost-effective; can target gag or polyadenylated RNA [40] [41].

Diagram 2: Comparison of Viral Amplification Systems. Modern QVOAs are increasingly using clonal cell lines to replace donor PBMCs, improving standardization and reproducibility.

Quantitative Data and Correlation with Other Modalities

QVOA typically reveals a very low frequency of latently infected cells in patients on long-term ART, with IUPM values often ranging from 0.1 to 1 [41]. This frequency is significantly lower than estimates from PCR-based assays for total HIV DNA, highlighting that the majority of persisting proviruses are defective [40]. In the context of CCR5Δ32/Δ32 HSCT, a negative QVOA—defined as the inability to recover replication-competent virus from tens of millions of resting CD4+ T cells—becomes a powerful piece of evidence for a cure.

Reservoir Measurements in Clinical Context

Table 3: Quantitative HIV-1 Reservoir Measurements in Key Studies

Study Context	QVOA Result (IUPM)	PCR-based Measurements	Clinical Outcome
Patients on suppressive ART [40]	Median ~3.3 [1.9–6.2] IUPM	Total HIV DNA: ~2 logs higher than QVOA. Inducible cell-associated RNA: ~1-2 logs higher than QVOA.	Viral rebound upon treatment interruption.
"London Patient" (CCR5Δ32/Δ32 HSCT) [11]	<0.029 IUPM (pooled from 24 million cells)	Undetectable HIV-1 DNA in peripheral CD4+ T lymphocytes.	Remission maintained 18+ months post-ATI.
"Düsseldorf Patient" (CCR5Δ32/Δ32 HSCT) [12]	No virus detected in repeated QVOA and in vivo outgrowth assays.	Sporadic traces of HIV-1 DNA detected, but no intact proviruses found.	Remission maintained 48+ months post-ATI.

Recent advancements have led to the development of inducible RNA assays, which measure the frequency of cells producing HIV-1 RNA (cell-associated, ca-RNA) or viral particles (cell-free, cf-RNA) after short-term (e.g., 3-day) stimulation [40]. These assays are more sensitive and have a wider dynamic range than QVOA. Importantly, the frequency of infected cells measured by the inducible cf-RNA assay strongly correlated with QVOA (r=0.67, p<.001) and was statistically equivalent in 60% of samples, suggesting it can serve as a faster, more scalable surrogate for quantifying the inducible, replication-competent reservoir [40].

QVOA's Role in Evaluating HIV-1 Cure Strategies

QVOA remains a cornerstone for evaluating the efficacy of HIV-1 cure strategies, including CCR5Δ32/Δ32 HSCT. Its specificity for replication-competent virus provides a high bar for success. In the documented cases of cure, repeated QVOA testing, in combination with other sophisticated reservoir assays, was used to build the evidence for the absence of the virus, ultimately leading to the safe interruption of ART [11] [12]. While newer, high-throughput assays like the intact proviral DNA assay (IPDA) and inducible RNA assays are being integrated into the research pipeline, QVOA's direct functional readout ensures its continued relevance in validating the findings of these indirect measures and in confirming a genuine reduction or elimination of the latent HIV-1 reservoir.

The pursuit of an HIV cure necessitates the accurate detection and quantification of replication-competent virus, particularly in the context of novel therapeutic interventions. Among the most promising developments are cases of HIV remission and cure following CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation (HSCT), a procedure that replaces the immune system with donor cells resistant to HIV infection [43] [12]. In these groundbreaking cases, researchers face a critical challenge: determining whether trace amounts of detected viral material represent true, replication-competent reservoirs capable of causing rebound. Humanized mouse models have emerged as indispensable tools for addressing this challenge, providing a sensitive in vivo platform for assessing the presence of infectious virus when conventional assays yield ambiguous or conflicting results.

These models serve as a crucial bridge between basic research and clinical application, offering a biologically relevant system to evaluate the efficacy of cure strategies. Their particular value lies in the ability to amplify even minute quantities of replication-competent virus that might evade detection in standard in vitro assays, thereby providing a more definitive assessment of reservoir eradication or control [43] [44]. This technical guide examines the foundational principles, methodological approaches, and practical applications of humanized mouse models for validating the presence of replication-competent HIV, with specific emphasis on their role in evaluating patient outcomes after CCR5Δ32/Δ32 HSCT.

Scientific and Technical Basis

Fundamental Principles of Humanized Mouse Models

Humanized mouse models are generated by engrafting human cells and tissues into immunodeficient mice, creating a chimeric system that supports HIV infection and replication. The core principle hinges on using mouse strains with severe compromises in both innate and adaptive immunity to prevent rejection of human xenografts [44] [45]. Key genetic modifications in these recipient strains include mutations in the IL-2 receptor common γ chain (IL2rg), which disrupts signaling for multiple cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) and eliminates natural killer (NK) cells, combined with mutations in either the protein kinase, DNA-activated, catalytic polypeptide (Prkdcscid) or recombination-activating genes (Rag1/Rag2), which prevent the development of mature T and B cells [44] [45].

The resulting strains—including NSG (NOD-SCID-γc knockout), NOG, and NRG mice—exhibit profoundly impaired immune function, allowing for enhanced engraftment and long-term persistence of human cells [44] [45]. Further refinements have included the development of triple knockout (TKO) models that additionally lack CD47, a "don't eat me" signal, reducing phagocytosis of human hematopoietic stem cells by murine macrophages and improving reconstitution efficiency [44].

HIV Reservoir and Detection Challenges in Cure Research

The primary obstacle to HIV cure is the viral reservoir, consisting primarily of latently infected CD4+ T cells that harbor replication-competent provirus but produce little to no virus under effective antiretroviral therapy (ART) [46] [47]. These reservoirs are established early during infection, are widely distributed throughout lymphoid tissues, and can persist for decades due to the long lifespan of memory T cells and homeostatic proliferation [46]. In patients who have undergone CCR5Δ32/Δ32 HSCT, the measurement of this reservoir presents unique challenges, as standard PCR-based assays may detect viral fragments or defective proviruses that do not constitute a genuine rebound threat [43] [12].

The gold-standard quantitative viral outgrowth assay (qVOA), while designed to quantify replication-competent virus, is labor-intensive, slow, and may underestimate the reservoir size because not all latently infected cells are induced to produce virus under experimental conditions [46]. Furthermore, patients achieving remission after HSCT may show sporadic positive signals for HIV DNA or RNA in tissues despite apparent cure, creating uncertainty about the clinical significance of these traces [43] [12]. Humanized mouse models address these limitations by providing a permissive in vivo environment where even minimal amounts of replication-competent virus can expand to detectable levels, serving as a highly sensitive biological amplifier.

Common Models and Their Applications

Different humanized mouse models offer distinct advantages for specific research questions, varying in their reconstitution methods, the spectrum of human immune cells produced, and their suitability for long-term studies.

Comparative Analysis of Model Characteristics

Table 1: Key Humanized Mouse Models for HIV Reservoir Research

Model Type	Engraftment Method	Human Immune Cells Generated	Key Advantages	Limitations
Hu-HSC	Intrahepatic or intracardiac injection of CD34+ hematopoietic stem cells into newborn mice [48] [49]	Multilineage reconstitution: T cells, B cells, monocytes, macrophages, dendritic cells [45]	Long-term studies possible (>1 year); multilineage hematopoiesis; some primary immune responses [45]	Immune cells are HLA-restricted by mouse thymus; variable engraftment levels [45]
BLT (Bone-Liver-Thymus)	Implantation of human fetal liver and thymus tissues under renal capsule + intravenous injection of autologous HSC [44] [45]	Comprehensive immune reconstitution: T cells, B cells, monocyte/macrophages, NK cells; human cells in mucosal tissues [45]	Robust mucosal engraftment; strong adaptive immune responses; excellent for transmission studies [44] [45]	Technically complex; requires fetal tissues; graft-versus-host disease (GvHD) may develop [44]
Hu-PBL	Intraperitoneal injection of human peripheral blood mononuclear cells (PBMCs) into adult mice [45]	Primarily mature T cells present in spleen, peripheral blood, and peritoneal cavity [45]	Simple procedure; immediate availability for infection studies; no surgery required [45]	Limited immune cell diversity; rapid GvHD development (3-4 weeks); short-term studies only [45]

Experimental Protocols for Detecting Replication-Competent Virus

In Vivo Viral Outgrowth Assay Workflow

The use of humanized mice as a biological amplifier for replication-competent HIV follows a standardized workflow with critical quality control checkpoints.

Detailed Methodological Procedures

Generation of Humanized Mice (Hu-HSC Model)

• Recipient Mouse Preparation: Utilize 1-3 day old neonatal BALB/c Rag2⁻/⁻γc⁻/⁻ or similar immunodeficient mice. Subject pups to sublethal irradiation (350 rads) to create niche space for human cell engraftment [48] [49].

• CD34+ Cell Isolation and Preparation: Obtain human CD34+ hematopoietic stem cells from fetal liver, cord blood, or G-CSF mobilized peripheral blood. Culture cells for 24 hours in cytokine-supplemented media (Iscove's medium with 10% FBS, IL-3, IL-6, and stem cell factor each at 25 ng/ml) to enhance viability and engraftment potential [48] [49].

• Engraftment Procedure: Inject 0.5-1×10⁶ CD34+ cells in a 30μL volume intrahepatically into irradiated neonatal pups. This route capitalizes on the ongoing hematolymphoid development in newborns [48] [49].

• Validation of Reconstitution: At 10-12 weeks post-engraftment, screen peripheral blood for human immune cell reconstitution using flow cytometry. Stain with antibodies against hCD45-APC, hCD3-FITC, and hCD4-PE. Mice with >40% hCD45+ cells are typically selected for experiments [48] [49].

In Vivo Outgrowth Assay Protocol

• Sample Preparation: Isolate CD4+ T cells or PBMCs from patient blood or tissue biopsies using standard Ficoll density gradient centrifugation or magnetic bead separation. Cell numbers typically range from 1-10 million cells per mouse, with viability >95% confirmed by trypan blue exclusion [43] [12].

• Inoculation: Administer prepared cells via intraperitoneal injection into engrafted humanized mice. Include negative controls (cells from HIV-negative donors) and positive controls (cells spiked with known quantities of HIV) to validate assay sensitivity [43].

• Monitoring Phase: Collect peripheral blood weekly for 4-12 weeks to monitor viral replication. For plasma viral load quantification, extract viral RNA using commercial kits (e.g., E.Z.N.A. Viral RNA Kit) and perform qRT-PCR with HIV-specific primers and probes [48] [49]. Target detection sensitivity should reach <50 copies/mL.

• Endpoint Analysis: At study completion, euthanize mice and harvest tissues (spleen, lymph nodes, bone marrow) for further analysis. Process tissues for nucleic acid extraction to quantify HIV DNA and RNA reservoirs, or for immunohistochemistry to visualize viral distribution [43] [12].

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for Humanized Mouse HIV Reservoir Studies

Reagent/Category	Specific Examples	Function & Application
Immunodeficient Mouse Strains	NSG (NOD.Cg-PrkdcscidIL2rgtm1Wjll/Sz), NOG, NRG, BRG [44] [45]	Provide in vivo environment for human cell engraftment; lack adaptive immunity and key innate immune components
Human Cell Sources	CD34+ hematopoietic stem cells (fetal liver, cord blood, mobilized peripheral blood), PBMCs from patient samples [48] [49]	Create human immune system in mice; serve as inoculum for outgrowth assays
Flow Cytometry Antibodies	Anti-hCD45, Anti-hCD3, Anti-hCD4, Anti-hCD8, Anti-hCD19 [48] [49]	Validate human immune reconstitution; monitor immune cell populations during infection
Molecular Detection Reagents	HIV-specific primers/probes (LTR, gag), RNA extraction kits, RT-PCR kits [48] [49]	Quantify plasma viral load; detect HIV DNA and RNA in tissues
Antiretroviral Drugs	Emtricitabine (FTC), Tenofovir alafenamide (TAF), Bictegravir (BIC), Dolutegravir [48] [19]	Maintain viral suppression in control groups; test therapeutic efficacy

Case Study: Validation of HIV Cure After CCR5Δ32/Δ32 HSCT

The critical role of humanized mouse models in validating HIV cure was prominently demonstrated in the case of a 53-year-old male (IciStem no. 19) who underwent CCR5Δ32/Δ32 allogeneic HSCT for acute myeloid leukemia [43] [12]. Despite achieving sustained remission off ART for over 4 years, the patient presented a complex diagnostic picture:

• Conflicting Signals: Droplet digital PCR and in situ hybridization assays sporadically detected traces of HIV-1 DNA in peripheral T-cell subsets and tissue-derived samples [43] [12].
• Definitive Resolution: Repeated in vivo outgrowth assays using two different humanized mouse models failed to detect replication-competent virus in the same samples, providing crucial evidence that the detected nucleic acids did not represent infectious reservoir [43] [12].
• Corroborating Evidence: The absence of replication-competent virus was supported by declining HIV-1 specific antibody responses and diminishing HIV-1 specific T-cell responses, indicating lack of ongoing antigen stimulation [43] [12].

This case highlights how humanized mouse models can resolve ambiguities left by molecular assays, providing critical biological validation of cure. The negative outgrowth results in humanized mice, combined with the absence of viral rebound after treatment interruption, provided sufficient evidence to declare this case a sterilizing cure [43] [12].

Technical Considerations and Limitations

While humanized mouse models provide unparalleled utility for HIV reservoir research, several important limitations must be considered:

• Engraftment Variability: The level of human cell reconstitution can vary significantly between individual mice, potentially affecting assay sensitivity and consistency. Careful pre-screening and selection of well-engrafted animals is essential [45].

• Incomplete Human Immune System: Despite improvements, these models do not fully recapitulate the complete human immune environment, particularly in terms of immune responses to HIV infection [44] [45].

• Graft-versus-Host Disease: Especially in Hu-PBL models, xenogeneic GvHD can develop within 3-4 weeks, limiting the duration of experiments [45].

• Cost and Technical Demands: The generation and maintenance of humanized mice requires significant resources, specialized facilities, and technical expertise [44].

• Sample Requirements: The sensitivity of the assay depends on having adequate numbers of viable cells from patient samples, which can be limiting, especially for longitudinal studies or when analyzing specific cell subsets [43].

Humanized mouse models represent an essential component of the HIV cure research toolkit, providing a biologically relevant in vivo system for validating the presence of replication-competent virus when molecular assays yield ambiguous results. Their application in assessing patients after CCR5Δ32/Δ32 HSCT has been particularly valuable, offering the sensitivity and biological context needed to distinguish between non-infectious viral fragments and genuine, replication-competent reservoirs capable of causing rebound.

As HIV cure research advances, with increasingly ambitious strategies targeting complete reservoir elimination or permanent viral control, the role of these models will continue to expand. Future developments will likely focus on improving the completeness of human immune reconstitution, enhancing model reproducibility, and increasing throughput to enable more comprehensive testing of candidate therapies. For now, humanized mouse models remain the gold standard for in vivo validation of replication-competent HIV, serving as a critical checkpoint before proceeding to analytical treatment interruptions in clinical trials.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from CCR5Δ32/Δ32 donors represents a transformative intervention in HIV-1 research, demonstrating the potential for sustained viral remission without lifelong antiretroviral therapy. This technical guide comprehensively details the immunological monitoring strategies required to assess HIV-1 persistence following such interventions. We synthesize data from multiple clinical cases and cohort studies to establish standardized methodologies for quantifying the decay kinetics of HIV-specific antibodies and T-cell responses, which serve as critical surrogate markers for residual viral reservoirs. The precise immunological profiling outlined herein provides researchers with validated frameworks for evaluating intervention efficacy and establishing correlates of HIV-1 remission in the context of CCR5Δ32/Δ32 hematopoietic stem cell transplantation.

The pursuit of an HIV-1 cure has accelerated with documented cases of sustained remission following allo-HSCT using stem cells from donors with a homozygous CCR5Δ32 mutation [11]. The CCR5 coreceptor serves as the primary portal for HIV-1 entry into CD4+ T-cells, and its absence confers natural resistance to R5-tropic HIV-1 variants. While the Berlin, London, and other similar patients demonstrated that CCR5Δ32/Δ32 allo-HSCT can eliminate detectable HIV-1 reservoirs, the precise immunological mechanisms facilitating this outcome require further elucidation [19].

Critical to understanding these mechanisms is the systematic monitoring of HIV-specific immune responses post-transplantation. In natural infection, HIV-1 persistence maintains continuous antigenic stimulation, sustaining robust HIV-specific T-cell responses and antibody production. When the viral reservoir is substantially reduced or eliminated, this antigenic drive diminishes, resulting in the progressive decay of HIV-specific immunity [50] [51]. Therefore, tracking the dynamics of these immunological parameters provides crucial indirect evidence of reservoir reduction complementary to direct viral quantification assays.

This technical guide establishes standardized approaches for monitoring HIV-specific antibody decay and T-cell responses within the unique context of CCR5Δ32/Δ32 allo-HSCT, providing researchers with comprehensive methodologies for assessing potential HIV-1 cure interventions.

HIV-Specific Antibody Responses and Decay Kinetics

Antibody Dynamics as Reservoir Biomarkers

HIV-1-specific antibodies, particularly those targeting viral envelope proteins, persist for years in individuals on conventional ART due to continuous low-level antigen stimulation from stable viral reservoirs. Following interventions that potentially eliminate these reservoirs, the disappearance of antigen production triggers a measurable decline in antibody levels and avidity [11] [51].

In the documented case of HIV-1 remission after CCR5Δ32/Δ32 allo-HSCT, researchers observed that "HIV-1-specific antibodies and avidities fell to levels comparable to those in the Berlin patient following transplantation" [11]. This consistent pattern across multiple patients suggests that antibody kinetics provide a valuable biomarker for assessing reservoir status after transformative interventions.

Quantitative Assessment Methodologies

Antibody Titer Quantification:

• Technique: Longitudinal serum sampling with standardized ELISA platforms
• Targets: Anti-gp120, anti-gp41, anti-p24 antibodies
• Frequency: Monthly for first 6 months post-ART interruption, then quarterly
• Controls: Pre-transplantation baseline, on-ART stability phase

Antibody Avidity Maturation:

• Principle: Low-avidity antibodies decline first; high-avidity antibodies persist longer
• Method: Guanidine hydrochloride dissociation ELISA
• Interpretation: Decreasing avidity suggests absence of antigen-driven B-cell maturation

Western Blot Profile Evolution:

• Application: Monitor disappearance of individual antibody specificities
• Pattern: Sequential loss of bands (typically p24 first, gp160 last)
• Endpoint: Indeterminate or negative Western blot

Table 1: Key Antibody Parameters in Post-Transplantation Monitoring

Parameter	Assessment Method	Frequency	Significance of Decline
Anti-Env IgG	Quantitative ELISA	Monthly	Suggests reduced antigen presentation
Antibody Avidity	Dissociation ELISA	Quarterly	Indicates loss of antigen-driven maturation
Western Blot Band Intensity	Densitometric analysis	Quarterly	Reveals specificity loss pattern
Neutralizing Antibody Titers	TZM-bl assay	Pre- and post-ATI	Correlates with protective immunity loss

T-Cell Response Monitoring in HIV Remission

HIV-Specific T-Cell Dynamics Post-Transplantation

HIV-specific T-cells play a dual role in HIV remission contexts: they contribute to viral control through cytolytic activity, while their persistence may indicate ongoing antigen exposure. Following substantial reservoir reduction, the disappearance of HIV-specific T-cell responses provides evidence of eliminated antigenic stimulation [50] [52].

In the case of CCR5Δ32/Δ32 allo-HSCT, investigators reported that "HIV-1 Gag-specific CD4 and CD8 T cell responses were lost after transplantation whilst Cytomegalovirus (CMV)-specific responses were detectable" [11]. This selective loss of HIV-specific responses amid preserved pathogen-specific immunity represents a critical indicator of successful reservoir elimination.

Technical Approaches for T-Cell Response Assessment

Intracellular Cytokine Staining (ICS):

• Stimulants: HIV-1 peptide pools (Gag, Pol, Nef, Env)
• Cytokines: IFN-γ, TNF-α, IL-2
• Phenotyping: CD4, CD8, memory/effector markers
• Gating Strategy: Lymphocyte > single cells > live cells > CD3+ > CD4+/CD8+ > cytokine+

Enzyme-Linked Immunospot (ELISPOT):

• Platform: IFN-γ ELISPOT using overlapping peptide libraries
• Cell Input: 100,000-200,000 PBMCs per well
• Controls: CEF peptide pool (positive), media alone (negative)
• Threshold: >50 SFU/10⁶ cells after background subtraction

Proliferation Assays:

• Method: CFSE dilution with HIV peptide stimulation
• Duration: 5-7 day culture
• Analysis: Flow cytometric detection of divided cells
• Significance: Proliferative capacity correlates with reservoir control [52]

Table 2: T-Cell Response Monitoring in Transplant Recipients

Assay Type	Measured Parameter	Sample Requirements	Interpretation Guidelines
ICS	Cytokine-producing HIV-specific T-cells	Fresh or cryopreserved PBMCs	Loss of response suggests antigen absence
ELISPOT	Frequency of reactive T-cells	Cryopreserved PBMCs	Background-level responses indicate remission
Proliferation Assay	Capacity for clonal expansion	Fresh PBMCs	Early predictive value for reservoir reduction
Tetramer Staining	Antigen-specific T-cell frequency	HLA-typed patients	Direct quantification of specific clones

Experimental Protocols for Core Assessments

Quantitative Viral Outgrowth Assay (QVOA)

Purpose: Quantify replication-competent HIV-1 in resting CD4+ T-cells Sample: Resting CD4+ T-cells purified from PBMCs (5-20 million cells) Method:

• Isolate resting CD4+ T-cells (CD4+ CD25- CD69- HLA-DR-)
• Plate limiting dilutions (e.g., 1×10⁶, 0.5×10⁶, 0.25×10⁶ cells/well)
• Activate with PHA and allogeneic irradiated feeder cells
• Co-culture with CD8-depleted PBMCs from healthy donors
• Measure HIV-1 p24 in supernatant at days 7, 14, and 21
• Calculate infectious units per million (IUPM) using statistical models

Interpretation: In remission cases, QVOA typically shows <0.03 IUPM with no virus recovery despite testing millions of cells [11].

HIV-1 DNA/RNA Quantification

Total HIV-1 DNA:

• Method: Digital PCR with LTR-gag primers
• Input: 1-2 million PBMCs or purified CD4+ T-cells
• Standards: Full-length HIV-1 DNA standards
• Sensitivity: <1 copy per million cells

Intact Proviral DNA Assay (IPDA):

• Targets: Multiplex amplification of packaging signal (psi) and envelope
• Discrimination: Intact (psi+env+), 3' defective (psi+env-), 5' defective (psi-env+)
• Advantage: Specifically quantifies genetically intact provinces

Cell-Associated HIV-1 RNA:

• Targets: Unspliced, multiply-spliced RNA
• Method: Reverse transcription digital PCR
• Significance: Measures transcriptional activity

Ultrasensitive Viral Load Testing

Technology: Single-copy assay with limit of detection <1 copy/mL Sample Processing: Ultracentrifugation of 1-5mL plasma Amplification: Nested or real-time PCR targeting conserved regions Frequency: Weekly for first 3 months post-ATI, then monthly Clinical Context: Essential for analytical treatment interruption (ATI) monitoring

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for HIV Reservoir and Immunity Monitoring

Reagent/Category	Specific Examples	Application	Technical Notes
HIV Peptide Libraries	Gag, Pol, Nef, Env overlapping peptides	T-cell stimulation assays	Use at 1-2μg/mL per peptide in pools
Cell Separation Kits	CD4+ T-cell isolation kits, resting CD4+ kits	Target cell purification	Multiple negative selection steps enhance purity
ELISPOT Kits	Human IFN-γ ELISPOT, IL-2 ELISPOT	T-cell frequency analysis	Optimize cell numbers to avoid saturation
Flow Cytometry Antibodies	CD3, CD4, CD8, CD45RA, CCR7, CD27, cytokines	Phenotyping and ICS	Include viability dye for dead cell exclusion
PCR Reagents	dPCR reagents for HIV LTR/gag, RNase P	Viral load and reservoir quantification	Digital PCR provides absolute quantification
Cell Culture Reagents	RPMI-1640, FBS, IL-2, PHA	QVOA and proliferation assays	Use consistent serum batches for reproducibility

Signaling Pathways in HIV-Specific Immunity

Diagram 1: HIV-Specific Immune Activation Pathways - This diagram illustrates the signaling cascades initiated by HIV antigen presentation, leading to both T-cell and B-cell activation, which are monitored post-transplantation to assess reservoir status.

Analytical Treatment Interruption Monitoring Framework

Structured ATI Protocol

Analytical treatment interruption represents the definitive test for HIV-1 remission but requires meticulous safety monitoring. The following framework synthesizes approaches from documented remission cases:

Pre-ATI Criteria:

• Stable full donor chimerism >95% for ≥6 months
• Undetectable HIV-1 DNA in PBMCs and CD4+ T-cells
• CD4 count >500 cells/μL without immunosuppression
• Absence of active GVHD

Monitoring During ATI:

• Plasma HIV-1 RNA: Weekly (weeks 1-12), then monthly
• CD4 count: Every 2 weeks
• HIV-1 serology: Monthly
• Reservoir assays: At baseline, 3, 6, and 12 months

Stopping Rules:

• Confirmed HIV-1 RNA >1,000 copies/mL on two consecutive tests
• CD4 decline to <350 cells/μL
• Clinical symptoms of acute retroviral syndrome

Integration of Immunological and Virological Data

Successful remission demonstrates coordinated decline across multiple parameters:

• HIV-1 RNA remains undetectable by single-copy assay
• HIV-1 DNA persists below detection threshold in CD4+ T-cells
• HIV-specific T-cell responses decline to background levels
• HIV-specific antibody titers and avidity progressively decrease

In the Geneva patient (IciS-34), sustained remission for 32 months post-ATI was accompanied by "declines in HIV antibodies and undetectable HIV-specific T cell responses" further corroborating the absence of viral rebound [19].

Comprehensive monitoring of HIV-specific antibody decay and T-cell responses provides critical insights into the status of the viral reservoir following CCR5Δ32/Δ32 hematopoietic stem cell transplantation. The methodologies detailed in this technical guide establish standardized approaches for evaluating intervention efficacy beyond direct virological assays alone. As HIV cure research advances, these immunological correlates will play an increasingly important role in identifying genuine remission and distinguishing it from mere reservoir reduction. The integrated framework presented here offers researchers a comprehensive toolkit for assessing the profound immunological changes associated with potential HIV-1 cure interventions.

Navigating Complexities: Interpretation of Residual Signals and Clinical Management

The pursuit of an HIV-1 cure has been underscored by cases of successful remission following CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation (allo-HSCT). A critical challenge in this field is the interpretation of sporadic HIV DNA signals detected in patients post-transplantation. This technical guide examines the body of evidence, including data from long-term remission cases, which distinguishes between non-infectious 'fossil' DNA—historical artifacts of past infection with no pathogenic potential—and genuine, replication-competent provirus. We detail the advanced virological and immunological assays essential for this differentiation, summarize quantitative findings in easy-to-reference tables, and provide standardized experimental workflows. This resource is intended to equip researchers and drug development professionals with the frameworks necessary for accurate reservoir monitoring and the evaluation of curative interventions.

Allo-HSCT from CCR5Δ32/Δ32 donors represents a paradigm-shifting intervention, demonstrating the potential for HIV-1 cure [53] [54] [55]. The procedure drastically reduces the measurable viral reservoir through a combination of conditioning chemotherapy, graft-versus-host immunity, and the replacement of susceptible host cells with CCR5-deficient donor cells that are resistant to the predominant CCR5-tropic virus [53] [54]. However, even in successful cases of cure, ultra-sensitive assays often continue to detect sporadic, low-level traces of HIV DNA in peripheral blood and tissues long after transplantation [53] [54]. The central question is whether these signals represent a residual, replication-competent reservoir capable of causing viral rebound, or merely defective 'fossil' DNA—non-viable genetic remnants of past infection that pose no threat of recrudescence.

Resolving this question is paramount for declaring a patient cured and for safely guiding clinical decisions, such as analytical treatment interruption (ATI). This guide provides an in-depth examination of the techniques and interpretive frameworks used to make this critical distinction.

The following tables consolidate key quantitative findings from pivotal studies of individuals who have undergone CCR5Δ32/Δ32 HSCT, as well as those on long-term ART, highlighting the frequency and nature of persistent HIV DNA.

Table 1: HIV DNA and RNA Detection in CCR5Δ32/Δ32 HSCT Cases with Sustained Remission

Case / Study Identifier	Time Post-HSCT / Post-ATI	Detection of HIV DNA	Detection of HIV RNA	Replication-Competent Virus (Outgrowth Assays)	Interpretation
IciStem no. 19 [54]	>9 years post-HSCT; 4 years post-ATI	Sporadic traces in T cell subsets & tissue biopsies (ddPCR, in situ hybridization)	Rare cells in tissue (RNAscope)	Not detected (ex vivo QVOA & in vivo humanized mouse models)	Fossil DNA; Cured
IciStem no. 34 [19]	72 months post-HSCT; 32 months post-ATI	Low levels sporadically detected; defective but not intact provirus	Undetectable in plasma	Not detected (CD4+ T cell culture post-ATI)	Fossil DNA; Sustained remission
Autopsy Study (IciS-05, IciS-11) [53]	Post-mortem tissue analysis	Proviral DNA in various tissues (e.g., lymph node)	Not Reported	Not Performed	Indicates tissue as a potential reservoir site, but viability unknown

Table 2: Clonality of the HIV Reservoir During Antiretroviral Therapy (ART) Studies show a majority of infected cells during ART are clonally expanded, which can include both defective and intact provinces [56] [57].

Study Focus	Sample Type	Key Finding on Clonality	Implication
Total HIV DNA [56] [57]	PBMCs from individuals on ART	1-16% of sequences were members of observed clones; ecological modeling infers >99% of infected cells are clonal.	Cellular proliferation, not viral replication, is the primary driver of HIV persistence on ART.
Replication-Competent HIV [56] [57]	Viral outgrowth assay isolates from individuals on ART	0-28% of sequences were members of observed clones; in samples with >20 sequences, the largest clone accounted for 11-42% of sequences.	The replication-competent reservoir is also highly clonal, arising from cellular proliferation.

Core Experimental Protocols for Reservoir Characterization

A multi-assay approach is critical to conclusively determine the nature of sporadic HIV DNA signals.

Ultrasensitive Nucleic Acid Detection

These assays are highly sensitive for detection but cannot distinguish viability.

• Droplet Digital PCR (ddPCR): Used for absolute quantification of HIV DNA targets (e.g., LTR, gag) in cell and tissue samples with high precision. It is the primary tool for detecting sporadic, low-copy signals [54].
• In Situ Hybridization (DNAscope/RNAscope): Provides spatial context by visually identifying cells harboring HIV DNA (DNAscope) or HIV RNA (RNAscope) within tissue sections (e.g., lymph node, gut). This confirms the presence of viral nucleic acids in anatomical reservoirs [54].

Assays for Replication-Competent Virus

These functional assays are the gold standard for proving the presence of an active reservoir.

• Quantitative Viral Outgrowth Assay (QVOA):

  • CD4+ T Cell Isolation: CD4+ T cells are purified from patient PBMCs or tissue homogenates via magnetic or fluorescence-activated cell sorting.
  • Limiting Dilution & Activation: Cells are serially diluted and activated with mitogens (e.g., PHA) and cytokines (e.g., IL-2) to induce virus production from latently infected cells.
  • Co-culture: Activated patient CD4+ T cells are co-cultured with CD8-depleted PBMCs from healthy donors (feeder cells) to amplify any released virus.
  • Detection of Viral Replication: Culture supernatants are tested periodically (e.g., days 7, 14, 21) for HIV p24 antigen by ELISA. A positive p24 signal indicates the presence of replication-competent virus in the original sample [54].

• In Vivo Outgrowth Assays (Humanized Mouse Models):

  • Cell Engraftment: PBMCs or CD4+ T cells from the patient are transplanted into immunodeficient mice (e.g., NSG mice).
  • Monitoring: Mouse plasma is monitored over several weeks for the emergence of HIV-1 RNA.
  • Confirmation: The absence of viremia in the mice provides strong in vivo evidence for a lack of replication-competent reservoir [54].

Intact Proviral DNA Assay (IPDA)

• Principle: The IPDA is a digital PCR-based assay that simultaneously targets two conserved regions of the HIV genome (e.g., psi and env) to discriminate between intact and defective proviruses.
• Procedure: The DNA sample is partitioned into thousands of droplets. Amplification signals in both channels indicate a high likelihood of an intact provirus. Defective proviruses, which constitute the vast majority of HIV DNA, show amplification in only one channel or none [19].

Immunological Correlates of Antigen Persistence

• HIV-Specific Antibody Response: A progressive decline and eventual loss of HIV-specific antibodies (measured by immunoblot) indicates a cessation of antigenic stimulation, supporting the absence of active virus [54].
• HIV-Specific T-Cell Responses: The waning and eventual disappearance of HIV-specific T-cell responses (measured by IFN-γ ELISpot or intracellular cytokine staining) further corroborates the lack of ongoing antigen presentation [54].

Diagram: A multi-assay framework is required to interpret sporadic HIV DNA signals and distinguish non-viable 'fossil' DNA from a replication-competent reservoir.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for HIV Reservoir Research

Research Reagent / Assay	Function and Application in Reservoir Studies
CCR5Δ32/Δ32 Donor Cells	Provides the source of HIV-resistant immune cells for transplantation studies; crucial for establishing a resistant host environment [53] [54].
Droplet Digital PCR (ddPCR)	Enables absolute quantification of low-abundance HIV DNA targets with high precision in patient samples; essential for detecting sporadic signals [54].
DNAscope/RNAscope Kits	Allows for visualization and spatial localization of HIV DNA and RNA within tissue sections, identifying anatomical sanctuaries [54].
QVOA Reagents	Mitogens (PHA), cytokines (IL-2), and feeder cells from healthy donors are used in co-cultures to induce and amplify replication-competent virus from latent reservoirs [54].
Humanized Mouse Models	Immunodeficient mice (e.g., NSG) serve as in vivo amplification systems to test for the presence of replication-competent virus in patient cells [54].
IPDA Primer/Probe Sets	Digital PCR assays designed to simultaneously probe multiple HIV genomic regions to discriminate intact from defective proviruses [19].
ELISpot Kits (IFN-γ)	Used to measure the frequency and potency of HIV-specific T-cell responses, which serve as a correlate of ongoing antigen exposure [54].

Discussion and Future Directions

The collective evidence from cured individuals confirms that the mere detection of HIV DNA, even in tissues, is not synonymous with the presence of a dangerous, replication-competent reservoir. Instead, a consistent pattern emerges: the convergence of negative findings from functional outgrowth assays, the specific absence of intact proviruses, and the waning of antiviral immune responses provides a robust signature of 'fossil' DNA [54] [19]. Furthermore, research in individuals on long-term ART shows that the persistence of HIV DNA is heavily driven by the clonal expansion of infected cells—a process that can perpetuate both defective and intact provinces, further complicating the interpretation of DNA signals [56] [57].

Future research must focus on refining the sensitivity and scalability of intact provirus assays and standardizing the definitions of remission and cure. The surprising case of sustained HIV remission after allo-HSCT with wild-type CCR5 donor cells, potentially aided by post-transplant immunosuppression (e.g., ruxolitinib), suggests that potent graft-versus-reservoir effects and other immune mechanisms can also contribute to viral control, opening new avenues for investigation [19]. As curative strategies evolve, the multi-assay framework outlined in this guide will remain essential for accurately evaluating their success.

{ remove this line and add the DOT script for diagram 1 }

{ remove this line and add the DOT script for diagram 2 }

Impact of Graft-versus-Host Disease (GvHD) and Immunosuppression on Reservoir Dynamics

Within the pursuit of an HIV cure, allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a powerful, albeit high-risk, intervention that can profoundly reshape the landscape of the viral reservoir. While transplants using CCR5Δ32/Δ32 donor cells have led to well-documented cures, the specific roles of Graft-versus-Host Disease (GvHD) and concomitant immunosuppressive therapies on reservoir dynamics are complex and critical to unravel. GvHD, a common complication of allo-HSCT, involves donor immune cells attacking recipient tissues. Emerging evidence from clinical observations suggests that this alloreactive response may concurrently target host cells harboring the HIV reservoir, a phenomenon often termed a "graft-versus-reservoir" (GvR) effect [58]. However, managing GvHD requires immunosuppressive drugs, which could theoretically blunt the very immune responses needed for viral clearance. This technical guide synthesizes current evidence on these intricate interactions, providing researchers with a framework for understanding and investigating reservoir dynamics in the context of allo-HSCT.

GvHD and the "Graft-versus-Reservoir" Effect

The association between GvHD and a reduction in HIV reservoirs is supported by clinical data, pointing toward an indirect graft-versus-reservoir effect.

Clinical Evidence and Proposed Mechanism

Evidence from the IciStem cohort, the largest prospective study of people with HIV undergoing allo-HSCT, indicates that the development of acute GvHD is correlated with a more substantial reduction in the frequency of infected cells compared to patients without GvHD [58]. This observation aligns with the hypothesis that the widespread allogeneic immune response against host tissues may also eliminate long-lived recipient immune cells that form the latent HIV reservoir. The mechanism is analogous to the established graft-versus-leukemia effect, where the same process helps prevent cancer relapse [16]. In this model, donor-derived alloreactive T cells, activated by host antigens, target and clear recipient CD4+ T cells—the primary reservoir for HIV—thereby purging the body of a significant portion of latently infected cells.

Quantitative Impact on Reservoir Metrics

The impact of transplantation, potentiated by GvHD, on the HIV reservoir is quantifiable through various virological markers. The following table summarizes the key changes observed in these parameters.

Table 1: Impact of Allo-HSCT and GvHD on HIV Reservoir and Immune Markers

Parameter	Pre-Transplant Levels	Post-Transplant Trends	Correlation with GvHD
Cell-Associated HIV DNA	Detectable at high levels (e.g., hundreds of copies/million cells) [19]	Rapid, profound reduction; often to undetectable levels [58]	Stronger reduction observed in patients with acute GvHD [58]
Replication-Competent Virus	Present in viral outgrowth assays	Loss of virus recovery in culture post-ART interruption [19]	Associated with clearance of latently infected cells
HIV-Specific Antibodies	Positive on Western blot and Ag/Ab assays	Progressive decline, sometimes to trace/negative levels [19] [59]	Declines lag behind reservoir reduction, indicating absence of antigen [58]
HIV-Specific T Cell Responses	Detectable	Waning to undetectable levels post-transplant [19] [59]	Suggests elimination of antigen-presenting host cells

Immunosuppression: A Double-Edged Sword

The management of GvHD with immunosuppressive drugs creates a therapeutic paradox. While necessary to mitigate tissue damage, these agents may theoretically interfere with the GvR effect. However, clinical evidence presents a more nuanced picture.

The Case for Ruxolitinib and Sustained Remission

A pivotal case challenging simple assumptions is the "Geneva patient" (IciS-34), who received a transplant from a wild-type CCR5 donor. This individual continued ART until 40 months post-transplant, at which point treatment was stopped. Despite receiving the Jak1/2 inhibitor ruxolitinib for chronic GvHD management, the patient maintained an undetectable plasma viral load for 32 months after ART interruption [19]. Low levels of proviral DNA were sporadically detected, but only defective—not intact—HIV DNA was found. Critically, no replication-competent virus could be amplified from cultured CD4+ T cells, and HIV-specific antibody and T-cell responses waned, corroborating the absence of active viral replication [19]. This case demonstrates that HIV remission is achievable even under ongoing immunosuppression, indicating that the reservoir-reductive effects of the transplant and GvHD can be durable.

Cautions and Contrasting Outcomes

Conversely, other cases highlight the risk of viral rebound years after transplant, underscoring that reservoir reduction is not always synonymous with elimination. In one reported case, a patient experienced a dramatic viral rebound with over 10 million RNA copies/mL nearly four years post-HSCT, despite having previously shown marked reductions in HIV antibodies and undetectable HIV DNA in peripheral blood CD4+ T cells [59]. This rebound confirms that replication-competent HIV can persist in tissue sanctuaries or at levels below the detection limit of current assays, and can re-emerge once immunosuppressive pressure is altered or the GvR effect wanes.

Experimental Protocols for Reservoir Monitoring

Robust experimental methodologies are essential for accurately assessing the size and composition of the residual HIV reservoir in the context of allo-HSCT. The following section details key protocols cited in the research.

Quantification of Cell-Associated HIV DNA

Objective: To measure the frequency of cells harboring HIV DNA (both total and intact provirus) in blood and tissue samples.

• Sample Collection: Serial samples of Peripheral Blood Mononuclear Cells (PBMCs), purified CD4+ T cells from blood, and bone marrow or lymph node cells are collected before and at multiple time points after transplantation [19] [59].
• Nucleic Acid Extraction: DNA is extracted from the cell samples using commercial kits.
• PCR Amplification: Droplet Digital PCR (ddPCR) or quantitative PCR (qPCR) assays targeting conserved regions of the HIV genome (e.g., pol or gag) are used to quantify total HIV DNA [19] [58].
• Intact Provirus Assay: More advanced assays, such as the Intact Proviral DNA Assay (IPDA), are employed to distinguish genetically intact, replication-competent proviruses from defective ones. This is critical, as the latter dominate the reservoir post-transplant [19].
• Data Analysis: Results are normalized to the number of input cells (e.g., copies per million cells) and tracked longitudinally.

Quantitative Viral Outgrowth Assay (QVOA)

Objective: To measure the frequency of CD4+ T cells harboring inducible, replication-competent HIV.

• Cell Isolation: CD4+ T cells are isolated in large numbers from patient PBMCs via negative selection.
• Limiting Dilution and Activation: The cells are serially diluted and activated using mitogens (e.g., PHA) and mixed with HIV-negative donor CD4+ T cells (feeder cells) to stimulate virus production from any latently infected cells [16].
• Co-culture and Amplification: The cultures are maintained for an extended period (e.g., 1-2 weeks), with periodic addition of fresh feeder cells to allow for amplification of released virus.
• Viral Detection: The culture supernatants are tested for the presence of HIV p24 antigen via ELISA. The frequency of infected cells is calculated based on the dilutions at which p24 is detected [16].

HIV-Specific Serology and T-Cell Response Profiling

Objective: To monitor the humoral and cellular immune response to HIV as an indirect marker of antigen presence.

• Antibody Detection: HIV antigen/antibody (Ag/Ab) tests (e.g., CMIA, EIA) and Western blot are performed on serial plasma samples. A progressive decline or seroreversion indicates a lack of ongoing antigenic stimulation [19] [59].
• T-Cell Assays: IFN-γ ELISpot or intracellular cytokine staining (ICS) is used to quantify T cells that produce cytokines in response to HIV-specific peptides (e.g., Gag, Nef). The waning of these responses suggests the elimination of host antigen-presenting cells [19] [59].

Visualizing the GvHD-Mediated Reservoir Clearance

The following diagram illustrates the proposed mechanism by which GvHD contributes to the clearance of the HIV reservoir.

Diagram 1: Proposed GvR effect mechanism. Allogeneic immunity from donor cells can target both host tissues (causing GvHD) and host CD4+ T cells containing the HIV reservoir (GvR effect), leading to reservoir reduction.

The Scientist's Toolkit: Key Research Reagents

Research into HIV reservoir dynamics requires a suite of specialized reagents and assays. The following table details essential tools for this field.

Table 2: Essential Research Reagents for HIV Reservoir Monitoring

Research Reagent / Assay	Function / Application	Technical Notes
Droplet Digital PCR (ddPCR)	Absolute quantification of total HIV DNA in cell lysates.	Provides high precision for low-abundance targets; critical for tracking reservoir decay post-HSCT [19] [58].
Intact Proviral DNA Assay (IPDA)	Multiplex ddPCR assay to distinguish intact from defective proviruses.	Targets two regions of HIV genome; essential for assessing the replication-competent reservoir, which is the true barrier to cure [19].
Quantitative VOA (QVOA)	Gold-standard functional assay to quantify inducible, replication-competent virus.	Labor-intensive and low-throughput, but provides the definitive measure of the latent reservoir [16].
IFN-γ ELISpot	Detection of HIV-specific T-cell responses.	Monitors adaptive immunity decline, which corroborates reservoir reduction [19] [59].
HIV Ag/Ab CMIA & Western Blot	Measurement of HIV-specific antibody levels and specificity.	Serological decline is a key indirect marker of sustained remission after ART interruption [19] [59] [58].

The interplay between GvHD, immunosuppression, and HIV reservoir dynamics is complex and defies simplistic conclusions. Clinical evidence confirms that GvHD is correlated with a profound reduction in reservoir measures, likely through a graft-versus-reservoir effect. Furthermore, the case of the Geneva patient demonstrates that sustained HIV remission is possible even with wild-type CCR5 grafts and ongoing immunosuppressive therapy with drugs like ruxolitinib. This suggests that the conditioning regimen and the initial alloreactive response may achieve a critical threshold of reservoir depletion that can be maintained. However, the risk of late viral rebound, as seen in other cases, underscores that some replication-competent virus can persist indefinitely. Future research must focus on identifying the specific immune effector cells and target antigens responsible for the GvR effect, optimizing immunosuppressive regimens to balance GvHD management and viral control, and developing more sensitive assays to detect the minimal residual reservoir that predicts lasting cure.

Despite the remarkable success of antiretroviral therapy (ART), the persistence of the HIV-1 reservoir remains the principal barrier to a cure. Viral rebound—the recrudescence of detectable viremia following ART interruption—is a critical endpoint in cure research, signifying the failure of an intervention to control the latent reservoir. This whitepaper analyzes documented cases of viral rebound, with a specific focus on the context of CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation (allo-HSCT), a intervention that has led to sustained remission in a few individuals. We synthesize data from clinical studies to delineate the factors that contribute to rebound and provide a technical overview of the advanced assays used to monitor the reservoir and predict rebound risk.

Documented Cases and Contributing Factors for Viral Rebound

The success of CCR5Δ32/Δ32 allo-HSCT in achieving HIV-1 remission is well-documented in cases like the "London" and "Düsseldorf" patients [11] [54]. However, these are exceptions, and analysis of failure cases reveals a consistent set of contributing factors. The following table summarizes key determinants of viral rebound, synthesizing evidence from both HSCT and ART-only contexts.

Table 1: Factors Contributing to Viral Rebound

Contributing Factor	Mechanism & Evidence	Supporting Data
Persistence of Viral Reservoirs in Tissues	Latently infected cells persist in lymphoid and gut tissues despite undetectable virus in blood; these cells can reinitiate replication post-treatment interruption [53].	Autopsy study detected HIV-1 DNA variants identical to pre-transplantation viruses in lymph node and other tissue biopsies post-CCR5Δ32/Δ32 HSCT, despite its absence in PBMCs [53].
Pre-existing CXCR4-tropic Virus	CCR5Δ32/Δ32 HSCT only protects cells from CCR5-tropic HIV; pre-existing minority variants that use the CXCR4 co-receptor can cause rapid rebound [11].	The "Essen Patient" experienced rapid viral rebound post-transplant with a pre-existing CXCR4-tropic variant, while patients with only CCR5-tropic virus achieved remission [11].
Poor Adherence to ART	Inconsistent drug intake leads to subtherapeutic drug levels, permitting viral replication and the development of drug resistance, directly causing rebound during therapy [60] [61].	Poor adherence to ART was the strongest predictor of viral rebound (aOR = 175.48) in a cohort study in Ghana [60]. Another study found good adherence was strongly associated with viral suppression [61].
Suboptimal ART Regimens	Less potent, older drug regimens with lower genetic barriers to resistance or poorer tolerability can lead to higher rates of virological failure [60] [62].	Nevirapine-based regimens were associated with higher odds of viral rebound compared to dolutegravir-based regimens [60] [62].
Advanced WHO Clinical Stage at Diagnosis	Advanced disease indicates a larger initial reservoir and potentially compromised immune function, making durable viral suppression more difficult to achieve [60] [61].	Diagnosis at WHO stage II and III was independently associated with higher odds of viral rebound [60]. Another study found WHO stage I was associated with viral suppression [61].
Socioeconomic & Behavioral Factors	Lower health literacy and financial barriers can impact adherence and retention in care [62].	A study in Ghana identified lower educational levels (up to Junior High School) as significantly associated with viral rebound [62].

The interplay of these factors can be conceptualized as a pathway leading to either viral suppression or rebound, as illustrated below.

The Scientist's Toolkit: Key Reagents and Assays for Reservoir Monitoring

Accurately quantifying the HIV-1 reservoir is essential for evaluating cure strategies and assessing rebound risk. The assays below represent the cornerstone of reservoir monitoring in clinical research.

Table 2: Essential Research Reagent Solutions for HIV-1 Reservoir Monitoring

Research Tool / Assay	Core Function & Principle	Key Application in Rebound Risk Assessment
Droplet Digital PCR (ddPCR) / Microfluidic dPCR	Partitions sample into thousands of nano-reactions for absolute quantification of nucleic acids without a standard curve. Offers high sensitivity and precision for low-abundance targets [7].	Total HIV DNA quantification as a surrogate for reservoir size. The duplex assay targeting HIV LTR and human RPP30 allows for precise normalization [7].
Intact Proviral DNA Assay (IPDA)	A digital PCR-based assay that simultaneously probes two conserved regions of the HIV genome (packaging signal and Rev response element) to distinguish genetically "intact" from "defective" provinces [38].	Quantifies the replication-competent reservoir, which is more clinically relevant than total DNA. Chip-based dPCR systems can automate IPDA workflow [38].
Quantitative Viral Outgrowth Assay (QVOA)	The historical gold-standard functional assay. Limits dilutions of patient CD4+ T cells are activated to induce virus production, which is then measured by co-culture with permissive cells [11] [54].	Provides a minimal estimate of the frequency of cells harboring replication-competent virus, reported in Infectious Units Per Million (IUPM) cells [11].
In Vivo Outgrowth Assay (Humanized Mouse Models)	An in vivo functional assay. Patient-derived cells are transplanted into immunodeficient mice engineered with a human immune system. The absence of viral rebound in the mice indicates a lack of replication-competent virus in the sample [54].	Used as a more sensitive follow-up to QVOA to confirm the absence of infectious virus in patients suspected of being cured [54].
In Situ Hybridization (RNAscope/DNAscope)	Preserves tissue architecture to visually localize and quantify cells harboring HIV-1 DNA or RNA within tissue sections (e.g., lymph node, gut) [54].	Critical for identifying and quantifying viral persistence in anatomical reservoirs that are not accessible in blood, providing context for rebound origins [53] [54].

Detailed Experimental Protocols for Key Assays

To ensure reproducibility and rigor in reservoir studies, detailed methodologies are paramount. Below are protocols for two foundational assays.

Protocol: Duplex Digital PCR for Total HIV-1 DNA Quantification

This protocol, adapted from the 2025 study by Sánchez et al., details the quantification of total HIV DNA on a microfluidic chamber array platform (e.g., Absolute Q) [7].

• Sample Preparation: Isolate genomic DNA from patient PBMCs or CD4+ T cells using a standard column-based or magnetic bead method. Preferentially use high-quality DNA with an A260/A280 ratio of ~1.8.
• Reaction Mix Setup:
  • Prepare a master mix containing:
    • 1X Absolute Q Digital PCR Master Mix.
    • 900 nM each of forward and reverse primers for the HIV-1 LTR-RU5 region.
    • 250 nM of FAM-labeled probe for HIV-1 LTR-RU5.
    • 900 nM each of forward and reverse primers for the single-copy human RPP30 gene.
    • 250 nM of VIC-labeled probe for RPP30.
    • Approximately 50-330 ng of sample DNA (adjust volume with nuclease-free water).
  • Include a no-template control (NTC) and positive controls (e.g., 8E5 cell line DNA).
• Loading and Partitioning: Pipette the reaction mix into the sample inlet of an Absolute Q Digital PCR Plate. The instrument automatically partitions the sample into ~20,000 individual microchambers.
• Thermal Cycling: Run the plate on the Absolute Q instrument with the following cycling conditions:
  • Enzyme Activation: 10 min at 96°C.
  • 40 cycles of:
    • Denaturation: 10 s at 96°C.
    • Annealing/Extension: 50 s at 60°C.
  • Hold: 4°C.
• Imaging and Analysis: The instrument performs endpoint fluorescence imaging of each chamber. Use the proprietary software to set fluorescence thresholds for FAM (HIV-1) and VIC (RPP30) channels. The software applies Poisson statistics to calculate the absolute concentration of HIV-1 DNA copies and RPP30 copies per microliter of reaction.
• Data Normalization and Reporting:
  • Normalize the HIV-1 DNA copies to the diploid genome equivalent calculated from the RPP30 copies (2 copies per cell).
  • Report the final result as HIV-1 DNA copies per million cells or per microgram of DNA.

Protocol: Intact Proviral DNA Assay (IPDA) on a Chip-Based dPCR System

This protocol is adapted from the work validating IPDA on chip-based systems [38].

• Assay Design and Validation: The IPDA uses two primer/probe sets targeting:
  • PSI (Ψ): A region in the packaging signal. Use a FAM-labeled probe.
  • RRE: A segment within the Rev response element. Use a VIC-labeled probe.
  • Critical Note: The original IPDA was designed for HIV-1 subtype B. Performance on non-B subtypes is variable and requires validation or subtype-specific primer/probe adjustments [38].
• Sample and Reaction Setup:
  • Use 50-200 ng of genomic DNA.
  • Prepare a master mix with the digital PCR master mix, primers, and probes for both PSI and RRE targets according to optimized concentrations.
• Chip-Based dPCR Run: Load the reaction mix onto the chip-based dPCR system (e.g., the BioMark HD system with Digital PCR chips). The system partitions the sample into individual reactions.
• Thermal Cycling and Imaging: Perform PCR amplification followed by endpoint fluorescence reading for both channels.
• Data Interpretation and Gating:
  • Intact Provirus: Chambers positive for both FAM (PSI) and VIC (RRE) are scored as containing an intact provirus.
  • 5'-Defective Provirus: Chambers positive for FAM (PSI) only.
  • 3'-Defective Provirus: Chambers positive for VIC (RRE) only.
  • Double Negative: Chambers negative for both signals.
  • The fraction of intact provinces is calculated using Poisson statistics and normalized to cell number, often reported as intact proviral copies per million cells.

Quantitative Data on Suppression and Rebound in Broader Populations

Beyond the unique context of HSCT, understanding viral rebound during standard ART is crucial for public health and clinical management. The following table compiles key metrics from recent observational studies.

Table 3: Epidemiological Data on Viral Suppression and Rebound from ART Cohort Studies

Study Location (Cohort)	Viral Suppression Rate	Viral Rebound Rate / Incidence	Key Associated Factors for Rebound
Kumasi, Ghana [60]	76.1%	21.0% of participants	Poor adherence, WHO stage II/III, Zidovudine/Lamivudine/Efavirenz regimen [60].
Greater Accra, Ghana [62]	88% at 18 months	13.61 per 1,000 person-months	Lower educational level (JHS or less) [62].
Kilifi, Kenya [61]	59% overall (site-specific: 12% - 82%)	41% overall; Incidence: 0.7 - 14.4 per 100 person-months	Poor ART adherence, WHO stage II, longer duration on ART (36 months) [61].

The risk of viral rebound is a multifaceted challenge, governed by virological, immunological, clinical, and socioeconomic factors. In the context of curative strategies like CCR5Δ32/Δ32 HSCT, the complete eradication of the reservoir—particularly from deep tissue sanctuaries—and the exclusion of CXCR4-tropic virus are critical determinants of success. For the broader population on ART, sustained adherence to potent regimens remains the cornerstone of preventing rebound. The ongoing development and standardization of sensitive, high-throughput reservoir assays, such as the duplex dPCR and IPDA, are indispensable for accurately quantifying the rebound-competent reservoir and evaluating the efficacy of future cure interventions. A comprehensive understanding of these factors and tools is essential for progressing toward the ultimate goal of a durable HIV-1 cure.

Analytical Treatment Interruption (ATI) represents an essential, yet carefully managed, component in clinical trials investigating novel HIV cure and remission strategies. As antiretroviral therapy (ART) effectively suppresses HIV viral load but cannot eradicate the infection, lifelong treatment is required for people living with HIV [63]. The main obstacle to eradication is the HIV reservoir—cells where HIV remains latent [63]. ATI provides the only definitive method to evaluate whether an intervention can induce sustained HIV remission by assessing viral control after stopping ART [63] [64]. In the context of CCR5Δ32/Δ32 hematopoietic stem cell transplantation (HSCT), a procedure that has led to documented cures of HIV [11] [12], ATI serves as the critical test to confirm whether HIV remission or cure has been achieved.

The design of ATI protocols has evolved significantly in response to safety concerns, particularly following the SMART study which showed that prolonged treatment interruption increased risks of opportunistic disease and death [63]. Modern ATI trials incorporate shorter interruption phases and more frequent viral load monitoring to mitigate risks associated with prolonged viremia [63] [64]. This technical guide outlines evidence-based protocols for implementing ATI in post-transplant settings, with specific consideration to the unique immunological environment following HSCT.

ATI Outcome Measures and Their Applications

The selection of appropriate virologic outcome measures is guided by the scientific question and the mechanism of action of the intervention being investigated [63]. The table below summarizes the primary endpoints used in ATI trials.

Table 1: Key Virologic Outcome Measures in ATI Trials

Outcome Measure	Definition	ATI Design	Primary Application	Safety Profile
Time to Viral Rebound	Time maintaining viral control below a preset HIV RNA threshold [63]	Time-to-event; ART resumed once viral load surpasses threshold [64]	Demonstrates ability of intervention to delay viral rebound [64]	Generally safer due to limited viremia duration [63] [64]
Viral Control	Binary assessment of whether HIV RNA remains below a threshold at a prespecified time point post-ATI [63]	Binary; ART resumed if predetermined viral set point not reached within timeframe [64]	Evaluates sustained viral suppression without ART; necessary for regulatory approval [63]	Variable; depends on threshold and monitoring frequency [64]
Viral Set Point	Level at which viremia stabilizes after initial rebound [63] [64]	Set point; allows some viral replication to establish new equilibrium [64]	Measures intervention's ability to induce post-rebound control [64]	Higher risk due to longer viremia exposure [64]

Special Considerations for Post-Transplant Settings

For individuals who have undergone CCR5Δ32/Δ32 HSCT, ATI protocols require particular attention to immune reconstitution and graft-versus-host disease (GvHD) management. Published cases of sustained remission show continuous monitoring for several years post-transplant before attempting ATI [19] [12]. The confirmed cures, including the "London patient" and "Geneva patient," underwent ATI only after achieving full donor chimerism and demonstrating undetectable reservoir metrics through extensive testing [11] [12].

Figure 1: ATI Decision Pathway Post-Transplant

Pre-ATI Patient Eligibility and Assessment

Eligibility Criteria

Consensus workshops have established standardized eligibility criteria for ATI trials [64]. These criteria ensure participant safety while enabling scientifically valid assessment of intervention efficacy.

Table 2: ATI Eligibility and Exclusion Criteria

Eligibility Criteria	Exclusion Criteria
Stable ART regimen with confirmed viral suppression (<50 copies/mL) for typically ≥2 years [64]	CD4+ T cell count <500 cells/μL [64]
CD4+ T cell count ≥500 cells/μL [64]	Active or poorly controlled psychiatric conditions [64]
No AIDS-defining illness within 12 months [64]	Pregnancy, breastfeeding, or unwillingness to use effective contraception [64]
Normal laboratory values (hematological, renal, hepatic) [64]	History of clinical resistance to proposed restart ART regimen [64]
Willingness to use highly effective barrier protection [64]	Receipt of long-acting ART or broadly neutralizing antibodies within past 2 years [64]

For post-transplant patients, additional criteria include full donor chimerism (≥95% in peripheral blood cells) and complete hematologic recovery [19] [12]. The timing of ATI must also consider immunosuppressive therapies for GvHD management, as these may affect viral dynamics and immune function [19].

Pre-ATI Reservoir Quantification Protocols

Comprehensive HIV reservoir assessment is essential before considering ATI. The following multi-assay approach provides complementary measures of reservoir size and activity:

• Intact Proviral DNA Assay (IPDA): This droplet digital PCR (ddPCR)-based method distinguishes intact from defective proviruses [12]. The protocol involves: (1) extraction of genomic DNA from purified CD4+ T cells; (2) amplification with primer/probe sets targeting HIV packaging signal (Ψ) and Rev response element (RRE); (3) quantification of intact (Ψ+RRE+), defective (Ψ+RRE- or Ψ-RRE+), and total proviruses [12].
• Quantitative Viral Outgrowth Assay (QVOA): This functional assay estimates the frequency of cells harboring replication-competent virus [11] [12]. The methodology includes: (1) limiting dilution of resting CD4+ T cells; (2) activation with mitogens; (3) co-culture with feeder cells; (4) measurement of p24 production in supernatants; (5) calculation of infectious units per million (IUPM) cells [11].
• Ultrasensitive Viral Load Testing: Employing assays with single-copy sensitivity (<1 copy/mL) to detect residual viremia [12].
• Viral Tropism Analysis: Deep sequencing of the V3 loop in HIV envelope to confirm CCR5-tropism, particularly important for CCR5Δ32/Δ32 transplant recipients [11].

ATI Monitoring and ART Resumption Protocols

Viral Load Monitoring Schedules

Frequent monitoring is critical for participant safety during ATI. The schedule should be tailored to the expected viral dynamics based on the ATI type.

Table 3: Recommended Monitoring Schedule During ATI

Period	Frequency	Assays	Special Considerations
Weeks 1-4	Weekly	Plasma HIV RNA (sensitivity <50 copies/mL) [65]	Initial viral rebound typically occurs at median of 16 days [65]
Weeks 5-12	Every 2 weeks	Plasma HIV RNA, CD4+ T cell count, clinical symptoms [64]	96% of participants rebound by week 12 [65]
Beyond Week 12	Monthly	Plasma HIV RNA, CD4+ T cell count, STI screening if applicable [64]	For set point ATI or post-treatment controller identification [64]
At ART Resumption	Weeks 2, 4, 8, 12	Plasma HIV RNA, drug level testing (if applicable) [66]	Ensure viral re-suppression; integrase inhibitors promote rapid suppression [66]

ART Resumption Criteria

Standardized ART restart criteria balance scientific objectives with participant safety [64]. The following conditions should trigger immediate ART reinitiation:

• Confirmed viral rebound: Two consecutive HIV RNA measurements >1,000 copies/mL or a single measurement >10,000 copies/mL [64]
• CD4+ T cell decline: CD4+ T cell count <350 cells/μL or decline >30% from baseline [64]
• Clinical indications: Any AIDS-defining illness, acute retroviral syndrome, or pregnancy [64]
• Participant request: Regardless of virologic or immunologic parameters [64]

For post-transplant patients, additional considerations include significant GvHD exacerbation or opportunistic infections that may compromise immune function [19].

Post-ATI Follow-up and Data Interpretation

Defining Remission and Cure

The field has established standardized terminology for describing outcomes after ATI:

• Post-Treatment Controller (PTC): Maintains viral suppression (HIV RNA <50 copies/mL) after ART discontinuation without intervention [65]. Only 4% of participants in control cohorts maintain suppression at day 84 post-ATI, with higher rates (6%) in those who started ART early [65].
• Post-Intervention Controller (PIC): Demonstrates sustained viral suppression after receiving an experimental intervention [64].
• Sustained Remission: Maintenance of aviremia for an extended period (typically ≥2 years) after ATI [12].
• Cure: Complete elimination of replication-competent virus, as demonstrated by extensive reservoir analyses and prolonged aviremia [12].

Essential Laboratory Methods for Remission Confirmation

Figure 2: Comprehensive Reservoir Assessment Workflow

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Research Reagents for HIV Reservoir Studies

Reagent/Category	Specific Examples	Research Application
Nucleic Acid Detection	ddPCR assays for HIV LTR/gag [12], IPDA [12], RNAscope/DNAscope [12]	Quantification of HIV DNA/RNA at single-copy sensitivity; spatial localization in tissues
Cell Culture & Viral Outgrowth	Humanized mouse models (NSG, BLT) [12], CD4+ T cell isolation kits, p24 ELISA [11]	Detection of replication-competent virus through in vivo and ex vivo outgrowth assays
Immunologic Assays	MHC tetramers for HIV epitopes [12], IFN-γ ELISpot [12], intracellular cytokine staining panels	Measurement of HIV-specific T-cell responses; assessment of immune reconstitution
Serologic Tests	HIV antibody avidity assays [11], Western blot [12]	Documentation of waning humoral immunity in absence of antigen
Tropism & Entry Assays	CCR5Δ32 genotyping kits [11], envelope sequencing primers [11], coreceptor antagonist	Confirmation of CCR5 tropism and resistance to infection

Ethical and Safety Considerations

ATI implementation requires careful attention to ethical considerations and risk mitigation [64]. Two confirmed HIV transmissions have occurred during ATI trials, highlighting the critical importance of partner protection strategies [64]. Recommended safeguards include:

• Comprehensive partner pre-exposure prophylaxis (PrEP) counseling and provision [64]
• Regular STI screening as a surrogate for barrier method adherence [64]
• Frequent safety monitoring with predefined thresholds for ART resumption [63] [64]
• Transparent risk-benefit discussions during informed consent [64]

Recent guidelines have removed the diagnosis of new STIs as an automatic ART restart criterion, instead emphasizing intensified counseling to assess and reduce transmission risk [64].

Analytical Treatment Interruption remains an indispensable component of HIV cure research, particularly in assessing the efficacy of CCR5Δ32/Δ32 hematopoietic stem cell transplantation. The protocols outlined in this document provide a framework for safely conducting ATI while generating scientifically valid endpoints. As the field advances toward combination interventions and less invasive approaches, ATI design will continue to evolve. Standardization of monitoring protocols, reservoir assays, and outcome measures across research groups will facilitate comparisons between studies and accelerate the development of scalable HIV cure strategies.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a promising but complex intervention for achieving HIV remission, particularly when using CCR5Δ32/Δ32 donor cells. Within this therapeutic framework, managing co-morbidities—specifically malignancy relapse and opportunistic infections (OIs)—is critical for patient survival and for accurately assessing the success of HIV reservoir eradication. The profound immunosuppression inherent to the transplant process, combined with the pre-existing immune dysfunction from HIV, creates a challenging clinical landscape. This guide synthesizes current evidence and protocols for monitoring and managing these co-morbidities, providing a technical resource for researchers and clinicians developing cure strategies.

Clinical Context: HIV Remission After Allo-HSCT

The Evolving Paradigm of CCR5Δ32 and Wild-Type Transplants

The paradigm for achieving HIV remission via allo-HSCT has evolved significantly. Initial success was exclusively linked to transplants from donors homozygous for the CCR5Δ32 mutation, which confers natural resistance to R5-tropic HIV by eliminating the coreceptor on the cell surface [15]. The cases known as the "Berlin," "London," and "Düsseldorf" patients all followed this model. However, a pivotal case (the "Geneva patient") demonstrated sustained HIV remission for over 32 months after ART interruption following an allo-HSCT from a wild-type CCR5 donor [19]. This suggests that factors beyond donor CCR5 genotype, particularly the graft-versus-reservoir (GvR) effect, play a crucial role in eliminating the viral reservoir [15].

The Critical Role of Full Donor Chimerism

A consistent hematological marker for successful HIV remission is the achievement of full donor chimerism. This state, where the recipient's hematopoietic system is completely replaced by donor-derived cells, is a prerequisite for the significant reduction of the HIV reservoir observed post-transplant [15]. The reservoir half-life shortens dramatically to several months following the establishment of full donor chimerism, underscoring the importance of aggressive monitoring of chimerism levels in total leukocytes and specific cell subpopulations (e.g., T cells, myeloid cells) [15].

Table 1: Key Cases of HIV Remission After Allo-HSCT

Patient Identifier	Donor CCR5 Status	Condition Treated	ART Interruption Outcome	Key Contributing Factors
Berlin Patient [15]	CCR5Δ32/Δ32	Leukemia	Cure	CCR5Δ32/Δ32 donor, conditioning, GvHD
London Patient [15]	CCR5Δ32/Δ32	Lymphoma	Cure	CCR5Δ32/Δ32 donor, full donor chimerism
Geneva Patient [19]	Wild-type	Myeloid Sarcoma	Remission >32 months	Full donor chimerism, GvR effect, ruxolitinib for GvHD
Düsseldorf Patient [15]	CCR5Δ32/Δ32	Leukemia	Cure	CCR5Δ32/Δ32 donor

Malignancy Relapse: Monitoring and Management

Pathogenesis and Risk Profile

Patients undergoing allo-HSCT for HIV often have an underlying high-risk hematologic malignancy. The risk of relapse is influenced by the original cancer's aggressiveness, the efficacy of the conditioning regimen, and the graft-versus-tumor effect. People with HIV (PWH) have a 2-3,000 times higher risk of cancer than the general population, with up to 9% developing cancer over the course of their HIV care [67]. Malignancies in PWH are broadly categorized as:

• AIDS-Defining Malignancies (ADMs): Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer [67].
• Non-AIDS-Defining Malignancies (NADCs): Include anal cancer, hepatocellular carcinoma, lung cancer, and Hodgkin lymphoma, which are increasingly common in PWH on long-term ART [67].

Management Strategies During Transplant

Managing the primary malignancy requires coordinated administration of chemotherapy and ART, which is complicated by overlapping toxicities and drug-drug interactions (DDIs) [68].

• ART Regimen Selection: The choice of ART during cancer treatment must be individualized. INSTI-based regimens are often preferred over PI- or NNRTI-based regimens due to a more favorable profile regarding DDIs and overlapping toxicities like bone marrow suppression [68].
• Concomitant Therapy Feasibility: Studies show that concomitant use of ART and chemotherapy is generally tolerable. For example, patients with Burkitt lymphoma receiving ART during hyperfractionated chemotherapy achieved complete remission, whereas those not on ART had poor outcomes [68].
• Post-Transplant Monitoring: Vigilant monitoring for malignancy relapse via imaging, tumor markers, and biopsy (as indicated) is essential. The persistence of recipient-derived malignant cells indicates incomplete chimerism and a higher risk of relapse.

Table 2: ART Management in Patients Undergoing Cancer Therapy

Challenge	Clinical Considerations	Recommended Strategies
Drug-Drug Interactions	PIs and NNRTIs interact with cytochrome P450, affecting chemo drug levels [68].	Use INSTI-based regimens (e.g., Dolutegravir, Raltegravir) to minimize interactions [68].
Overlapping Toxicities	Bone marrow suppression from both chemotherapy and some NRTIs (e.g., zidovudine) [68].	Avoid ART agents with high myelotoxicity; monitor blood counts closely.
Treatment Burden	Patient adherence to both complex chemo and ART schedules [68].	Simplify ART regimen; coordinate care between oncologist and ID specialist.

Opportunistic Infections: Risk Stratification and Prophylaxis

Risk Profile and Clinical Presentation

The risk for OIs is highest in the period immediately following transplant due to severe lymphopenia, and it persists in the context of chronic GvHD and its requisite immunosuppressive therapy. The spectrum of OIs in PWH is well-characterized, and this knowledge informs post-transplant prophylaxis.

A study of 137 HIV-positive patients with OIs found that fever (67.1%) and gastrointestinal symptoms (55.4%) were the most common presenting symptoms, followed by respiratory (50.3%) and neurological symptoms (33.5%) [69]. The same study provided the median CD4+ counts at which specific OIs typically occur, offering a guide for risk stratification.

Table 3: Common Opportunistic Infections and Associated CD4+ Counts in PWH

Opportunistic Infection	Frequency in Study (%)	Median CD4+ Count (cells/µL)
Tuberculosis	42.3	162
Oral Candidiasis	34.3	174
Pneumonia	Not specified	214
Cytomegalovirus (CMV)	2.9	369.5
Herpes Zoster	2.9	299
Toxoplasmosis	3.6	101
Pneumocystis jirovecii Pneumonia (PCP)	5.8	96
Cryptococcal Meningitis	2.1	42

Prophylaxis and Monitoring Strategies

• Pre-Transplant Assessment: A thorough screening for latent infections (e.g., tuberculosis, hepatitis B/C, CMV, syphilis) is mandatory.
• Post-Transplant Prophylaxis: The choice of prophylaxis should be based on the patient's pre-transplant OI history, current CD4+ count, and the level of immunosuppression. Standard prophylaxis for PCP and fungal infections is recommended, with duration guided by immune reconstitution and GvHD status.
• Immune Reconstitution: Monitoring CD4+ count recovery is essential for guiding the duration of OI prophylaxis. The risk of OIs decreases significantly once the CD4+ count is sustained above 200 cells/µL.

Diagram 1: Managing co-morbidities and reservoir monitoring post-allo-HSCT.

Advanced HIV Reservoir Monitoring Techniques

Confirming HIV remission requires sophisticated methods to quantify and characterize the persistent viral reservoir. Key techniques include assays that measure total HIV DNA and those that provide deeper transcriptional or intact proviral analysis.

Total HIV DNA Quantification by Digital PCR

The duplex digital PCR (dPCR) assay on a microfluidic chamber array platform (e.g., Absolute Q) allows for absolute quantification of total HIV DNA without a standard curve [7].

• Workflow: The assay simultaneously targets the HIV LTR-RU5 region and the human RPP30 gene (single-copy reference gene for cell count normalization) in a duplex reaction.
• Performance: The assay demonstrates good linearity (R² = 0.977) and a 95% lower limit of detection (LLOD) of 79.7 HIV DNA copies per million cells [7]. It accurately differentiates between ART-treated persons with HIV (PWH), who have a median of 995.3 copies/million CD4+ T cells, and ART-naïve PWH, who have significantly higher levels (median 16,565 copies/million PBMCs) [7].
• Advantages: dPCR offers precise absolute quantification and higher sensitivity for low-abundance targets compared to qPCR, making it ideal for monitoring reservoir decay in patients on ART or after interventions like allo-HSCT.

Flow-FISH for Characterizing Transcriptional Activity

The flow cytometry-fluorescent in situ hybridization (flow-FISH) assay provides insight into the transcriptional state of the HIV reservoir, moving beyond mere DNA quantification [70].

• Workflow: This method uses a combination of probes targeting different HIV RNA sequences: the TAR region/5' LTR and the Gag sequence. Using the branched-DNA method to amplify the signal, it can distinguish between cells expressing:
  • Abortive HIV-1 transcripts (TAR+ Gag-): A hallmark of latent infection.
  • Elongated, productive transcripts (TAR+ Gag+): Indicating active viral gene expression.
• Advantages: A key feature is that it does not require cell activation for HIV-1 detection, thereby preserving the original phenotypic landscape of the cells for concurrent surface marker staining [70]. This allows for the phenotypic characterization of latently infected cells.

Diagram 2: Key experimental workflows for HIV reservoir monitoring.

The Scientist's Toolkit: Essential Reagents and Assays

Table 4: Key Research Reagent Solutions for HIV Reservoir Monitoring

Reagent / Assay	Function	Application in HIV Reservoir Research
Digital PCR Systems (e.g., Absolute Q) [7]	Absolute quantification of nucleic acids without a standard curve.	Measures total HIV DNA load in patient CD4+ T cells or PBMCs; critical for assessing reservoir reduction post-intervention.
LTR-RU5 & RPP30 Primers/Probes [7]	Target amplification and detection in duplex dPCR.	Simultaneously quantifies HIV LTR DNA and the single-copy human RPP30 gene for precise cell-normalized reservoir measurement.
Flow-FISH Probe Sets (TAR & Gag) [70]	Detection of specific HIV RNA transcripts via fluorescent in situ hybridization.	Characterizes the transcriptional activity of the reservoir (abortive vs. elongated transcripts) at the single-cell level.
8E5 Cell Line [7]	Reference cell line containing one copy of HIV provirus per cell.	Serves as a critical positive control and standard for assay calibration and determining copy number per cell in dPCR.

Integrated Monitoring and Clinical Correlations

Successful management requires an integrated approach where monitoring for co-morbidities is synchronized with assessing the HIV reservoir. The development of chronic GvHD, often requiring long-term immunosuppression with drugs like ruxolitinib, is a double-edged sword. While it increases the risk of OIs and other complications, the associated alloreactive immune response is believed to be a key driver of the graft-versus-reservoir (GvR) effect [19] [15]. Therefore, patients must be meticulously monitored for both the beneficial and adverse effects of this immunologic activity.

A comprehensive post-transplant monitoring plan must include:

• Frequent Plasma HIV RNA Testing: Using ultrasensitive assays (with limits of detection below 1 copy/mL) to confirm the absence of viral rebound after ART interruption [19].
• Longitudinal Reservoir Quantification: Using the dPCR and Flow-FISH methods described above to track the decay of the reservoir over time.
• Correlative Serology and T-cell Responses: The decline and eventual loss of HIV-specific antibodies and T-cell responses provide additional evidence of a non-rebounding, functionally cured state [19].

This multi-pronged monitoring strategy, coupled with aggressive management of malignancy and OIs, provides the foundation for achieving and validating long-term HIV remission in the allo-HSCT setting.

Defining Cure: Validating Remission and Comparative Outcomes Across Donor Types

The persistence of the human immunodeficiency virus (HIV) reservoir remains the principal barrier to a cure. While antiretroviral therapy (ART) suppresses viral replication, it does not eliminate the integrated provirus within long-lived cellular reservoirs [71]. For researchers investigating curative strategies, particularly those involving CCR5Δ32/Δ32 haematopoietic stem cell transplantation (HSCT), precise and comprehensive reservoir analysis is paramount. This procedure aims to replace the susceptible host immune system with CCR5-deficient cells, potentially conferring resistance to the predominant CCR5-tropic HIV variants [11] [72]. The success of such interventions is evaluated by measuring the reduction or elimination of the viral reservoir, necessitating sophisticated and multi-faceted analytical approaches.

This technical guide provides an in-depth overview of the core methodologies for HIV reservoir analysis in key anatomical compartments—blood, lymphoid tissue, and the central nervous system (CNS)—following CCR5Δ32/Δ32 HSCT. The complex and heterogeneous nature of the reservoir requires a combination of virological and immunological assays to accurately quantify the residual virus and assess its replication competence. We detail the experimental protocols, data interpretation, and integration of findings, framing this within the broader context of HIV cure research after stem cell transplantation.

Core Analytical Assays for HIV Reservoir Quantification

A multi-assay approach is essential to fully characterize the HIV reservoir post-HSCT, as no single method can capture all aspects of viral persistence. The following assays form the cornerstone of reservoir analysis.

Table 1: Core Assays for HIV Reservoir Analysis Post-CCR5Δ32/Δ32 HSCT

Assay Category	Assay Name	Measured Parameter	Key Strength	Key Limitation
Viral Outgrowth	Quantitative Viral Outgrowth Assay (QVOA)	Replication-competent virus (Infectious Units per Million cells, IUPM)	Functional measure of the inducible, replication-competent reservoir	Underestimates reservoir size; labor-intensive
Nucleic Acid Detection	Intact Proviral DNA Assay (IPDA)	Genomically intact vs. defective proviruses	Differentiates intact from defective provinces; higher throughput than QVOA	Does not assess transcriptional activity or replication competence
	Droplet Digital PCR (ddPCR)	Total or integrated HIV DNA	Highly sensitive and precise quantification of viral DNA	Cannot distinguish between intact and defective proviruses
Viral Transcript Detection	RT-PCR / RNAscope	Cell-associated HIV RNA (unspliced, multispliced)	Indicates recent or ongoing viral transcriptional activity	Transcripts may originate from defective provinces
In Vivo Testing	Analytical Treatment Interruption (ATI)	Plasma viral rebound	The ultimate test for cure; confirms absence of replication-competent virus	Clinical risk of viral rebound and potential immune deterioration

Ex Vivo Viral Outgrowth Assays

The Quantitative Viral Outgrowth Assay (QVOA) is considered a gold standard for quantifying the replication-competent latent reservoir [11] [12]. This assay involves:

• Cell Isolation and Activation: Resting CD4+ T cells are purified from patient peripheral blood mononuclear cells (PBMCs) or tissue samples. These cells are then activated ex vivo using mitogens (e.g., phytohaemagglutinin) and co-cultured with feeder cells (e.g., CD8-depleted PBMCs from healthy donors) that are highly susceptible to HIV infection.
• Viral Amplification: The activation induces latent provinces to produce virions, which then infect and replicate in the feeder cells over a period of 1-2 weeks.
• Viral Detection: The culture supernatants are tested periodically for the presence of HIV p24 antigen via ELISA. The frequency of infected cells that released virus is calculated using statistical models (e.g., maximum likelihood estimation), reported in Infectious Units per Million (IUPM) cells.

A reported case of HIV cure post-CCR5Δ32/Δ32 HSCT showed no reactivatable virus in a total of 24 million resting CD4+ T cells tested, yielding a combined reservoir estimate of <0.029 IUPM [11]. Another study reported negative QVOA results on multiple time points post-transplant and after analytical treatment interruption (ATI) [12].

Nucleic Acid-Based Detection Assays

These assays directly measure HIV nucleic acids and are crucial for sensitive reservoir tracking.

• Droplet Digital PCR (ddPCR): This method provides absolute quantification of HIV DNA (e.g., LTR, gag) with high precision, even at very low copy numbers. It is highly sensitive for detecting traces of viral DNA. In cured patients, sporadic, very low-level signals may be detected, which are often attributed to false positives, contamination, or defective provinces incapable of causing rebound [11] [12].
• Intact Proviral DNA Assay (IPDA): The IPDA uses a multiplex ddPCR approach to simultaneously probe two different regions of the proviral genome (e.g., psi and env) to distinguish genomically intact provinces from those with fatal deletions or hypermutations. This provides a more accurate estimate of the potential rebound-competent reservoir than total DNA measurements [12].

In Vivo Viral Outgrowth and Treatment Interruption

The most definitive evidence for HIV cure is the absence of viral rebound after stopping ART.

• Analytical Treatment Interruption (ATI): After extensive reservoir analysis suggests a profound reduction or elimination of replication-competent virus, ART is carefully discontinued under close clinical monitoring [12]. Patients are monitored weekly or monthly for plasma HIV-1 RNA rebound using ultrasensitive assays (e.g., <1 copy/mL). Successful remission is defined as sustained undetectable viremia for months or years post-ATI, as demonstrated in the "London" and "Geneva" patients [11] [12] [71].

Multi-Compartment Sampling and Analysis Protocols

The HIV reservoir is not confined to blood; it persists in tissues. A comprehensive analysis must therefore include samples from key sanctuary sites.

Peripheral Blood Sampling

Peripheral blood is the most accessible compartment for longitudinal monitoring.

• Sample Collection: Whole blood is collected in EDTA or heparin tubes.
• PBMC Isolation: PBMCs are isolated via density gradient centrifugation (e.g., Ficoll-Paque). Cells are counted and viably frozen for batch analysis or used fresh.
• CD4+ T Cell Subset Isolation: Using immunomagnetic beads (e.g., Miltenyi MicroBeads) or fluorescence-activated cell sorting (FACS), resting CD4+ T cell subsets (naïve [TN], central memory [TCM], transitional memory [TTM], and effector memory [TEM]) can be purified. Studies show that replication-competent HIV-1 is predominantly present in TN and TCM cells, while TTM and TEM cells often harbor defective provinces [73].
• Downstream Analysis: Isolated cells are used for QVOA, DNA/RNA extraction for PCR-based assays, or phenotypic analysis by flow cytometry.

Lymphoid Tissue Sampling and Analysis

Lymphoid tissues (e.g., lymph nodes, gut-associated lymphoid tissue) are major reservoirs for HIV and require specialized sampling and processing.

• Sample Collection: Lymph node biopsies (e.g., inguinal) and gut biopsies (e.g., terminal ileum, colon) are obtained during scheduled procedures.
• Single-Cell Suspension Preparation: Tissues are mechanically dissociated and enzymatically digested (e.g., with collagenase/DNase) to create single-cell suspensions for functional assays like QVOA or flow cytometry.
• Histological Analysis (In Situ Hybridization): Formalin-fixed, paraffin-embedded (FFPE) tissue sections are analyzed using techniques like RNAscope and DNAscope to visually identify cells harboring HIV RNA or DNA within their architectural context. One study of a cured patient detected sporadic HIV RNA+ and DNA+ cells in inguinal lymph node and gut biopsies at levels just above the assay's limit of detection, but these were not associated with replication-competent virus [12].

Diagram 1: Lymphoid tissue analysis workflow for HIV reservoir studies.

Central Nervous System (CNS) Sampling

The CNS is a potential reservoir site, though its analysis in the context of HSCT cure remains less common due to sampling challenges.

• Cerebrospinal Fluid (CSF) Collection: CSF is obtained via lumbar puncture. It can be used for:
  • Ultra-sensitive Viral Load Testing: Measuring HIV-1 RNA levels.
  • Cytology and Flow Cytometry: Identifying and characterizing infiltrating immune cells.
• CSF as a "Liquid Biopsy": Analysis of cell-free HIV RNA or DNA in CSF can provide insights into the CNS reservoir without direct brain tissue sampling [74].
• Imaging Modalities: Non-invasive imaging techniques like [18F]-FDG-PET scans can detect CNS inflammation that may be associated with persistent infection, though this lacks specificity for HIV [75].

Integration of Virological and Immunological Correlates

Reservoir analysis is complemented by assessing the host immune response, which provides indirect evidence of antigen exposure.

• HIV-Specific Antibodies: A progressive decline in the titer and avidity of HIV-specific antibodies (e.g., loss of reactivity on Western blot) is observed in cured individuals, indicating a lack of ongoing antigenic stimulation [12].
• HIV-Specific T Cell Responses: The frequency and function of HIV-specific CD8+ and CD4+ T cells can be measured using intracellular cytokine staining (ICS) or IFN-γ ELISpot upon stimulation with HIV peptide pools. In cured patients, these responses wane over time post-transplant and do not increase after ATI, unlike robust and persistent responses to other pathogens like CMV [12].
• Immune Phenotyping and Activation: Comprehensive flow cytometry panels are used to monitor immune reconstitution, CD4+ T cell count recovery, and the absence of CCR5 expression on donor-derived cells. Low levels of T cell activation (e.g., HLA-DR, CD38 expression) post-ATI further support the absence of active viral replication [12].

Table 2: Key Immunological Correlates of HIV Cure Post-CCR5Δ32/Δ32 HSCT

Immunological Parameter	Assay Method	Finding in Cure	Interpretation
HIV-Specific Antibodies	Immunoblot (Western Blot), Avidity Assays	Decline in titer and avidity; loss of band reactivity over time	Cessation of ongoing antigen production
HIV-Specific T Cells	IFN-γ ELISpot, Intracellular Cytokine Staining (ICS), MHC Tetramers	Weak or undetectable responses that wane post-ATI	Lack of antigen-driven T cell stimulation
CMV-Specific T Cells	IFN-γ ELISpot, ICS	Strong and persistent responses	Confirms general immune competence
Immune Activation	Flow Cytometry (CD38, HLA-DR on T cells)	Levels within normal range, comparable to HIV- controls	No evidence of ongoing inflammation from viral replication
CCR5 Expression	Flow Cytometry	Absent on circulating CD4+ T cells	Successful engraftment of CCR5Δ32/Δ32 cells

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents for Multi-Compartment Reservoir Analysis

Reagent / Tool	Function / Application	Example Use Case
Anti-CD3/CD28 Microbeads	Polyclonal T cell activation	Activating resting CD4+ T cells in QVOA to induce latent virus [12]
Immunomagnetic Beads (e.g., CD4+ T cell Isolation Kit)	Cell separation and subset isolation	Purifying resting CD4+ T cells or memory subsets from PBMCs/tissue [73]
ddPCR Supermix & Assays	Absolute quantification of nucleic acids	Measuring HIV DNA copies/million cells with high sensitivity [11] [12]
RNAscope/DNAscope Probes	In situ detection of HIV RNA/DNA	Visualizing and quantifying HIV+ cells in tissue sections [12]
HIV Peptide Pools (Gag, Pol, Nef)	Antigen-specific T cell stimulation	Measuring HIV-specific T cell responses via ICS or ELISpot [12]
Flow Cytometry Antibodies (anti-CCR5, CD4, CD45RO, CD27)	Immunophenotyping	Confirming absence of CCR5 and analyzing T cell differentiation [11] [12]

Diagram 2: Logical flow of a multi-compartment reservoir study from sampling to interpretation.

Achieving a cure for HIV after CCR5Δ32/Δ32 HSCT represents a monumental scientific achievement, and its verification relies entirely on rigorous multi-compartment reservoir analysis. This guide outlines a comprehensive framework, combining sensitive virological assays for quantifying and characterizing the reservoir in blood and tissues with careful immunological monitoring. The consistent application of these protocols—from QVOA and digital PCR to ATI—has established a high bar for defining a cure. Future research will continue to refine these tools, particularly for hard-to-access compartments like the CNS, and adapt them for evaluating next-generation curative strategies beyond HSCT, driving the field closer to a scalable cure for all people living with HIV.

For millions of people living with HIV, antiretroviral therapy (ART) provides effective viral suppression but requires lifelong adherence as it cannot eliminate the viral reservoir. Achieving a sustained ART-free remission represents a paramount goal of cure research, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) has emerged as a unique intervention that can, in rare cases, facilitate this outcome. This whitepaper examines the two critical, interconnected biomarkers defining sustained HIV remission: prolonged undetectable viral load and loss of HIV-specific immunity, with a specific focus on the research context following CCR5Δ32 allo-HSCT.

The cases of the Berlin, London, and Düsseldorf patients demonstrated that remission was possible with CCR5Δ32/Δ32 donor cells, establishing a paradigm where donor cell resistance to HIV infection provided a protective barrier against viral rebound [15] [2]. However, the recent Geneva patient case has compellingly shown that sustained remission for over 32 months post-ART interruption is also achievable using wild-type CCR5 donor cells, challenging the assumption that CCR5 absence is strictly necessary [19]. This evolving evidence base underscores the need to precisely define and monitor the virological and immunological metrics that collectively signify a state of sustained remission.

Core Biomarkers of Sustained Remission

Undetectable Viral Load

The foundational metric of HIV remission is the sustained absence of detectable virus in blood plasma after cessation of ART, indicating a failure of the viral reservoir to initiate a systemic rebound.

• Definition and Measurement Standards: In clinical remission studies, "undetectable" is typically defined using ultrasensitive viral load assays with a detection limit below 1 copy of HIV RNA per milliliter of plasma [19]. This surpasses the sensitivity of conventional clinical assays. For example, in the reported Geneva case, the patient's viral load remained below this 1-copy/mL threshold in all tests conducted over the 32-month post-ART period [19].
• Associated Reservoir Assessments:
  • Proviral DNA: The frequency of cells harboring HIV DNA is dramatically reduced post-allo-HSCT. Critically, the sporadic, low levels of proviral DNA that are detected post-transplantation often comprise only defective sequences, with no intact, replication-competent provirus found [19].
  • Viral Outgrowth Assays: A definitive functional test for remission is the quantitative viral outgrowth assay (qVOA), where a patient's CD4+ T cells are activated in culture to induce virus production. In sustained remission, these cultures consistently fail to amplify replication-competent virus, despite the patient's CD4+ T cells remaining fully susceptible to new HIV infection in vitro [19].

Table 1: Key Virological Metrics for Confirming HIV Remission

Metric	Methodology	Finding in Sustained Remission	Significance
Plasma HIV RNA	Ultrasensitive PCR (limit <1 copy/mL)	Consistently undetectable post-ART	Indicates no active viral replication or rebound from reservoirs [19].
Cell-Associated HIV DNA	PCR for total/integrated DNA; near-full-genome sequencing for intactness	Very low/undetectable levels; only defective proviruses detected	Demonstrates quantitative and qualitative reduction of the cellular reservoir [19].
Replication-Competent Virus	Quantitative Viral Outgrowth Assay (qVOA)	No virus amplified from CD4+ T cells	Confirms functional absence of infectious virus within the latent reservoir [19].

Loss of HIV-Specific Immunity

The decline and eventual disappearance of HIV-specific antibody and T-cell responses serve as a crucial immunological correlate of remission, indicating a lack of antigenic stimulation from the viral reservoir.

• Serological Markers: In a state of remission, the consistent absence of HIV antigens leads to a progressive decline in anti-HIV antibodies. This can be measured via standard HIV serology (e.g., Western Blot, ELISA) or more quantitative antibody titers. The waning of this humoral response provides strong indirect evidence that the viral reservoir is not producing antigen [19].
• Cellular Immunity Markers: Similarly, HIV-specific T-cell responses, which are typically robust in chronic infection, become undetectable in remission. This includes the loss of CD8+ and CD4+ T cells that respond to HIV antigens, as measured by intracellular cytokine staining (ICS) or ELISpot assays. The disappearance of these responses suggests that T cells are no longer being exposed to HIV peptides presented by infected cells [19].

Table 2: Key Immunological Metrics for Confirming HIV Remission

Metric	Methodology	Finding in Sustained Remission	Significance
HIV-Specific Antibodies	ELISA, Western Blot,定量抗体滴度	Progressive decline to seronegativity	Indicates loss of ongoing antigen exposure from a productive reservoir [19].
HIV-Specific T-Cell Responses	IFN-γ ELISpot, Intracellular Cytokine Staining (ICS)	Undetectable T-cell responses to HIV antigens	Suggests absence of viral protein expression and antigen presentation [19].

Experimental Protocols for Key Metrics

Protocol: Ultrasensitive Viral Load Testing

Objective: To quantify plasma HIV RNA with a sensitivity superior to commercial assays, crucial for monitoring potential low-level viremia post-ART.

• Sample Processing: Collect plasma via venipuncture in EDTA tubes. Process within 6 hours by centrifugation to separate plasma from cellular components.
• Virus Concentration: Ultracentrifuge a large volume of plasma (e.g., 1-10 mL) at high speed (e.g., 23,000 × g for 1 hour at 4°C) to pellet viral particles.
• RNA Extraction: Extract total RNA from the viral pellet using a commercial kit (e.g., QIAamp Viral RNA Mini Kit). Include carrier RNA if necessary to improve yield.
• Reverse Transcription and PCR: Perform reverse transcription to generate cDNA. Use a highly sensitive, nested or real-time PCR protocol targeting a conserved region of the HIV genome (e.g., pol or gag). The assay should be calibrated with a standard curve of known copy numbers to achieve a validated limit of detection of <1 copy/mL [19].

Protocol: Quantitative Viral Outgrowth Assay (qVOA)

Objective: To quantify the frequency of resting CD4+ T cells harboring replication-competent HIV.

• Cell Isolation: Isolate patient CD4+ T cells from peripheral blood mononuclear cells (PBMCs) using negative selection magnetic beads.
• Limiting Dilution and Activation: Serially dilute the CD4+ T cells and plate them in replicate wells. Co-culture with a feeder cell mix (e.g., PBMCs from healthy donors pre-stimulated with PHA and IL-2) to provide T-cell activation signals that induce viral production from latently infected cells.
• Viral Amplification and Detection: Culture for 2-3 weeks, periodically collecting supernatant. Test the supernatant for HIV p24 antigen by ELISA. A well is scored positive if p24 is detected.
• Data Analysis: The frequency of infected cells is calculated using statistical models (e.g., maximum likelihood method) and reported as infectious units per million (IUPM) CD4+ T cells. Sustained remission is characterized by an IUPM of zero [19] [76].

Protocol: Assessment of HIV-Specific T-Cell Responses

Objective: To detect and quantify T-cell responses to HIV-specific antigens.

• PBMC Stimulation: Isolate patient PBMCs. Incubate them in duplicate or triplicate wells with overlapping peptide pools covering HIV proteins (e.g., Gag, Pol, Nef), a positive control (e.g., Staphylococcal Enterotoxin B), and a negative control (no peptide).
• ELISpot Assay: Perform an IFN-γ ELISpot assay per manufacturer's instructions. Briefly, after an incubation period (16-24 hours), detect spots representing IFN-γ-secreting cells.
• Analysis: Count spots using an automated ELISpot reader. The result is calculated as spot-forming units (SFU) per million PBMCs after subtracting the background from the negative control. Remission is indicated by responses that are undetectable and not significantly different from the background [19].

Visualizing the Remission Assessment Workflow

The following diagram illustrates the integrated experimental pathway for confirming sustained remission, from clinical monitoring to advanced reservoir and immune analysis.

The Scientist's Toolkit: Essential Research Reagents

This table details key reagents and their applications in the experimental assessment of HIV remission.

Table 3: Key Research Reagents for HIV Remission Studies

Reagent / Assay	Primary Function	Research Application
Ultracentrifugation & RNA Kits	Concentrate virions and extract viral RNA from large plasma volumes.	Enables ultrasensitive viral load testing down to <1 copy/mL [19].
HIV Peptide Pools (Gag, Pol, Nef)	Synthetic peptides covering HIV proteins for antigen-specific stimulation.	Used in ELISpot and ICS to detect and quantify HIV-specific T-cell immunity [19].
IFN-γ ELISpot Kit	Detect and enumerate cytokine-secreting cells at a single-cell level.	Measures the frequency of T cells responding to HIV antigens; loss indicates remission [19].
CD4+ T Cell Isolation Kits	High-purity negative selection of CD4+ T cells from PBMCs.	Critical for preparing target cells for qVOA and proviral DNA analysis [19] [76].
qPCR Assays for HIV DNA	Quantify total and integrated HIV DNA; sequence for intactness.	Assesses the size and quality (defective vs. intact) of the persistent viral reservoir [19] [76].
HILT (HIV-1-Induced Lineage Tracing) System	Genetic switch (Cre-lox) to permanently mark HIV-infected cells in model systems.	A research tool in humanized mice to track latently infected cells and their lineages during ART [77].

The coordinated assessment of undetectable viral load and loss of HIV-specific immunity provides a robust framework for defining sustained HIV remission in the research setting, particularly following interventions like allo-HSCT. The case of the Geneva patient demonstrates that these metrics can be met even with wild-type CCR5 donor cells, shifting focus toward the role of transplant-associated factors like full donor chimerism and graft-versus-reservoir effects in achieving this outcome [19] [15]. For researchers and drug developers, the standardized experimental protocols and reagents outlined herein are essential for rigorously evaluating the efficacy of curative strategies, from transplantation to novel gene therapies aiming to mimic these curative mechanisms.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has emerged as a notable intervention in HIV-1 research, primarily for patients with concomitant hematological malignancies. This technical analysis compares the outcomes of two distinct approaches: transplantation with stem cells from donors with a homozygous CCR5Δ32 mutation versus donors with wild-type CCR5. The CCR5Δ32/Δ32 genotype confers natural resistance to R5-tropic HIV-1 by preventing surface expression of the CCR5 co-receptor. Historically, this was considered essential for achieving post-transplant HIV-1 remission. However, emerging evidence now documents sustained HIV-1 remission after allo-HSCT with wild-type CCR5 donor cells, challenging the established paradigm. This whitepaper synthesizes current clinical data, details the experimental protocols for reservoir monitoring, and explores the underlying immunological mechanisms, providing a framework for researchers developing curative HIV strategies.

The CC chemokine receptor 5 (CCR5) is a G-protein coupled receptor (GPCR) expressed on macrophages, dendritic cells, and memory T cells. Its natural ligands include MIP-1α, MIP-1β, and RANTES [78]. For HIV-1, CCR5 acts as a crucial co-receptor for viral entry. The process initiates when the viral envelope glycoprotein gp120 binds to the host CD4 receptor. This binding induces a conformational change in gp120, allowing it to interact with CCR5 (or the alternative CXCR4 co-receptor). This second interaction enables gp41 to mediate fusion of the viral and host cell membranes, culminating in viral entry [78] [79]. Viruses that preferentially use CCR5 are classified as R5-tropic and are responsible for the vast majority of primary transmissions [79].

A natural 32-base pair deletion in the CCR5 gene (CCR5Δ32) results in a truncated, non-functional protein that is not expressed on the cell surface. Individuals homozygous for this mutation (CCR5Δ32/Δ32) are highly resistant to infection by R5-tropic HIV-1 strains [78] [80]. This discovery laid the groundwork for using CCR5Δ32/Δ32 allo-HSCT as a strategy to reconstitute a patient's immune system with HIV-1-resistant cells.

The success of this approach was first demonstrated in the "Berlin Patient" and subsequently in several others, establishing CCR5Δ32/Δ32 HSCT as a proof-of-concept for HIV-1 cure [11] [12] [13]. However, the rarity of the CCR5Δ32/Δ32 genotype, particularly in non-Caucasian populations, limits its broad applicability [80]. Furthermore, recent cases of sustained remission after transplantation with wild-type CCR5 cells suggest that alternative mechanisms, such as graft-versus-host disease (GvHD) and associated immunosuppressive treatments, may also contribute to viral reservoir clearance and long-term remission [81] [19].

Clinical Outcomes: A Comparative Analysis

The table below summarizes key clinical data from representative cases of HIV-1 remission following allo-HSCT, comparing outcomes between recipients of CCR5Δ32/Δ32 and wild-type CCR5 donor cells.

Table 1: Comparative Clinical Outcomes of Allo-HSCT with CCR5Δ32/Δ32 vs. Wild-Type CCR5 Donor Cells

Case Reference	Donor CCR5 Genotype	Underlying Malignancy	Conditioning & GvHD Prophylaxis	Post-ATI Remission Duration	Key Virological Findings
"London Patient" [11]	CCR5Δ32/Δ32	Hodgkin’s Lymphoma	Reduced-intensity (LACE + Alemtuzumab)	≥18 months (2019)	Undetectable plasma RNA (<1 copy/mL), no reactivatable virus in QVOA (24M cells)
IciStem 19 [12]	CCR5Δ32/Δ32	Acute Myeloid Leukemia	Reduced-intensity (Fludarabine/Treosulfan/ATG)	≥48 months (2023)	No replication-competent virus in murine models, sporadic HIV DNA traces
Mixed-Race Woman [13]	CCR5Δ32/Δ32	Acute Myeloid Leukemia	Haplo-cord transplant	≥18 months (2023)	100% cord blood chimerism, no detectable HIV-1 DNA/RNA, loss of HIV antibodies
IciStem 34 [81] [19]	Wild-Type	Myeloid Sarcoma	Myeloablative (Clofarabine/Cyclo/TBI 8Gy)	32 months (2024)	Undetectable plasma RNA, only defective proviral DNA, susceptible CD4+ T cells in vitro

The data demonstrates that sustained HIV-1 remission is achievable with both CCR5Δ32/Δ32 and wild-type CCR5 donor cells. A critical distinction lies in the susceptibility of the new immune system to HIV-1. In CCR5Δ32/Δ32 recipients, CD4+ T cells lack the CCR5 co-receptor and are resistant to R5-tropic virus infection [11]. In contrast, in the IciStem 34 case, the recipient's CD4+ T cells remained fully susceptible to HIV-1 infection in vitro, yet no viral rebound occurred for 32 months post-ART interruption [19]. This suggests that in the wild-type CCR5 context, the lack of rebound may be due to the effective elimination or profound suppression of the viral reservoir, rather than target cell resistance.

Core Experimental Protocols for HIV Reservoir Monitoring

Rigorous post-transplant monitoring is essential to define the state of HIV-1 remission. The following are key experimental protocols employed in the cited research.

Ultrasensitive Viral Load and HIV DNA Quantification

• Objective: To detect and quantify extremely low levels of cell-free HIV-1 RNA and cell-associated HIV-1 DNA.
• Methodology:
  • Plasma HIV-1 RNA: Use of droplet digital PCR (ddPCR) or other ultrasensitive assays with a limit of detection of <1 copy of HIV-1 RNA per mL of plasma. This provides a more sensitive measure of ongoing viral replication than standard clinical assays [11] [19].
  • Cell-Associated HIV-1 DNA: Quantification of total or integrated HIV-1 DNA from peripheral blood mononuclear cells (PBMCs) or purified CD4+ T cells using quantitative PCR (qPCR) or ddPCR. Results are expressed as copies per million cells [11] [19] [12].
• Application: In the IciStem 34 case, this methodology showed a rapid decline in HIV DNA to very low or undetectable levels after transplant, with only sporadic detection of defective proviral DNA [19].

Quantitative Viral Outgrowth Assay (QVOA)

• Objective: To measure the frequency of resting CD4+ T cells that harbor replication-competent, "inducible" virus—considered the definitive gold standard for quantifying the latent reservoir.
• Methodology: [11] [12]
  • Cell Isolation: Resting CD4+ T cells are purified from patient PBMCs.
  • Limiting Dilution & Activation: Cells are serially diluted and activated using mitogens (e.g., PHA) and mixed with CD3/CD28 antibodies to induce viral transcription.
  • Co-culture: Activated patient cells are co-cultured with uninfected, phytohemagglutinin (PHA)-blasted CD4+ T cells from healthy donors (feeder cells) to amplify any released virus.
  • Virus Detection: Culture supernatants are tested periodically (e.g., days 7, 14, 21) for HIV-1 p24 antigen by ELISA.
  • Statistical Analysis: The frequency of infectious units per million (IUPM) resting CD4+ T cells is calculated using statistical models like maximum likelihood.
• Application: In the "London patient," QVOA performed on a total of 24 million resting CD4+ T cells found no reactivatable virus, yielding an IUPM estimate of <0.029 [11].

In Vivo Outgrowth Assays in Humanized Mouse Models

• Objective: To provide an in vivo assessment of the presence of replication-competent virus in patient samples, which can be more sensitive than in vitro QVOA.
• Methodology: [12]
  • Mouse Engraftment: Immunodeficient mice (e.g., NSG or NOG strains) are engrafted with human CD34+ hematopoietic stem cells to create a human-like immune system ("humanized mice").
  • Adoptive Transfer: Patient-derived PBMCs or CD4+ T cells are injected into these humanized mice.
  • Monitoring: Mice are monitored over several weeks for the emergence of HIV-1 viremia in plasma, typically measured by sensitive RNA assays.
• Application: This assay confirmed the absence of replication-competent virus in the IciStem 19 (CCR5Δ32/Δ32) patient, even when tissue samples were tested [12].

HIV-1 Specific Immune Responses

• Objective: To monitor the decline of HIV-1-specific humoral and cellular immunity as an indirect indicator of absent antigenic stimulation.
• Methodology:
  • Antibody Responses: Serial immunoblot (Western blot) analyses to track the decline in titers and avidity of HIV-1-specific antibodies [11] [12].
  • Cellular Responses: Interferon-γ (IFNγ) ELISpot or intracellular cytokine staining (ICS) using overlapping peptide pools spanning HIV-1 Gag, Pol, and Nef proteins to quantify antigen-specific T-cell responses [12].
• Application: A progressive loss of HIV-1-specific antibody responses and T-cell reactivity was observed in both CCR5Δ32/Δ32 and wild-type CCR5 transplant recipients who achieved remission, while responses to other pathogens like CMV persisted [19] [12].

Visualization of Key Concepts and Workflows

HIV-1 Entry and the Role of CCR5

The following diagram illustrates the critical role of the CCR5 co-receptor in the HIV-1 entry process and how the CCR5Δ32 mutation confers resistance.

Post-Transplant Reservoir Monitoring Workflow

This flowchart outlines the multi-assay strategy used to evaluate HIV-1 reservoir and remission status after allo-HSCT.

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for HIV Reservoir Research Post-Allo-HSCT

Reagent / Assay	Primary Function	Key Characteristics & Application
Droplet Digital PCR (ddPCR)	Absolute quantification of HIV-1 RNA and DNA	Ultra-sensitive; no standard curve needed; LOD of <1 copy/mL plasma [11] [12]
HIV-1 Gag/Pol/Nef Peptide Pools	Stimulation antigens for T-cell assays	Overlapping peptides for IFNγ ELISpot or ICS to monitor HIV-specific cellular immunity [12]
Anti-CD3/CD28 Dynabeads	Polyclonal T-cell activation	Used in QVOA to maximally activate latent virus from resting CD4+ T cells [11]
PHA-Blasted CD4+ T Cells	Feeder cells for viral amplification	Healthy donor cells expanded with PHA; essential for supporting virus growth in QVOA co-cultures [11]
p24 Antigen Capture ELISA	Detection of viral replication	Measures HIV-1 p24 protein in culture supernatants for QVOA endpoint analysis [11] [12]
Humanized Mouse Models (e.g., NSG)	In vivo viral outgrowth assay	Provides a more physiologically relevant system to test for replication-competent reservoir [12]

Discussion and Future Directions

The comparative analysis reveals a paradigm shift: while CCR5Δ32/Δ32 allo-HSCT provides a robust mechanism for cure by creating an HIV-1-resistant immune system, sustained remission is also achievable with wild-type CCR5 donors, likely through different mechanisms. In the latter scenario, the conditioning chemotherapy, combined with a graft-versus-host and graft-versus-reservoir effect, may eliminate the majority of HIV-1-infected cells [82] [19]. Furthermore, ongoing immunosuppression (e.g., with ruxolitinib, a JAK1/2 inhibitor used for GvHD treatment in the IciStem 34 case) may concurrently suppress residual viral replication or the activation of latently infected cells, contributing to sustained remission despite the presence of susceptible target cells [19].

Future research must focus on:

• Elucidating Mechanisms: Deciphering the precise immunological and virological mechanisms that enable remission with wild-type CCR5 cells, particularly the role of alloreactive immune responses.
• Biomarker Identification: Validating biomarkers that can predict remission success post-transplant, such as specific chimerism levels or immune activation profiles.
• Therapeutic Translation: Leveraging these insights to develop less invasive, scalable therapies that mimic these curative effects, such as gene editing of CCR5 in vivo, or immunotherapies that direct allogeneic responses against the HIV-1 reservoir.

The journey from the seminal "Berlin Patient" to the recent cases involving wild-type CCR5 donors illustrates a significant evolution in the understanding of HIV-1 remission via allo-HSCT. CCR5Δ32/Δ32 transplantation remains a definitive, albeit rare, path to a cure. However, the emerging evidence that wild-type CCR5 transplantation can also lead to sustained remission significantly broadens the potential donor pool and opens new avenues for research. The key to success in both scenarios appears to be an intensive reduction of the viral reservoir, sufficient to prevent rebound even in the presence of susceptible target cells. Continued in-depth monitoring of these remarkable individuals, coupled with the sophisticated experimental protocols detailed herein, will be essential for translating these findings into viable, widespread curative strategies for HIV-1.

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) represents the only intervention that has consistently led to sustained HIV remission in the absence of antiretroviral therapy (ART), with six documented cases of cure or long-term remission to date [31]. The International Collaboration to guide and investigate the potential for HIV cure by Stem Cell Transplantation (IciStem) consortium was established to systematically investigate the mechanisms behind HIV reservoir reduction after allo-HSCT in people with HIV (PWH) who require transplantation for hematological malignancies [83]. This collaborative project brings together hematologists, infectious disease specialists, virologists, and immunologists across Europe and Canada to prospectively study the impact of allo-HSCT on HIV persistence. The consortium's work is particularly focused on understanding the dynamics of virological and immunological markers of HIV persistence, which provides critical insights for the development of future curative strategies [84] [31].

The IciStem cohort represents the most comprehensive observational study of PWH undergoing allo-HSCT, with detailed longitudinal sampling and state-of-the-art reservoir measurements. Previous reports from this consortium have described individual cases of cure, including the Düsseldorf and Geneva patients, but the integrated analysis of 30 transplant recipients provides unprecedented insights into the mechanisms of reservoir depletion and the relative importance of donor CCR5 genotype versus allogeneic immune effects [31] [19]. This whitepaper synthesizes the key findings from this prospective cohort, with particular emphasis on quantitative reservoir dynamics, methodological approaches for reservoir monitoring, and implications for future cure strategies.

Cohort Design and Methodological Framework

Participant Recruitment and Study Design

The IciStem cohort currently includes 48 registered participants from 7 European countries and Canada, with 30 transplanted individuals having sufficient sample collection and follow-up for detailed analysis [31]. Participants were enrolled both prospectively and retrospectively between June 1, 2014, and April 30, 2019, with the cohort including any PWH scheduled for or having received allogeneic stem cell transplantation [84]. The study was conducted across multiple centers in Belgium, Canada, Germany, Italy, the Netherlands, Spain, Switzerland, and the UK, with approval from respective research ethics committees and informed consent from all participants [31].

Table 1: IciStem Cohort Demographic and Clinical Characteristics

Category	Details
Total Participants	30 transplanted individuals with available samples
Gender Distribution	26 male, 4 female
Age at HSCT	Range: 31-62 years
Time since HIV Diagnosis	Range: 0-28 years before HSCT
Donor CCR5 Genotype	10 with CCR5Δ32/Δ32 donors, 20 with wild-type CCR5 donors
Underlying Conditions	Hematological malignancies requiring allo-HSCT
Assessment Schedule	Monthly for first 6 months, annually thereafter

The cohort design incorporated detailed longitudinal sampling, with assessments tailored to accommodate individual health status [84]. In the first six months post-transplantation, participants underwent monthly assessments, followed by annual assessments thereafter. The comprehensive sample collection included peripheral blood, bone marrow, ileum, lymph nodes, and cerebrospinal fluid, enabling unprecedented analysis of reservoir dynamics across multiple anatomical compartments [84] [31].

Analytical and Methodological Approaches

The IciStem consortium employed a multifaceted analytical strategy to characterize HIV reservoir dynamics and immunological changes post-transplantation. The methodologies encompassed state-of-the-art virological and immunological assays, complemented by mathematical modeling.

Table 2: Key Experimental Methodologies and Their Applications

Methodology	Specific Application	Technical Details
HIV DNA Quantification	Reservoir size in blood and tissues	qPCR/digital PCR for total and intact HIV DNA
Ultrasensitive Viral Load	Plasma HIV RNA detection	Single-copy assay with sensitivity of <1 copy/mL
Viral Outgrowth Assay	Replication-competent virus	Quantitative co-culture of CD4+ T cells with feeder cells
HIV-Specific Antibodies	Humoral immune responses	Multiplex analysis of levels and functionality
Integration Site Analysis	Genomic location of proviruses	LAM-PCR and next-generation sequencing
Immune Cell Phenotyping	Reconstitution kinetics	Flow cytometry for T, B, and NK cell subsets
Mathematical Modeling	Reservoir decay kinetics	Modeling half-life of latently infected cells

Statistical analyses included Wilcoxon signed-rank tests for longitudinal comparisons and Mann-Whitney U tests for unpaired data when paired tests were not feasible [84]. The mathematical model developed to study factors influencing HIV reservoir reduction incorporated key parameters including conditioning chemotherapy intensity, donor chimerism kinetics, and allogeneic immunity effects [84].

Key Findings on Reservoir Dynamics and Clearance Mechanisms

Quantitative Reservoir Reduction Across Anatomical Compartments

The IciStem cohort analysis demonstrated that allo-HSCT leads to a dramatic reduction of HIV reservoirs in peripheral blood immediately after full donor chimerism is achieved [84]. This reduction was consistently accompanied by undetectable HIV-DNA in key reservoir sites including bone marrow, ileum, lymph nodes, and cerebrospinal fluid, regardless of donor CCR5 genotype [84]. The mathematical modeling developed by the consortium revealed that the half-life of latently infected replication-competent cells decreased from 44 months to just 1.5 months after transplantation, indicating massively accelerated clearance [84].

The data challenge the previously held assumption that CCR5Δ32 homozygous donors are strictly necessary for HIV cure, as significant reservoir reduction occurred irrespective of donor genotype [31]. This finding is further supported by the case of the Geneva patient (IciS-34), who achieved sustained HIV remission for 32 months after ART interruption following transplantation with CCR5 wild-type cells [19]. In this individual, low levels of proviral DNA were detected sporadically after allo-HSCT, but only defective (not intact) HIV DNA was found, and no replication-competent virus could be recovered from cultured CD4+ T cells after treatment interruption [19].

Temporal Dynamics of Virological and Immunological Markers

A critical finding from the IciStem cohort is the differential decay kinetics between direct reservoir markers and indirect serological markers. HIV-specific antibody levels and functionality declined more slowly than direct HIV reservoir measurements, decaying significantly only months after full donor chimerism was established [84]. This temporal disconnect suggests that antibody responses may not be the optimal marker for predicting residual viraemia after transplantation.

The research raises the important question of which marker can best serve as the final indicator of residual viraemia, postulating that the absence of T-cell immune responses might be a more reliable marker than antibody decline after allo-HSCT [84]. This has significant implications for monitoring strategies in future cure interventions, suggesting that multi-parameter assessment incorporating both virological and immunological markers is essential for accurate evaluation of cure efficacy.

Mechanisms of Reservoir Clearance

The IciStem research identified multiple interconnected mechanisms contributing to reservoir reduction:

• Conditioning Chemotherapy Effect: The initial massive reservoir reduction occurs during conditioning chemotherapy before transplantation, eliminating a substantial proportion of infected cells [84].

• Allogeneic Immunity: Mathematical modeling suggests that allogeneic immunity mediated by donor cells is the main viral reservoir depletion mechanism after the initial conditioning effect [84]. This graft-versus-reservoir effect represents a form of immunotherapy that specifically targets remaining infected cells.

• Immune Reconstitution and Dilution: The replacement of recipient immune cells with donor-derived cells gradually dilutes the residual reservoir and establishes a new immune system less susceptible to infection [31].

The case of the Geneva patient provides additional insights into potential supporting mechanisms. This individual received ruxolitinib, a JAK inhibitor, for chronic graft-versus-host disease management, which may have contributed to HIV remission by modulating immune activation and creating an unfavorable environment for viral persistence [19].

Visualization of Experimental Workflows and Biological Mechanisms

HIV Reservoir Dynamics After Allo-HSCT

Multi-Compartment Reservoir Analysis Workflow

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Essential Research Reagents for HIV Reservoir Studies

Reagent/Category	Specific Application	Function and Importance
ddPCR/QPCR Assays	HIV DNA quantification	Absolute quantification of total and intact HIV DNA in limited samples
LAM-PCR Reagents	Integration site analysis	Identification of genomic locations of persisting proviruses
Feeder Cell Lines	Viral outgrowth assays	Support for ex vivo amplification of replication-competent virus
CCR5 Genotyping Kits	Donor/recipient screening	Determination of CCR5Δ32 status for donor selection
Chimerism Assays	Engraftment monitoring	Quantification of donor vs. recipient cell populations
Multiplex Bead Arrays	Antibody profiling	Simultaneous measurement of multiple HIV-specific antibodies
Cell Separation Kits	Immune cell isolation	Isolation of specific subsets (CD4+ T cells) from tissues

Implications for HIV Cure Research and Future Directions

The IciStem cohort findings have substantial implications for the development of HIV cure strategies. The demonstration that allo-HSCT with wild-type CCR5 donors can achieve sustained remission expands the potential donor pool for such interventions and suggests that CCR5 disruption, while beneficial, may not be absolutely necessary for cure [19]. This is particularly important given the low frequency of the CCR5Δ32 mutation in most populations [85].

The evidence supporting a potent graft-versus-reservoir effect indicates that immunotherapeutic approaches harnessing allogeneic immunity could be developed without the need for full transplantation. Future research directions should focus on:

• Understanding Graft-versus-Reservoir Mechanisms: Identifying the specific immune cell populations and molecular pathways responsible for reservoir clearance to develop targeted immunotherapies [84] [31].

• Optimizing Conditioning Regimens: Balancing the intensity of conditioning chemotherapy to maximize reservoir reduction while minimizing toxicity [84].

• Combination Approaches: Integrating HSCT with other interventions such as latency-reversing agents, therapeutic vaccines, or broadly neutralizing antibodies to enhance reservoir clearance [86].

• Biomarker Development: Validating sensitive biomarkers of reservoir elimination that can reliably predict sustained remission after ART interruption [84] [19].

The IciStem cohort continues to provide invaluable insights into HIV persistence and clearance mechanisms. As the cohort matures and additional participants are enrolled, further refinement of our understanding of reservoir dynamics post-transplantation will emerge, guiding the development of safer, more scalable cure strategies for the broader population of people living with HIV.

The development of a curative intervention for Human Immunodeficiency Virus (HIV) represents one of the highest priorities in infectious disease research. While antiretroviral therapy (ART) can suppress viral replication to undetectable levels, it cannot eliminate the virus due to its ability to establish persistent latent reservoirs in long-lived host cells [71]. The only successful interventions that have led to sustained HIV remission have involved CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation (allo-HSCT), primarily administered as treatment for concomitant hematological malignancies [11] [12] [58].

This technical guide consolidates the virological, immunological, and clinical benchmarks for validating HIV cure from published cases and cohort studies. These criteria establish a framework for researchers and drug development professionals to standardize the assessment of curative strategies beyond CCR5Δ32/Δ32 allo-HSCT, including novel approaches such as gene editing and "kick and kill" methodologies [87] [88]. The complex nature of HIV persistence necessitates a multi-dimensional validation strategy that extends beyond the mere absence of detectable virus after treatment interruption.

Established Cases of HIV Cure and Remission

To date, a limited number of cases have provided proof-of-concept that HIV cure is achievable. These cases, summarized in the table below, share the common intervention of CCR5Δ32/Δ32 allo-HSCT but differ in their conditioning regimens, clinical courses, and follow-up monitoring strategies.

Table 1: Documented Cases of HIV Cure Following CCR5Δ32/Δ32 Allo-HSCT

Patient Identifier	Primary Malignancy	Conditioning Regimen	ART Cessation Timeline	Remission Duration Post-ATI	Key References
Berlin Patient	Acute Myeloid Leukemia	Total Body Irradiation + Chemotherapy	Post-transplant	>10 years	Hütter et al., 2009 [58]
London Patient (IciStem 36)	Hodgkin's Lymphoma	Reduced-Intensity (LACE + Alemtuzumab)	16 months post-transplant	18+ months	Gupta et al., 2019 [11]
Düsseldorf Patient (IciStem 19)	Acute Myeloid Leukemia	Reduced-Intensity (Fludarabine/Treosulfan/ATG)	69 months post-transplant	48+ months	Jensen et al., 2023 [12]
New York Patient	Acute Myeloid Leukemia	Cord Blood + Haploidentical	Not specified	14+ months	Hsu et al., 2023 [58]
Geneva Patient (IciStem 34)	Not Specified	Not Specified	Post-transplant	20+ months	IAS 2023 [71]

Beyond these individual cases, the prospective IciStem cohort (n=30) has provided the most comprehensive data on HIV persistence after allo-HSCT. This multi-center observational study has demonstrated that transplantation with both CCR5Δ32/Δ32 and wild-type CCR5 cells can substantially reduce the viral reservoir, with certain immunological correlates associated with superior reservoir reduction [58].

Consolidated Validation Criteria for HIV Cure

Validation of HIV cure requires a multi-parameter approach spanning virological, immunological, and clinical domains. The benchmarks below represent consolidated criteria derived from published cases and studies.

Virological Benchmarks

The absence of replication-competent virus across multiple compartments is the cornerstone of cure validation.

Table 2: Virological Benchmarks for HIV Cure Validation

Parameter	Assay Methodology	Target Benchmark	Supporting Evidence
Plasma HIV RNA	Ultrasensitive RT-PCR with LOD <1 copy/mL	Undetectable at multiple time points post-ATI	Düsseldorf patient: undetectable at 48 months post-ATI [12]
Cell-Associated HIV DNA	ddPCR for total HIV DNA; Intact Proviral DNA Assay (IPDA)	<0.65 copies/million PBMCs	London patient: <0.029 IUPM in pooled QVOA of 24 million resting CD4 T cells [11]
Replication-Competent Virus	Quantitative Viral Outgrowth Assay (QVOA)	No reactivatable virus in large cell numbers	Düsseldorf patient: negative QVOA and in vivo outgrowth assays in humanized mice [12]
Tissue Reservoir	DNA/RNAscope in situ hybridization; Tissue QVOA	Rare/undetectable HIV RNA/DNA+ cells in lymphoid tissue, gut	IciStem cohort: Substantial reservoir reduction in lymphoid tissue, association with donor cell immunity [58]

Immunological and Clinical Benchmarks

Immune correlates provide critical supporting evidence for the absence of ongoing antigen stimulation.

Table 3: Immunological and Clinical Benchmarks for HIV Cure Validation

Parameter	Assessment Method	Target Benchmark	Rationale
HIV-Specific Antibodies	Serial immunoblot; antibody avidity testing	Progressive decline to levels comparable to negative controls	Waning antibody responses suggest absent antigenic stimulation [12]
HIV-Specific T-Cells	IFN-γ ELISpot; MHC tetramer staining; intracellular cytokine staining	Loss of detectable HIV-specific CD4+ and CD8+ T-cell responses	Düsseldorf patient: HIV-specific T-cells declined below detection while CMV-specific responses remained detectable [12]
Immune Activation	Flow cytometry for activation markers (CD38, HLA-DR) on T cells and NK cells	Levels within range of HIV-negative controls	Normalization of immune activation suggests absence of ongoing viral replication [12]
Clinical Status	Monitoring for acute retroviral syndrome after ATI	No signs or symptoms of viral rebound	Düsseldorf patient: no clinical or laboratory signs of acute retroviral syndrome after ATI [12]

Experimental Protocols for Cure Validation

Standardized experimental methodologies are critical for comparing results across studies and validating cure interventions.

Reservoir Quantification Assays

Quantitative Viral Outgrowth Assay (QVOA) The QVOA remains the gold standard for quantifying replication-competent HIV despite limitations in sensitivity and scalability.

• Protocol Summary: Resting CD4+ T-cells are isolated from patient PBMCs via immunomagnetic selection. Cells are activated with phytohemagglutinin (PHA) and irradiated allogeneic PBMCs from HIV-negative donors. Co-culture supernatants are transferred periodically to indicator cell lines (e.g., CEM-GXR or TZM-bl) to detect HIV-1 p24 production via ELISA or luciferase activity. The frequency of infected cells is calculated using maximum likelihood estimation and reported as infectious units per million (IUPM) cells [11] [12].

• Key Considerations: Testing large cell numbers (≥20 million resting CD4+ T-cells) enhances detection sensitivity. The assay may underestimate the reservoir if not all replication-competent provinces are induced by the activation stimulus.

Intact Proviral DNA Assay (IPDA) IPDA uses droplet digital PCR (ddPCR) to distinguish genetically intact provinces from defective ones.

• Protocol Summary: Two multiplex ddPCR reactions are performed. The HIV-1 discrimination reaction uses probes targeting the packaging signal (Ψ) and Rev-responsive element (RRE) to distinguish intact from defective provinces. The reference reaction quantifies a single-copy human gene (e.g., RPP30) to normalize cell count and assess DNA quality. Results are reported as intact or total HIV-DNA copies per million CD4+ cells [88].

• Advantages: IPDA is highly scalable and specifically quantifies putunctional replication-competent provinces, providing a more accurate reservoir measure than assays detecting total HIV DNA.

Virological Confirmation Assays

In Vivo Outgrowth Assays Humanized mouse models provide an in vivo environment for potential virus amplification.

• Protocol Summary: Immunodeficient mice (e.g., NSG or BLT models) are engrafted with human hematopoietic stem cells to create a human-like immune system. Patient-derived PBMCs or tissue homogenates are administered to these mice, which are monitored for several weeks. Plasma is regularly tested for HIV RNA, and tissues are analyzed for viral replication at endpoint [12].

Ultrasensitive Nucleic Acid Detection

• Plasma HIV RNA: Requires assays with limit of detection (LOD) <1 copy/mL, typically employing large sample volumes (3-6 mL) with concentration methods [11] [12].
• Tissue HIV DNA/RNA: In situ hybridization (RNAscope/DNAscope) allows spatial localization of viral nucleic acids in tissue sections with single-cell resolution, critical as nearly 99% of HIV-infected cells reside in lymphoid tissues [89].

Conceptual Framework for Cure Validation

The pathway to validating an HIV cure involves sequential assessment across virological, immunological, and clinical domains, as illustrated in the following workflow:

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Research Reagents for HIV Cure Validation Studies

Reagent/Cell Line	Primary Application	Function in Assay
CEM-GXR Cell Line	QVOA	Reporter cell line expressing GFP upon HIV infection
TZM-bl Cell Line	QVOA, Neutralization	Reporter with β-galactosidase/luciferase under HIV promoter
ACH-2 Cell Line	IPDA Control	Positive control containing single HIV provirus per cell
CEM.NKRCCR5 Cells	IPDA Control	Negative control for HIV DNA detection
NSG/BRG Mice	In Vivo Outgrowth	Immunodeficient models for human cell engraftment
Anti-CD3/CD28 Beads	T-cell Activation	Polyclonal T-cell activation in QVOA
PHA-P	QVOA	T-cell mitogen for activation of latent reservoir
ddPCR Supermix	IPDA	Digital PCR chemistry for absolute quantification

Emerging Strategies and Future Directions

While CCR5Δ32/Δ32 allo-HSCT has proven the concept of HIV cure, its scalability is limited by donor availability, transplantation-associated mortality, and toxicity [71]. Current research focuses on developing safer, scalable approaches including:

Gene Editing Therapies

• EBT-101: A CRISPR-based gene therapy designed to excise integrated proviral DNA from the host genome, currently in clinical trials with FDA Fast Track designation [71].

"Kick and Kill" Strategies

• Latency Reversal Agents: Compounds such as Maraviroc administered at ART initiation have shown promise in reducing HIV reservoir size by reversing latency during active viral replication [88].
• mRNA-Based Approaches: Novel lipid nanoparticles can deliver mRNA to resting CD4+ T-cells, forcing viral expression and exposing the reservoir for elimination, representing a breakthrough in targeted latency reversal [87].

Alternative Transplantation Approaches Research from the IciStem cohort suggests that allogeneic immunity may contribute substantially to HIV reservoir reduction through a graft-versus-reservoir effect, even with CCR5 wild-type donors [58]. This insight opens avenues for immune-based strategies that mimic this effect without requiring transplantation.

The validation of HIV cure requires rigorous, multi-dimensional assessment spanning extended timeframes. The benchmarks established from CCR5Δ32/Δ32 allo-HSCT cases provide a foundational framework for evaluating novel curative interventions. As the field progresses toward scalable solutions, standardized application of these virological, immunological, and clinical criteria will be essential for comparing outcomes across studies and advancing the ultimate goal of making HIV cure accessible to the millions living with HIV worldwide.

Conclusion

The meticulous monitoring of HIV reservoirs after CCR5Δ32 HSCT has been pivotal in validating several cases of sterilizing cure, fundamentally reshaping the paradigms of HIV eradication. Key takeaways confirm that successful cure hinges on a multifaceted mechanism combining the CCR5 barrier, complete donor chimerism, and a potent graft-versus-reservoir effect. While the detection of sporadic, defective viral sequences presents an interpretive challenge, the consistent absence of replication-competent virus in blood and tissues, coupled with waning HIV-specific immune responses, provides a robust validation framework. The surprising remission in a patient with wild-type CCR5 donor cells further suggests that alloreactive immunity alone can be profoundly effective. Looking forward, these insights are directly informing the development of safer, scalable strategies—such as gene editing of CCR5, CAR-T therapies, and novel immunotherapies—aimed at mimicking the curative effects of HSCT without its associated risks, thereby accelerating the trajectory toward a universally accessible HIV cure.

References

• 1. CCR5-Δ32 biology, gene editing, and warnings for the ... [https://pubmed.ncbi.nlm.nih.gov/32257106/]
• 2. In pursuit of an HIV cure: from stem cell transplants to gene ... [https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2025.1634193/full]
• 3. Deep Thought on the HIV Cured Cases - PubMed Central - NIH [https://pmc.ncbi.nlm.nih.gov/articles/PMC11940578/]
• 4. Mechanism of Transdominant Inhibition of CCR5-mediated ... [https://www.sciencedirect.com/science/article/pii/S0021925819895844]
• 5. A common mechanism of clinical HIV-1 resistance to the ... [https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-10-43]
• 6. Resistance to CCR5 antagonists [https://pubmed.ncbi.nlm.nih.gov/19372879/]
• 7. Duplex digital PCR assay on microfluidic chamber arrays ... [https://www.nature.com/articles/s41598-025-17392-5]
• 8. High frequency CCR5 editing in human hematopoietic ... [https://www.nature.com/articles/s41467-025-55873-3]
• 9. CCR5 gene editing and HIV immunotherapy - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC12213807/]
• 10. HIV Persistence, Latency, and Cure Approaches [https://pmc.ncbi.nlm.nih.gov/articles/PMC11281696/]
• 11. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7275870/]
• 12. In-depth virological and immunological characterization of ... [https://www.nature.com/articles/s41591-023-02213-x]
• 13. HIV-1 remission and possible cure in a woman after haplo ... [https://www.sciencedirect.com/science/article/pii/S0092867423001733]
• 14. Allogeneic immunity clears latent virus ... - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC10524637/]
• 15. The power of ten in HIV remission: insights from hematopoietic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12337928/]
• 16. Progress Toward Curing HIV Infections With Hematopoietic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4296106/]
• 17. Graft-versus-tumor effect [https://en.wikipedia.org/wiki/Graft-versus-tumor_effect]
• 18. The Graft-Versus-Leukemia Effect in AML [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01217/full]
• 19. Sustained HIV remission after allogeneic hematopoietic ... [https://www.nature.com/articles/s41591-024-03277-z]
• 20. New Frontiers in Measuring and Characterizing the HIV ... [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02878/full]
• 21. Early donor chimerism levels predict relapse and survival after ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4194246/]
• 22. Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7606918/]
• 23. CROI 2025: Summary of Basic Science Research in HIV - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12324712/]
• 24. HIV cured at Charité: the next Berlin patient [https://www.charite.de/en/service/press_reports/artikel/detail/hiv_cured_at_charite_the_next_berlin_patient]
• 25. EACS 2025: Second Berlin patient has unusual immune ... [https://www.eatg.org/hiv-news/eacs-2025-second-berlin-patient-has-unusual-immune-response-that-seems-to-have-removed-his-hiv/]
• 26. HIV-AIDS : inspiring patients | [https://www.pasteur.fr/en/research-journal/news/hiv-aids-inspiring-patients?language=fr]
• 27. HIV/AIDS research has saved millions of lives globally and ... [https://www.fredhutch.org/en/news/releases/2025/10/hiv-aids-research-has-saved-millions-of-lives-globally.html]
• 28. The next Berlin Patient: Another man cured of HIV after ... [https://www.eatg.org/hiv-news/the-next-berlin-patient-another-man-cured-of-hiv-after-stem-cell-transplant/]
• 29. The "Geneva patient": first case of HIV cure with stem cell ... [https://www.irsicaixa.es/en/geneva-patient-first-case-hiv-cure-stem-cell-transplant-without-protective-mutation]
• 30. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4747624/]
• 31. a prospective observational cohort analysis - PMC [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417461]
• 32. Digital PCR: from early developments to its future application ... [https://pubs.rsc.org/en/content/articlehtml/2025/lc/d5lc00055f]
• 33. Adaptation of Droplet Digital PCR-Based HIV Transcription ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10384802/]
• 34. Development of a Duplex-ddPCR assay for accurate ... [https://www.sciencedirect.com/science/article/abs/pii/S0042682224003350]
• 35. decay of Differential and intact in... defective proviral DNA [https://pmc.ncbi.nlm.nih.gov/articles/PMC7101154/]
• 36. Intact proviral DNA assay analysis of large cohorts ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7414172/]
• 37. How we measure success matters when evaluating HIV ... [https://www.fredhutch.org/en/news/spotlight/2023/09/vidd-reeves-natcommun.html]
• 38. Considerations and limitations for establishing an Intact ... [https://www.sciencedirect.com/science/article/pii/S0166093425000989]
• 39. HIV-1 diversity considerations in the application of ... [https://www.nature.com/articles/s41467-020-20442-3]
• 40. Improved assays to measure and characterize the inducible ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6197429/]
• 41. Rapid Quantification of the Latent Reservoir for HIV-1 Using a ... [https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003398]
• 42. A highly reproducible quantitative viral outgrowth assay for the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5324126/]
• 43. In-depth virological and immunological characterization of HIV ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10033413/]
• 44. Humanized Mouse Models for Human Immunodeficiency ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6542458/]
• 45. Use of Humanized Mouse Models for Studying HIV ... [https://www.scientificarchives.com/article/use-of-humanized-mouse-models-for-studying-hiv1-infection-pathogenesis-and-persistence]
• 46. How to best measure HIV reservoirs? - PMC - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC3763804/]
• 47. Determinants of HIV-1 reservoir size and long-term ... [https://www.nature.com/articles/s41467-019-10884-9]
• 48. A dual-purpose humanized mouse model for testing ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11570277/]
• 49. Assessing HIV-1 subtype C infection dynamics, therapeutic ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1552563/full]
• 50. Decay Kinetics of Human Immunodeficiency Virus-Specific ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC114374/]
• 51. B cell responses to HIV-1 infection and vaccination [https://pmc.ncbi.nlm.nih.gov/articles/PMC3053087/]
• 52. HIV-specific CD8+ T-cell proliferative response 24 weeks ... [https://elifesciences.org/reviewed-preprints/106402]
• 53. Autopsy Study Defines Composition and Dynamics of the... [https://pubmed.ncbi.nlm.nih.gov/36146874/]
• 54. In-depth virological and immunological characterization of HIV -1 cure... [https://www.nature.com/articles/s41591-023-02213-x?error=cookies_not_supported&code=33919c86-6d7a-46f9-9eef-1feb712cbebd]
• 55. of Transplantation - CCR / 5 May Cure Δ Infection 32 Δ 32 Stem Cells HIV [https://link.springer.com/chapter/10.1007/978-94-017-7233-4_3]
• 56. A majority of HIV persistence during antiretroviral therapy is ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6240116/]
• 57. A majority of HIV persistence during antiretroviral therapy is ... [https://www.nature.com/articles/s41467-018-06843-5]
• 58. Dynamics of virological and immunological markers of HIV ... [https://www.sciencedirect.com/science/article/abs/pii/S2352301824000900]
• 59. Impact of allogeneic hematopoietic stem cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6097982/]
• 60. Factors associated with viral suppression and rebound among ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9131580/]
• 61. Incidences and factors associated with viral suppression or ... [https://www.sciencedirect.com/science/article/pii/S1201971220304045]
• 62. Factors affecting viral suppression or rebound in people ... [https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full]
• 63. Analytical Treatment Interruption in HIV Trials [https://pmc.ncbi.nlm.nih.gov/articles/PMC8251690/]
• 64. The role of analytical treatment interruptions in shaping HIV ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12517717/]
• 65. Time to HIV viral rebound and frequency of post-treatment ... [https://www.nature.com/articles/s41467-025-56116-1]
• 66. a systematic review and meta-analysis - PubMed - NIH [https://pubmed.ncbi.nlm.nih.gov/39155436/]
• 67. HIV/AIDS Comorbidities: Impact on Cancer ... - NCBI [https://www.ncbi.nlm.nih.gov/books/NBK525185/]
• 68. Management of HIV Infection in Patients With Cancer ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4305124/]
• 69. Clinical presentation and spectrum of opportunistic infections ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12178529/]
• 70. Flow Cytometric Quantification of HIV-1-Infected Cells ... [https://pubmed.ncbi.nlm.nih.gov/40741400/]
• 71. HIV cure: ending the HIV epidemic [https://viivhealthcare.com/ending-hiv/towards-a-hiv-cure/]
• 72. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 ... [https://www.sciencedirect.com/science/article/pii/S0006497120431672]
• 73. HIV-1 diversity in viral reservoirs obtained from circulating T ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11410260/]
• 74. Diagnostic markers for CNS lymphoma in blood and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6099264/]
• 75. Visualization of HIV-1 reservoir: an imaging perspective [https://pmc.ncbi.nlm.nih.gov/articles/PMC8214835/]
• 76. The Biology of the HIV-1 Latent Reservoir and Implications for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7219958/]
• 77. Tracking HIV persistence across T cell lineages during ... [https://www.nature.com/articles/s41467-025-57368-7]
• 78. C-C chemokine receptor type five (CCR5): An emerging target ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5133339/]
• 79. The chemokine receptor CCR5: multi-faceted hook for HIV-1 [https://retrovirology.biomedcentral.com/articles/10.1186/s12977-024-00634-1]
• 80. Identification and frequency of CCR5Δ32/Δ32 HIV-resistant ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4021858/]
• 81. Sustained HIV remission after allogeneic hematopoietic stem ... [https://pubmed.ncbi.nlm.nih.gov/39222660/]
• 82. Editorial: Immune Surveillance of the HIV Reservoir [https://pmc.ncbi.nlm.nih.gov/articles/PMC7005218/]
• 83. IciStem [https://www.icistem.org/]
• 84. Dynamics of virological and immunological markers of HIV ... [https://pubmed.ncbi.nlm.nih.gov/38816141/]
• 85. Beyond HIV infection: Neglected and varied impacts of CCR5 ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7260533/]
• 86. CCR5 gene editing and HIV immunotherapy [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1590690/full]
• 87. World-first discovery harnesses mRNA in the search for an ... [https://www.doherty.edu.au/news-events/news/world-first-discovery-harnesses-mrna-in-search-for-hiv-cure]
• 88. Impact of the initial administration of an antiretroviral drug ... [https://www.nature.com/articles/s41598-025-09474-1]
• 89. Study by UMN Researchers Quantifies Scope of HIV ... [https://med.umn.edu/news/study-umn-researchers-quantifies-scope-hiv-reservoir-infected-people-and-points-potential-curative-strategies]